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ABSTRACT 
 
Proteomics of Oxidative Stress Using Inducible CYP2E1 Expressing HepG2 Cells and 
3T3-L1 Adipocytes as Model Systems.  
(May 2011) 
Billy Walker Newton, B.S.; M.S., Texas A&M University 
Chair of Advisory Committee: Dr. Arul Jayaraman 
 
The overall goal of this research was to investigate oxidative stress related changes to 
the proteomes of 3T3-L1 adipocytes and an inducible CYP2E1 expressing HepG2 cells.  
Enhanced oxidative stress in hypertrophic adipocytes is associated with metabolic 
dysregulation and insulin resistance.  Because mitochondria generate reactive oxygen 
species (ROS), we monitored changes to the adipocyte mitochondrial proteome during 
differentiation and enlargement. We labeled mitochondrial extracts from 3T3-L1 cells 
that were 0, 4, 7, 10, 14, and 18 days post differentiation with iTRAQ, followed by MS 
based identification. We found citric acid cycle proteins such as pyruvate carboxylase, 
citrate synthase, as well as beta-oxidation enzymes; cartinine acyl transferase and long-
chain enoyl-CoA hydratase up-regulated from 7 through 18 days post differentiation 
onset.  These data indicate TCA up-regulation for enhanced metabolic and citrate output 
necessary for lipid synthesis in adipocytes.  Paradoxically, the data also show the 
simultaneous increase in the fatty acid oxidation, indicating a metabolic overdrive state.  
Biochemical assays showing peaks in ATP and ROS generation in 3 day old adipocytes 
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provide further evidence of this overdrive state.  A second peak in ROS generation 
occurred in 10 day old adipocytes; concurrent ATP generation reduced to near pre-
adipocyte levels and this may indicate a metabolic shift that may be responsible for 
increased oxidative stress in hypertrophic adipocytes.   
 
We developed a doxycycline inducible CYP2E1 expressing HepG2 cell line using the 
pTet-On/pRevTRE expression system to allow greater control and sensitivity in the 
generation CYP2E1 mediated oxidative stress.  Our cell line (RD12) demonstrated 
stability and tight expression control.  After induction, RD12 cells showed 30 percent 
higher CYP2E1 activity when compared to the constitutive E47 cell line.  RD12 cells 
showed 30% greater toxicity than E47 cells and 25% less free glutathione when exposed 
to 20 mM acetaminophen, indicating RD12 cells are more sensitive to the effects 
reactive intermediates and oxidative stress generated by CYP2E1.   
 
We conducted a survey of the toxicity of dietary fatty acids (oleic, linoleic, and palmitic) 
on HepG2 cells to determine fatty acid doses that induced metabolic changes, but did not 
cause excessive cell death.  The dose of 0.20 mM linoleic and palmitic acid for 48 hours 
produced low toxicity, but oleic acid actually produced lower toxicity than untreated 
cells.  After exposure cells were treated with a pro-oxidant to determine which fatty acid 
increased the susceptibility to protein carbonylation.  The carbonylated protein isolation 
procedure indicated the palmitic acid may induce more carbonylation than oleic acid, but 
greater efficiency in the isolation procedure is required for a confidant determination.  
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CHAPTER I  
                 INTRODUCTION 
 
1.1. BACKGROUND   
It is becoming increasingly evident that oxidative stress plays a major role in the 
manifestation of many (1) diseases (1), including Alzheimer’s disease (2), athero-
sclerosis (3), type II diabetes (4), obesity (5),  alcoholic and non-alcoholic liver 
disease (5, 6), and the aging process itself (7).  Reactive oxygen species (ROS) are 
ubiquitous and an unavoidable consequence of aerobic respiration, and normal 
metabolism results in the generation of different ROS, such as the superoxide ion (8). In 
a normal cell, the ROS generated are normally cleared away by the cellular anti-oxidant 
machinery, and a state of oxidative stress arises when the rate of generation (and the 
deleterious effects) of reactive oxygen species (ROS) is much greater than their rate of 
removal by the antioxidant systems (8).  The excess ROS present are capable of 
targeting all classes of biomolecules including DNA, protein, and lipids (1, 8).  The 
accumulation of such oxidatively-damaged biomolecules can lead to cellular dysfunction 
and cell death, and oxidatively-modified proteins have been detected in neurons of 
Alzheimer’s patients (9), adipose tissue of obese mice (10), and in liver tissue from 
alcohol-fed rats (11).  Oxidative stress has also been linked to impaired glucose transport 
in adipocytes (12) and in the progression to steatohepatitis in hepatocytes (5). 
 
____________ 
This dissertation follows the style of The Journal of the Federation of American 
Societies for Experimental Biology. 
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Oxidative stress has been linked to impaired glucose transport in adipocytes (12) and in 
the progression of steatosis to steatohepatitis in hepatocytes (5).  Characterizing ROS 
and oxidative stress, i.e., production and removal of free radicals, is challenging for two 
reasons.  The half-life of free radicals is very short (10-9 s for the hydroxyl radical (8)) 
which makes accurate determination of ROS concentrations very difficult.  In addition, 
the redox state of the cell can change very rapidly, such that a single measurement of 
ROS may not accurately represent the ROS concentration and its effects.  An alternate 
approach to characterizing oxidative stress is to focus on the effects of these free radicals 
on biomolecules, especially proteins, since protein levels and modifications are more 
stable, i.e., like a molecular footprint, are more amenable to detection, and whole-
proteome monitoring technologies are well established (13-15).  Furthermore, since 
proteins provide structure and conduct biochemistry of cells and cellular dysfunction 
typically arises from changes in protein levels or activity, it is more pertinent to monitor 
changes in the proteome due to an imbalance of oxidative stress in cells. 
 
Our overall goal is to develop and utilize model systems for characterizing oxidative 
stress modifications to the proteome and investigating their role in cellular dysfunction 
and disease. To accomplish this, we plan to conduct quantitative proteomic studies using 
two model systems - 3T3-L1 adipocytes and hepatocytes.  These are both relevant and 
valid model systems, as oxidative stress and ROS affect the function of both adipose 
tissue and the liver (4-6, 12, 16).  
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1.2. MOTIVATION 
It is estimated that approximately 21 million people in the U.S. have type II diabetes, 
and the annual total cost for treatment is over $80 billion (17).  As of 2002, diabetes was 
the sixth leading cause of death listed on US death certificates (17), and 90 percent of 
new diabetes cases suffer from type II diabetes (18).  Clearly type II diabetes is a major 
public health issue.  Insulin resistance seen in type II diabetes has been linked to 
inflammation and oxidative stress in hypertrophic adipocytes (12, 19), and 
understanding mechanisms for these processes will lead to targets for improved therapy. 
 
Alcoholic and non-alcoholic fatty liver diseases are also conditions where the 
accumulation fat in cells is linked to metabolic problems.  While alcoholic and non-
alcoholic fatty liver disease share different initial causes, there is believed to similarities 
in both conditions (such as enhanced oxidative stress and/or inflammation) that cause 
them to progress to serious conditions of steatohepatitis and eventually cirrhosis  (5, 20-
22).  The healthcare treatment cost for alcohol related diseases, especially alcoholic liver 
disease and alcoholic cirrhosis is over $20 billion annually in the U.S. (23).  Non-
alcoholic fatty liver disease (NAFLD) is also a major growing public health problem 
 (24), with one-third of diagnoses developing end-stage cirrhosis (25).  NAFLD typically 
shares some of same symptoms associated with type II diabetes such as insulin 
resistance, obesity, and high triglycerides (5).  The current studies involving 3T3-L1 
adipocytes and CYP2E1 expressing hepatocytes are at a cellular and mechanistic level.  
The information provided on how oxidative stress manifests in cells can be used to help 
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understanding in other conditions associated with oxidative stress and the effects of 
ROS.  These studies also provide information for targets of further study in the 
understanding the development and eventual treatment for diseases (type II diabetes, 
insulin resistance, and alcoholic and non-alcoholic liver disease) with severe public 
health consequences and costs.  
 
1.3. RESEARCH OBJECTIVE, IMPORTANCE, AND NOVELTY 
We looked at three systems to measure the effects of oxidative stress in 3 cell culture 
based models that moved from more natural to more engineered approaches as out lined 
in Figure 1.1.  The first system was where ROS and oxidative stress occur naturally in 
differentiating and enlarging adipocytes, the second system aimed to determine if dietary 
fatty acids could modulate ROS and their effects, and last we sought to create a 
controllable system where ROS could induced at specific time points.     
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                                Figure 1.1. Outline of research goals. 
 
 
 
Overall Goal:  Study effect of
oxidative stress on cellular 
proteome using 3 model systems
Most natural system  Most engineered system 
Aim 2: Investigate
effect of fatty acids on
pro-oxidant mediated
protein carbonylation
and toxicity
Aim 1: Study
proteomic changes
during adipocyte
aging and 
enlargement
Aim 3: Develop and
validate regulatable
CYP2E1 expressing
line & verify small
molecule toxicity
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The increase in adipose tissue mass arises in part due to progressive lipid loading and 
triglyceride accumulation in adipocytes. Enlarged adipocytes produce the highest levels 
of pro-inflammatory molecules and reactive oxygen species (ROS). Since mitochondria 
are the site for major metabolic processes, e.g., TCA cycle, that govern the extent of 
triglyceride accumulation as well as the primary site of ROS generation, we 
quantitatively investigated changes in the adipocyte mitochondrial proteome during 
different stages of differentiation and enlargement. Mitochondrial proteins from 3T3-L1 
adipocytes at different stages of lipid accumulation (days 4 through 18) were digested 
and labeled using the iTRAQ 8-plex kit. The labeled peptides were fractionated using a 
liquid phase isoelectric fractionation system (MSWIFT) to increase the depth of 
proteome coverage, and analyzed using LC-MS/MS.  While the 3T3-L1 adipocyte 
nuclear proteome and secreted proteome has been characterized during differentiation 
(through day 7) using SILAC (15), and the mitochondrial proteome studied in 
isoproternol-treated adipocytes at a single time point (26), the 3T3-L1 mitochondrial 
proteome has not been profiled from the pre-differentiated state through 18 day old 
hypertrophic adipocytes, as was undertaken in the current study. 
 
The forced over-expression of CYP2E1 in hepatoma cells with a constitutive CMV 
promoter has been shown to lead to increased oxidative stress (27); however, forced 
constitutive expression of CYP2E1 also leads to adaptation of HepG2 to oxidative stress 
through an increase in the basal expression of anti-oxidant systems (28). Therefore we 
developed an inducible CYP2E1 expression system for two major reasons: 1) enhanced 
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sensitivity to CYP2E1 mediated oxidative stress, and 2) control over CYP2E1 induction 
to allow pre-treatment with pharmacological or labeling agents.  These advantages will 
enhance investigations of effects of CYP2E1 generated ROS and oxidative stress, and 
development of inducible expression of CYP2E1 in HepG2 hepatocytes has not been 
reported. 
 
Dietary fatty acids have modulated ROS in cells differently, with palmitic acid 
increasing ROS generation (29), and oleic acid inducing protection against added 
oxidants (30).  We conducted a detailed survey of the toxicity of dietary fatty acids 
(oleic, linoleic, and palmitic) on HepG2 hepatocytes in order to determine fatty acid 
doses that induced metabolic changes, but did not cause excessive cell death.  After fatty 
acid exposure cells were treated with the pro-oxidant tert-butyl hydroperoxide (t-BHP) 
to determine which fatty acid increased the susceptibility to protein carbonylation.  A 
study determining the extent and type of protein carbonylation to the aforementioned 
fatty acids has not been reported.   
 
The specific objectives in this course of study were to: 
 Determine global mitochondrial proteome expression profiles from 3T3-L1 
adipocytes that were 0,4,7,10,14,18 days post differentiation 
 
 8 
 Conduct concurrent biochemical assays to determine lipid loading, ATP 
production, and ROS generation in 3T3-L1 adipocytes during differentiation and 
hypertrophy 
 Develop a pRevTRE-CYP2E1 expression plasmid and verify its sequence and 
functionality 
 Create a stable doxycycline inducible CYP2E1 expressing HepG2 hepatocyte 
cell line using the pRevTRE-CYP2E1 expression plasmid 
 Characterize the controlled expression and enhanced oxidative stress sensitivity 
of doxycycline inducible CYP2E1 expressing HepG2 cell line 
 Survey the cyto-toxic effects of fat pre-loading HepG2 hepatocytes with varying 
concentrations of dietary fatty acids (oleic, linoleic, and palmitic), both prior to 
and after the addition of the pro-oxidant t-BHP 
 Isolate carbonylated protein from fatty acid and t-BHP treated HepG2 cells 
using affinity chromatography, in order to determine the extent and pattern of 
protein carbonylation produced by different fatty acids 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1. METABOLISM AND GLUCOSE HOMEOSTASIS 
Maintaining homeostasis in the human body requires interplay between various organs 
and systems to maintain appropriate metabolites levels. These metabolites, e.g., blood 
glucose, are maintained in a tight range despite periods of rapid ingestion of 
carbohydrate followed by periods of varying energy expenditure such as during physical 
activities or periods of extended fasting such as during sleep. Figure 2.1 demonstrates a 
typical blood glucose and insulin level during a 24-hour period.  The maintenance of 
blood glucose within the reference range of 3.6 - 5.8 mmol (0.6 – 1.2 g/L) is perhaps the 
simple most important metabolic functions and is primarily carried out by the 
insulin/glucagon system (31). 
 
Beta cells of pancreas produce insulin. Insulin is a 5300 Dalton peptide hormone whose 
primary function is to stimulate muscle and adipose tissue cells to take up  glucose from 
the blood (31). The combination of muscle and adipose tissue cells represents 2/3 of total 
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Figure 2.1. Typical 24-hour blood glucose and insulin levels (32).  
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body cells and the action of insulin lowers blood sugar (33). Insulin is also anabolic by 
promoting uptake of amino acid and protein synthesis (34). Glucose is the main source 
of energy for the brain since neuron cells in the brain are not able to use fat as fuel.  
 
In contrast to insulin is the enzyme glucagon (35). Glucagon is secreted by pancreas 
when blood sugar levels are too low. Glucagon first stimulates breakdown of glycogen 
to glucose and induces glycogenesis in the liver. It also promotes synthesis of glucose 
from amino acids and triglycerides. Glucose produced from liver in turn can be excreted 
to the blood stream. This way, glucagon always stimulates insulin release. The glucose 
produced is available to be taken up by insulin dependent tissues. 
 
Insulin binds to receptors on muscle cells (myocytes) and fat cells (adipocytes) and 
triggers signaling cascades that result in the localization of additional glut-4 glucose 
transporters to the plasma membrane. The activation of glut-4 in the membrane 
facilitates diffusion of glucose into these cells. Once in the cell, glucose enters the 
glycolysis pathway and is rapidly phosphorylated by a hexokinase so it cannot diffuse 
out of the cell.  Table 2.1 shows all of the enzymes involved in a glycolysis. 
Hexokinases I-II are found in peripheral tissue and have low kinetic constant, Km, so 
they are still able to function with low glucose level. They are allosterically inhibited by 
their product glucose-6-phosphate. Glucokinase (hexokinase IV) is only found in the 
liver and has much higher Km, so it is only active at higher glucose concentration. It is 
not allosterically inhibited which allows the liver to regulate blood sugar levels. 
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Table 2.1. Glycolysis pathway  (31). 
 
 
 
 
Step Substrate Enzyme
1 Glucose Hexokinase
2 Glucose-6-phosphate Phosphoglucose isomerase
3 Fructose 6-phosphate Phosphofructokinase
4 Fructose 1,6-bisphosphate Fructose bisphosphate aldolase Glyceraldehyde 3-phosphate + Dihydroxyacetone phosphate
5 Dihydroxyacetone phosphate Triosephosphate isomerase 
6 Glyceraldehyde 3-phosphate Glyceraldehyde phosphate dehydrogenase
7 1,3-bisphosphoglycerate Phosphoglycerate kinase
8 3-phosphoglycerate Phosphoglycerate mutase  
9 2-phosphoglycerate Enolase
10 Phosphoenolpyruvate Pyruvate kinase
2-phosphoglycerate
Phosphoenolpyruvate
Pyruvate
Product
Glucose-6-phosphate
Fructose 6-phosphate 
Fructose 1,6-bisphosphate
Glyceraldehyde 3-phosphate 
1,3-bisphosphoglycerate
3-phosphoglycerate
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2.2. HYPERGLYCEMIA AND TYPE II DIABETES AND OBESITY 
If glucose cannot be sufficiently removed from the blood stream, hyperglycemia results 
and this is the hallmark of diabetes mellitus. Diabetes type I, i.e., juvenile diabetes, 
results from destruction of the beta cells that produce insulin, typically at an early age. 
The exact reason for the destruction of beta cells remains unknown. Diabetes type I is 
characterized as a polygenic multifactorial process. Genetic susceptibility, diabetic 
triggers, and one or more antigens result an autoimmune response that destroy beta cells 
 (36, 37).  Environmental factors are important, as monozygotic twins of a parent with 
diabetes type I only both develop the disease about 50 percent of the time (36, 37). 
Currently, treatment of type I diabetes relies on the daily administration of exogenous 
insulin to control blood sugar level (17).  
 
In contrast to type I diabetes, type II diabetes is a metabolism disorder. It typically 
appears later in life. It is increasingly being observed in adolescence and young adults 
 (38). The resulting hyperglycemia found in type II diabetes comes from the existing 
insulin being unable to sufficiently control the blood glucose level (18). The normally 
insulin responsive tissue in type II diabetes are said to be “insulin resistant” (18) and  
develop a relative insulin deficiency, whereas in type I diabetes, the insulin producing 
cells no longer exist. In either case, hyperglycemia, if left untreated can lead to the 
development of debilitating conditions such as heart attack, stroke, kidney failure, 
blindness and limb amputation. 
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Type II diabetes is characterized as a combination of lifestyle and genetic factors. In one 
recent study, those who have high levels of activity, did not smoke, maintained a healthy 
weight, ate a diet high in fiber and low in saturated fat have an 89 percent lower rate of 
type II diabetes (39). Over 55 percent of type II case are associated with obesity (40). 
Type II diabetes when accompanied by co-morbidities of obesity, hypertension, and high 
triglycerides is often referred as metabolic syndrome (12, 41). There is a genetic 
component of type II diabetes. Having a first degree relation with it increases risk 
substantially and there is a specific mutation in the gene for islet amyloid peptide that 
results in earlier onset and severity of the disease (42, 43). But clearly, environmental 
and lifestyle factors are important as it has been shown in recent immigrants from 
populations with traditionally low incidents of type II diabetes have a substantial 
increase in type II diabetes when they adopt a Western lifestyle (33). 
 
Much ongoing research aims to study the link between obesity, type II diabetes, and its 
associated insulin resistance.  Adipose tissue, especially that from the mesenteric organs 
(visceral adipose tissue), is not thought of as simple fat storage depot but rather an organ 
capable of carrying out several metabolic reactions, such as lowering blood glucose, 
providing satiety signals, and excreting cytokines. Adipocytes have been shown to 
produce cytokines TNF, IL-6 and IL-8  (44). Treatment of cultured adipocytes with 
TNF decreased mitochondrial membrane potential, reduced ATP levels, and increased 
ROS production, implying it has role in adipocyte dysfunction (45). Adipocytes also 
produce the recently discovered adipocyte specific hormones leptin (46) and adiponectin 
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 (47). The cytokine IL-6 is a major mediator of the inflammation response (48).  Leptin 
is primarily produced in adipose tissue. It produces a satiety signal and reduces appetite.  
Leptin is found in high concentration in obese people and they are referred to as being 
leptin resistant, in the same sense as people with type II diabetes are insulin 
resistant (49).   There is a strong correlation between adipocyte cell volume and the 
excretion of leptin, TNF, IL-6, IL-8 (44), thus hypertrophic adipocytes are the most 
metabolically active. For this reason, studying metabolism and dysfunction in 
hypertrophic adipocytes can lead to better understanding of the metabolic dysregulation 
of adipose tissue.  Adiponectin has been inversely correlated to body fat percentage and 
administration of adiponectin has lowered blood glucose levels and improved insulin 
sensitivity (50).  
 
Oxidative stress has been linked to adipocytes and obesity. One study has shown the 
increased oxidative stress markers in the plasma and adipose tissue of obese mice (12). 
Another study shows the increased production of reactive oxygen species in cultured 
3T3-L1 adipocytes to be proportional to the glucose concentration in culture media (19). 
Kobayashi et al. found cultured adipocytes to have a lower response to insulin after 
exposure to hydrogen peroxide  (51).  All of these taken together indicate the importance 
of oxidative stress in adipocytes and in glucose metabolism. In light of current research 
on the subject, type II diabetes and obesity are viewed as metabolic disorders with 
inflammatory and oxidative stress related components. 
 
  
16 
2.3. STEATOSIS 
Steatosis is defined as the accumulation of fat in the liver that is manifested in a variety 
of conditions, and is categorized as either being related to alcoholic fatty liver disease 
(ALD) or non-alcoholic fatty liver disease (NAFLD) (6, 52).  Steatosis is an important 
condition because it often marks the onset of possible problems with liver function that 
if left untreated could progress to more serious conditions such as steatohepatitis. 
 
Steatosis is the first and most common pathology in ALD and occurs in up to 90 percent 
of alcoholics.  Fatty liver is thought to be mainly a result of metabolic disturbances, such 
as decreased fatty acid oxidation, increased triglyceride synthesis, reduced fat export, 
and mobilization of extra-hepatic fat stores (16, 53-55).  The metabolism of ethanol to 
acetaldehyde and its subsequent conversion to acetate produces NADH.  The cellular 
accumulation of NADH increases substrate available for fatty acid synthesis, as well as 
disrupts mitochondrial beta oxidation, thereby leading to fat accumulation (56).  
Steatosis has long been considered a benign condition, as even severe cases of AS 
recovered after 3-4 weeks of alcohol withdrawal (57-59).   However, more recent studies 
indicate that the metabolic changes taking place during the steatosis may also sensitize 
the cells to further injury (60-63).  Lieber (54) suggested that metabolic changes of fatty 
liver alone may be insufficient to cause inflammation.  It is now believed that degree of 
fat accumulation in the liver correlates to the susceptibility of subsequent liver damage 
 (21).  Researchers have shown that fatty liver is highly vulnerable to oxidative stress or 
injury mediated by endotoxins or cytokines, and Day has referred to this as the “two-hit” 
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hypothesis (60, 64, 65).  While these studies show vulnerabilities of steatotic livers, one 
study also showed that a fatty liver induced by 5 weeks of ethanol exposure 
demonstrated enhanced capacity to regenerate and consequent decrease in hepatic 
injury (66).  This was not due to reduced CYP2E1 activity, but possibly through 
activation of the transcription factor NF-B (66).   
 
Evidence exists that alcohol alone may not be enough to cause steatohepatitis and 
necrosis, and further studies are needed to understand mechanisms of AS, and identify 
biomarkers leading to subsequent pathological stages of ALD (6).  While a detailed 
understanding of the mechanisms underlying the transition from AS to ASH is lacking, it 
is known that continued consumption of alcohol in humans eventually results in 
neutrophilic steatohepatitis (67, 68).  Neutrophil infiltration into the liver is hallmark of 
ASH and contributes to the pathology of ALD.  Alcoholic steatohepatitis reverts back to 
normal hepatic histopathology approximately only 10 percent of the time (69).  Most 
patients with steatohepatitis (almost 50 percent) go on to develop fibrosis and cirrhosis 
(Figure 2.2).  Steatohepatitis therefore represents a major rate limiting step in the 
progression towards cirrhosis and clinical liver disease (70, 71).  It would be beneficial 
to patients with ALD to receive diagnosis and intervention before the onset of 
steatohepatitis and even cirrhosis.  The term non-alcoholic steatohepatitis (NASH) was 
only recently coined in 1980 (72).  NAFLD is now estimated to affect between 15 - 30 
percent of adults in the U.S. (5) and parallels the incidence of obesity, insulin resistance, 
type II diabetes, high triglycerides, hypertension and other markers for the  “metabolic  
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Figure 2.2. Progression of alcoholic liver disease.  Consumption of ethanol produces 
hepatic pathology in sequence, ranging from steatosis (fatty liver) on one extreme, to 
fibrosis/cirrhosis on the opposite end of the spectrum  (6). 
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syndrome” (5, 24).  NAFLD strongly correlates with markers of the metabolic 
syndrome (73, 74), especially with insulin resistance in the liver and adipose tissue (75, 
76).  Non-alcoholic steatosis follows a similarity with alcoholic steatosis, in that not 
every case proceeds to steatohepatitis, or cirrhosis.  Only 1 – 5 percent of non-alcoholic 
steatosis cases develop into cirrhosis  (24).  This is still a very significant number 
however, and further highlights the benefits early intervention in steatosis.  The “two-
hit” hypothesis outlined by Day (21, 24, 77) still applies to NASH.   
 
NASH has been linked to mitochondrial dysfunction and production of increased ROS 
 (78), and an increase in serum tumor necrosis factor alpha (TNF) has been strongly 
linked to the progression of steatosis to NASH (79), and CYP2E1 activity has been 
found elevated in NASH patients (80).  Current research is dedicated to understanding 
the mechanisms behind the progression of steatosis to NASH, as well as the underlying 
insulin resistance and dislypedemia found in NAFLD.   
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2.4. CYTOCHROME P450 2E1 
The cytochrome P-450 (CYP) system is a large family of mono-oxygenase enzymes 
primarily found in the liver. The P-450 system is responsible for the modification and 
detoxification for a large variety of endogenous and exogenous substrates. Humans have 
more than 50 separate cytochrome P450 genes (81, 82).  Many drugs or small molecules 
are inducers of P450 enzymes.  Phenobarbitol induces CYP3A4 (83) and ethanol and 
pyrazole induce CYP2E1 (84-86).  Steroid hormones are also an important class of 
endogenous substrates, e.g., CYP19A1 converts testosterone to estradiol (82).  A major 
function of P450 catalyzed reactions is to hydroxylate compounds into a metabolite that 
can be easily excreted from the body. These reactions are referred to as phase I drug 
metabolism reactions. The addition of a hydroxyl group allows subsequent conjugation 
by phase II enzymes such glutathione-S transferase. This further detoxifies the 
compound and increases water solubility of metabolites, thereby, facilitating excretion.  
Not all xenobiotics are converted to water-soluble (harmless) intermediates, as 
compounds such as carbon tetrachloride and acetaminophen (86-88) are converted by 
P450 to a toxic intermediates which damage cells.  For P450s to function catalytically, 
they need a source reducing equivalents such as NADPH cytochrome P450 reductase to 
reduce the heme iron. 
 
Cytochrome P450 enzymes are regarded as a source of ROS (89, 90).  While the overall 
P450 catalytic cycle is very efficient, small amounts of the superoxide anion radical   
(O2-) can be produced from premature decoupling of the oxygenated P450 complex.  
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Fridovich and others have estimated between 0.1 - 1.0  percent of molecular oxygen 
entering such cycles forms superoxide ions (90).  Most of the oxygen decoupling 
happens between steps 3 and 4 in the P450 catalytic cycle represented in Figure 2.3.   
 
Cytochrome P450 2E1 (CYP2E1) metabolizes a broad range of small molecules, 
including ethanol, pyrazole, aniline, p-nitrophenol, and acetaminophen (84, 85, 91).  
CYP2E1 is rapidly induced by ethanol.  Cultured primary hepatocytes experience a 
nearly 200 percent increase in CYP2E1 activity after exposure to 100 mM ethanol for 12 
hours (92).  CYP2E1 has been highly studied as source of increased ROS and oxidative 
stress that occurs during chronic alcohol consumption (93, 94).  
   
CYP2E1 displays high NADPH oxidase activity, as it produces superoxide ions at a 
higher rate than several other P450 enzymes, and this may result from poor coupling 
with NADPH-cytochrome P450 reductase (95, 96). CYP2E1 has been reported to 
generate the most lipid peroxidation in a study of five isolated P450 enzymes (96).  
CYP2E1 is primarily located in the endoplasmic reticulum (86), however it has been 
detected in the mitochondria, and one study estimated about 25 percent of total CYP2E1 
is present in the mitochondrion (97).  CYP2E1 expression is believed to have a high 
degree of post translation control, as incubation with the substrate methyl-pyrazole 
decreased the degradation rate (98). When CYP2E1 has been induced by chronic ethanol 
exposure, it takes part in what has been referred to as the microsomal ethanol oxidizing  
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Figure 2.3. The catalytic cycle of cytochrome P450 2E1 (99). 
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system (MEOS), however this was found to likely only oxidize 10 percent of the ethanol 
when compared to alcohol dehydrogenase (100).   
 
Alcohol is a major substrate for the CYP2E1 enzyme. Rats fed a Leiber-DiCarli ethanol 
based diet for 4 weeks experienced a 3-5 fold increase in CYP2E1 expression and a 2-3 
fold increase superoxide ion production (101).  A variety of metabolic or nutritional 
conditions can also induce CYP2E1 expression.  Obese rats fed a high fat diet have 
elevated CYP2E1 levels (102) and diabetic rats have increased CYP2E1 mRNA  (103), 
and this may be related to the fact that ketone bodies increase CYP2E1 expression 
 (104). Ethanol-fed rats were more sensitive to the toxic effects of the endotoxin 
lipopolysaccaride and had higher TNFα levels in plasma when compared to control rats 
 (6, 105, 106)  Although CYP2E1 is implicated in ethanol-induced oxidative damage, 
there has been some controversy in the role of CYP2E1 in alcohol induced liver injury.  
Using an intra-gastric feeding model, Thurman et al. reported that endotoxin, activation 
of Kupffer cells, and cytokines such as TNFα play the largest role in the alcohol-induced 
liver injury (107, 108). More importantly, they also reported that inhibition with 
gadolinium chloride and CYP2E1-knockout mice suggest a limited role for CYP2E1 in 
alcohol-induced liver injury (109, 110)  But using the same intra-gastric model Bardag-
Gorce et al. (111) reported that ethanol-induced oxidative stress and inactivation of the 
proteasome complex were completely prevented in these mice (CYP2E1 knock-out and 
inhibited mice). Based these findings it was concluded that CYP2E1 induction was 
  
24 
responsible for the decrease in proteasome activity and accumulation of oxidatively-
modified liver proteins. 
 
Several cell lines, such as the HepG2 E47 line, have been engineered to constitutively-
express CYP2E1 (27, 112).  Sequential exposure of E47 cells to ethanol, polyunsaturated 
fatty acids (PUFA) and iron is required to induce toxicity and lipid peroxidation in E47 
cells. Exposure to the glutathione pathway inhibitor, buthionine sulfoxamine (BSO), also 
increased toxicity in E47 cells with or without the addition of toxic enhancers (93).  
Another study found that the enhancer cocktail (ethanol, PUFA, and iron) also increased 
ROS levels in E47 cells and the amount of carbonylated proteins and detection of protein 
adducts bound to the lipid peroxidation product 4-hydroxynonenal (4-HNE) (113).  E47 
cells were found to have increased glutathione activity compared to control cells, and 
increased mRNA levels for gamma glutamyl cysteine synthetase, an enzyme involved in 
glutathione biosynthesis.  The authors of this study believed that this high-level of anti-
oxidant activity was a result of adaptation in E47 cells developed to compensate for 
persistent CYP2E1-mediated increase in oxidative stress.  HepG2 cells transduced with 
an adenovirus to express CYP2E1 also exhibited more toxicity to acetaminophen than 
non CYP2E1- expressing controls (114).  Acetaminophen is bioactivated by CYP2E1 to 
the toxic intermediate N-acetyl-p-benzoquinone imine, (NAPQI), and this intermediate 
was shown to produce protein adducts (87).   
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Overall, there is much evidence linking CYP2E1 enzyme activity to enhanced ROS 
production and oxidative stress.  It is clear that the amount of tissue and cellular injury 
caused by this oxidative stress depends on the overall metabolic and nutritional state, as 
well as the presence of toxic enhancers such as poly-unsaturated fatty acids and iron. 
These factors and their role in the induction, activity, stabilization, and degradation rate 
of CYP2E1 may account for the variability seen between different research studies.  
Research will continue on the effects of ROS generated by CYP2E1 and this will lead to 
better understanding and potential treatment of oxidative stress related damage caused 
by ethanol and other conditions. 
 
2.5. MITOCHONDRIAL FUNCTION AND REACTIVE OXYGEN SPECIES 
GENERATION 
Mitochondria are the cellular powerhouse providing to ATP energy currency used by the 
rest of the cell (31). In addition, they are involved in other processes such as signaling, 
metabolite production, cell cycle and cell death. Mitochondria are enclosed in lipid 
bilayer double membrane and have their own proteome and genome. There have been 
over 900 separate proteins reported for rat mitochondria (115), and mitochondrial DNA 
only encode for approximately 37 of them (116) with the rest being encoded in the 
nucleus. These proteins must be imported through the TIM//TOM import complex. 
Mitochondrial proteins are translocated to the outer membrane (OMM), inner membrane 
(IMM), intermembrane space, cristae or inner matrix. The number of mitochondria 
varies per cell from approximately 100 to 800 in some cells such as hepatocytes (117).  
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The production of ATP in the mitochondria requires the operation of two major 
metabolic pathways: the citric acid cycle (TCA) and the electron transport chain (ETC). 
The purpose of the TCA cycle is to produce the reducing equivalents NADH and 
FADH2, which are used by the ETC to drive ATP production. The majority of TCA 
cycle enzymes are located in mitochondrial matrix. The main input to the TCA cycle is 
pyruvate formed from glycolysis in the cytosol. Pyruvate goes through a branch point 
where the pyruvate either receives a carboxyl group from pyruvate carboxylase to enter 
the cycle as oxaloacetate or is decarboxylated by pyruvate dehydrogenase to become 
acetyl CoA as shown in Figure 2.4. This shunting of pyruvate through either path 
depends on the metabolic conditions in the cell. Generally every molecule of citrate 
exported requires a molecule of pyruvate to be converted to oxaloacetate. Fatty acid 
synthesis requires citrate and therefore a high rate of pyruvate conversion to 
oxaloacetate. Citrate is converted to aconitate and then to isocitrate by aconitase. 
Isocitrate dehydrogenase converts isocitrate to -ketoglutarate, which is converted to 
succinyl CoA by -ketoglutarase dehydrogenase.  There is evidence that -ketoglutarase 
dehydrogenase may be an important source of ROS, especially in neurons (118). 
 
Oxaloacetate and acetyl CoA are combined to form citrate by citrate synthase. Citrate 
can also be considered a product of the TCA cycle, as well as other intermediates at 
certain time. Succinyl CoA synthetase strips the CoA group to form succinate. Succinate 
dehydrogenase converts succinate to fumarase and FAD+ to FADH2.  By this action, 
succinate dehydrogenase also simultaneously participates in the ETC.  Fumarase 
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converts fumarate to malate, which is coverted to oxaloacetate by malate dehydrogenase, 
thus completing the cycle. If all the above reactions are combined, then per pyruvate 
molecule, the balanced equation (31) is  
 
Pyruvate + 4 NAD +  FAD+ + GDP + Pi + 2 H2O  
                                    4 NADH + 3H+ + FADH2 + GTP + 3 CO2                                           (1) 
 
Carbon dioxide produced from respiration is produced in the TCA cycle.  The electron 
transport chain is a series of protein complexes that uses the chemical energy in NADH 
(and to lesser extent FADH2) to drive formation of electrochemical proton gradient. The 
potential of this gradient is, in turn, used to phosphorylate ADP to ATP. The ETC is 
carried out by series of protein complex in the IMM. In contrast to the OMM, the IMM 
is not freely permeable to small molecules, so that the electrochemical gradient is 
maintained. The ETC complex are represented by Figure 2.5.   
 
ETC complex I (NADH dehydrogenase) is largest and most complicated enzyme 
complex in the ETC, consisting of 45 sub units (119). NADH dehydrogenase binds 
NADH at the flavin mononucleatide (FMN) prosthetic group and transfers two electrons 
along with two H+ ions creating FMNH2. The electrons are passed through a series of 
seven iron-sulfur sub units to a site where ubiquinone (CoQ) is reduced to ubiquinol 
(CoQH2) (119, 120).  Koopman et al. and Murphy have written excellent reviews of the 
current understanding on how mitochondria, especially the ETC complex 1 produce  
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 Figure 2.4. The citric acid cycle. 
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Figure 2.5. The electrons transport chain. 
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ROS, such as superoxide (119, 120).  The FMN group where NADH binds and the 
ubiquinone binding site mentioned above are two sites are recognized as being the most 
likely sources electron leakage and superoxide generation, primarily due to the fact they 
allow closest physical distance between oxygen and electrons extracted from NADH 
 (120, 121).   It is believed that superoxide production by ETC complex I is not constant 
but depends on the metabolic state of the cell.  Murphy has summarized three particular 
metabolic modes that are likely to affect the rate of ROS production (120): 
 Mode 1:  NADH/NAD+ ratio is high, H+ gradient is high or low, ATP 
production is low, and O2 consumption is low.  ROS generation is high 
 Mode 2: CoQH2/CoQ ratio is high, H+ gradient is high, ATP 
production is low, and O2 consumption is low.  ROS generation is high 
 Mode 3: NADH/NAD+ ratio is low, H+ gradient is low, ATP 
production is high, and O2 consumption is high.  ROS generation is low 
 
Mode 1 is a situation where low ATP demand has likely caused the NADH/NAD+ ratio 
to increase; this ratio leads to more reduced FMN, and allows for easier transfer of 
electron to O2.  Mode 2 occurs when an excess of reduced electron carriers leads to a 
highly reduced CoQ pool.  This high CoQH2/CoQ ratio in the presence of high H+ 
gradient leads to reverse electron transport (RET) back onto complex I at the CoQ 
binding site. The mechanisms underlying the subsequent generation of superoxide is not 
well understood but may be the result of electrons backing up to FMN site (120).   Mode 
3 is thought as the most normal operating mode, where the cell is consuming oxygen and 
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generating ATP.  This may also be the most significant source of superoxide over time 
because it is presumed the cell will be predominantly in mode 3, and it is not generally 
known how often or how much time is spent in modes 1 and 2 (120).   
 
ETC complex II (succinate dehydrogenase) is much smaller in comparison and couples 
the oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol. As 
mentioned this enzyme also participates in the TCA cycle. 
 
ETC complex III (cytochrome C reductase) reduces cytochrome C by oxidizing 
ubiquinol (CoQH2) back to ubiquinone (CoQ). This is coupled to moving H+ ions from 
the matrix to the intermembrane space. This process, referred to as the Q cycle (122, 
123), is a complex cycle that ultimately binds 2 ubiquinol molecules at site Q0 and 
ubiquinone molecule at site Q1 along with 2 molecules of oxidizer cytochrome C. The 
net result of the complex III cycle is the oxidation of two ubiquinol molecules to 
ubiquinone, the reduction of the ubiquinone and two cytochrome C units along with 
moving two H+ ions to the inter membrane space.  There is evidence that ETC Complex 
III is a significant source of ROS production, especially when cell is operating in what 
Murphy referred to as “mode 2” (120), where there is an excess of reduced electron 
carriers leading to highly reduced CoQ pool (124, 125).  Murphy states ETC complex 1 
likely still produces more ROS than complex 3 in mode 2, but in the “normal” operating 
mode the amount of ROS produced by complex 3 may be significant (120).  There are 
auxiliary electron carriers that make significant contributions to the reduced CoQ pool 
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besides ETC complex II (succinate dehydrogenase), such as the electron transferring 
flavoprotein (ETF). Electron transferring flavoproteins contain an FAD co-factor 
reduced during fatty acid beta oxidation. They then transfer their electrons to the CoQ 
pool via ETF:CoQ oxidoreductase (126).  
  
ETC complex IV (cytochrome C oxidase) receives a total of 4 cytochrome C units, 
removes 4 electrons from them and transfers them to an O2 molecule to form two 
molecules of water along with moving 4 H+ ions to the inter-membrane space. Complex 
IV is critical to operation of the entire ETC and is the terminal electron acceptor where 
molecular oxygen is reduced. It is inhibited by cyanide and carbon monoxide.  
 
ETC complex V (ATP synthase) is the final enzyme in the oxidative phosphorylation 
pathway (31). This enzyme is ubiquitous to all forms of life and functions the same way, 
by using potential energy from the protein gradient generated by the rest of the ETC. 
Three to four protons are estimated to be required to form one molecule of ATP. 
 
2.6. REACTIVE OXYGEN SPECIES, LIPID PEROXIDATION AND 
PROTEIN MODIFICATION  
The biological formation of reactive oxygen species (ROS) and their subsequent effect 
on biological systems has garnered much interest.  A state of oxidative stress exists when 
effects of ROS begin to overwhelm cellular antioxidant and repair mechanisms.  Almost 
all organisms rely on the use of oxygen as final electron acceptor to drive the energetic 
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processes necessary for life, but doing so efficiently is not simple. Biological systems 
typically use oxygen by binding it to a metal atom such as iron.  The iron is complexed 
in an organic prosthetic group, such as heme, which in turn, is part of a larger protein, 
i.e., hemoglobin (31). The oxygen can only bind to iron when it is in the +2 state, and 
after binding iron, it is considered to be in the +3 state. More importantly, the bound 
oxygen is considered to be in the superoxide (O2-) form (31, 127).  Because of the 
unpaired electron, this bound superoxide has inherent degree of instability (99), and a 
certain fraction of this bound superoxide can decouple from the iron (as shown in the 
P450 catalytic cycle in the previous section Fig. 2.3) (99, 128, 129).  The superoxide ion 
is considered to be the most abundant ROS in biological systems, even though precise 
measurement of concentrations in vivo remains difficult (99, 119, 120, 130).  Evidence 
for the toxicity of superoxide is given by the fact that in most cells there are three forms 
of the enzyme superoxide dismutase (90), which catalyze the reaction of superoxide to 
hydrogen peroxide and oxygen. 
         (2) 
The largest source of superoxide ion is considered to be ETC complex I (NADH 
dehydrogenase) in the mitochondria (99, 119, 120, 130).  ETC complex III (cytochrome 
c reductase) is also a source for superoxide ions and the relative amounts produced at 
each site is likely dependent on the metabolic and redox state of the cell (120, 124). 
Complex III is also considered important because it can produce superoxide on both 
sides of the inner mitochondrial membrane (124).  Complexes I and III do not bind 
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oxygen as part of their catalytic function; superoxide is believed to formed by electron 
leakage occurring at certain sites and directly reducing a nearby oxygen molecule to 
form the superoxide ion (120).    
 
Other major sources of superoxide ions include members of the cytochrome P450 mono-
oxygenase family such as CYP2E1 that has been discussed in the previous section.  Up 
to now sources of superoxide have been categorized as more or less accidental 
byproducts of catalytic processes.  However, the specific purpose of NADPH oxidase is 
to produce superoxide, and it is primarily expressed by white blood cells as part of 
immune defense.  The purpose of this superoxide is to attack and kill bacteria, this is 
known as the respiratory burst (131).  However, infiltration and accumulation of white 
blood cells is implicated in several chronic disease such as arthrosclerosis (132) and 
alcoholic steatohepatitis (77), and the ROS produced by NADPH oxidase from white 
blood cells is significant in these conditions.   
  
While superoxide itself is toxic and found to deactivate iron-sulfur centers of some 
proteins like acconitase (130), it also is catalyzed into other ROS.  Superoxide is also 
catalyzed into H2O2 by superoxide dismutase, and H2O2 is detoxified by catalase, as 
shown below.  
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          (3) 
When hydrogen peroxide encounters a metal ion such as iron it can participate in Fenton 
chemistry, to form the extremely reactive hydroxyl radical (HO*), as shown below. 
                          
The hydroxyl radical has an oxidation potential of 2.9 V, second only to fluorine, and an 
estimated half-life of 10-9 seconds (119), essentially reacting with any molecule it 
encounters.  Catalase contains a heme center has been found vulnerable to modification 
by ROS (133). In addition to forming the hydroxyl radical, superoxide has been shown 
to form other ROS (90), hypochlorous acid (HOCl) (134), and peroxynitrite (ONOO-) 
 (135).  ROS can damage all classes of biomolecules: fatty acids, proteins, and nucleic 
acids (129).   
  
Because ROS has short half-lives and rapid turnover, accurate measurement of them is 
difficult if not impossible (119, 120, 130); therefore, many researchers have chosen to 
study the effects of ROS on biomolecules. Measurement of the type and extent of ROS-
mediated modifications have been used as markers for oxidative stress (1, 11).  DNA is  
 
 
 
 
(4) 
(5) 
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vulnerable to ROS, and amount of oxidized deoxyguanosine (8-Oxo-2'-deoxyguanosine) 
has been used as measure of oxidative stress in a mouse model (136).  Lipids are subject 
to oxidative attack by ROS and this can initiate systematic chemical deterioration of 
unsaturated fatty acids known as lipid peroxidation (137, 138).  The chemical 
mechanism of lipid peroxidation and the formation of the peroxidation end product 4-
hydroxynenal are shown in Figures 2.6 and 2.7.  Proteins are subject to oxidative 
modifications by ROS and types of modification fall into two broad categories: 
reversible and irreversible (1, 89).  Reversible oxidative protein modifications can occur 
spontaneously when ROS contact a vulnerable site of protein, or can be enzyme 
mediated.  In either case they can be reversed by enzymatic action (1), and reversible 
oxidative protein modifications are shown in Table 2.2. Nitrosylation and sulfination 
occur spontaneously, but glutathiolation and disulfide cross-linking are enzymatically 
mediated (1). In many cases reversible modifications are involved in cell signaling, or 
may actually protect residues from a permanent modification (1, 139).   
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Figure 2.6. The chain reaction of lipid peroxidation (138). 
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Figure 2.7. Formation of 4-HNE  (138). 
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Table 2.2. Reversible and irreversible protein modifications. 
 
 
Glutathiolation R-SH + GSH → -RS-SG
Nitrosylation  R-SH + NO → -RS-NO
Disulfide cross-linking  R-SH + R-SH → -RS-SR-
Sulfination -SH + (ROS) →  (-SOH)
Nitration R-SH + (ONOO
-
) →  (R-NO2)
Sulfonation –SH + (ROS) →  (-SO3H)
Direct oxidation of amino acid side chains (Lys, Arg, Pro, and Thr)
Cleavage of polypeptide backbone by a-amidation or oxidation of Glu residues
Addition of oxidized sugars to free amine of lysine residues (AGE’s)
Addition of lipid peroxidation products, such as 4-hydroxy nonenal (4-HNE) to Lys, Cys or His residues
Carbonylation
Reversible Modifications
Irreversible Modifications
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Irreversible protein modification results in permanent damage to a protein (Table 2.2, 
lower) , and if it causes change in conformation or loss of function, these proteins are 
degraded and re-synthesized, as these modifications are highly disruptive to cells (1, 89). 
Nitration and sulfonation tend to disrupt active sites because they modify tyrosine or 
sulfur containing residues (140, 141).  The last major class of irreversible class of 
protein modification is protein carbonylation, which is encompasses a variety of 
spontaneous chemical reactions the result in the non-enzymatic covalent addition of a 
carbonyl group to a protein (1, 89).  Protein carbonylation has been used a biomarker for 
oxidative stress in numerous studies (10, 113, 142, 143).  Four major classes of reactions 
have been described that result in the covalent addition of a carbonyl group to a protein 
 (1).  Direct oxidation of amino acid side chains (Lys, Arg, Pro, and Thr) by hydroxyl 
radical mediated reactions has been detailed by Stadtman (144).  In addition, cleavage of 
the polypeptide back-bone by -amidation or oxidation of Glu residues has also been 
studied (139, 144, 145).  In either of these cases the end of reaction process results in the 
creation of aldehyde groups.   Sugars such as glucose or mannose can be oxidized so that 
they form an aldehyde group.  This sugar-aldehyde can bind to a primary amine, forming 
a Schiff base (146).  When this reaction involves the primary amine of a lysine, this is 
referred to as the Maillard reaction and these products are referred to as advanced 
glycation end products (AGE) (147, 148).  A fourth method of carbonylated protein 
occurs by the addition of lipid peroxidation products, such as 4-hydroxynonenal (4-
HNE) to Lys, Cys or His residues (1, 10, 128), as shown in Figure 2.8, and currently, 4-
HNE is a highly studied carbonylation source.   
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Figure 2.8. The Michael addition of 4-HNE. 
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CHAPTER III  
PROTEOMIC ANALYSIS OF 3T3-L1 ADIPOCYTE MITOCHONDRIA 
DURING DIFFERENTIATION, MATURATION, AND ENLARGEMENT 
 
3.1. OVERVIEW 
The increase in adipose tissue mass arises in part due to progressive lipid loading and 
triglyceride accumulation in adipocytes. Enlarged adipocytes produce the highest levels 
of pro-inflammatory molecules and reactive oxygen species (ROS). Since mitochondria 
are the site for major metabolic processes (e.g., TCA cycle) that govern the extent of 
triglyceride accumulation as well as the primary site of ROS generation, we 
quantitatively investigated changes in the adipocyte mitochondrial proteome during 
different stages of differentiation and enlargement. Mitochondrial proteins from 3T3-L1 
adipocytes at different stages of lipid accumulation (days 4 through 18) were digested 
and labeled using the iTRAQ 8-plex kit. The labeled peptides were fractionated using a 
liquid phase isoelectric fractionation system (MSWIFT) to increase the depth of 
proteome coverage, and analyzed using LC-MS/MS.  A total of 398 mitochondrial 
proteins, including endoplasmic reticulum-associated mitochondrial proteins, were 
identified and classified into 12 functional categories. The identified proteins included 
enzymes and transporters involved in the TCA cycle, fatty acid oxidation, and ATP 
synthesis.  Our results indicate that cultured adipocytes enter a state of metabolic-
overdrive where increased flux through the TCA cycle and increased fatty acid oxidation 
occur simultaneously.  The proteomic data also suggest that accumulation of reduced 
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electron carriers and the resultant oxidative stress may be attractive targets for 
modulating adipocyte function in metabolic disorders. 
 
3.2. INTRODUCTION 
Obesity is a risk factor in the development of cardiovascular disease, stroke, cancer and 
type II diabetes (41). Obesity arises from an imbalance in energy metabolism, wherein 
the intake of energy exceeds the energy expenditure for extended periods of time (41, 
149). The excess energy is stored in adipocytes, which are the main constituents of white 
adipose tissue (150), as triglycerides, and as a result, there is a significant expansion in 
the mass of white adipose tissue. The increase in adipose tissue mass can occur through 
either an increase in the number of adipocytes (hyperplasia) or an increase in the size of 
existing individual adipocytes (hypertrophy). While hyperplasia involves the recruitment 
of recruitment, proliferation and differentiation of precursor preadipocytes, hypertrophic 
enlargement, arises due to the increase in the lipid content in adipocytes. A number of in 
vivo studies (151-153) support a “critical fat cell size” hypothesis, where recruitment of 
new fat cells occurs when adipocytes reach a threshold critical size (154).  This 
hypothesis is also consistent with observations that suggest that an increase in the size of 
the mature adipocytes usually precedes the proliferation of precursor cells, and 
adipocytes do not have an unlimited capacity for expansion in size (44, 155).  The 
presence of hypertrophic adipocytes has been correlated with type II diabetes (156) as 
well as abnormal levels of pro-inflammatory molecules such as cytokines (interleukin-6, 
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interleukin-8) and leptin (44). Together, these studies underscore the importance of 
hypertrophic enlargement of adipocytes in obesity and its associated disorders.  
 
Obesity has also been strongly correlated with increased oxidative stress.  Furukawa et 
al., found elevated levels of the oxidative stress marker malondialdehyde in the plasma 
and white adipose tissue of obese mice (12).  Kobayashi et al., reported that activity of 
the anti-oxidant enzyme glutathione peroxidase was reduced 40 percent in obese mice, 
with a corresponding increase in gamma glutamylcysteine which is used in de novo 
synthesis of glutathione (51). These authors also reported that 3T3-L1 adipocytes 
demonstrated reduced insulin signaling after exposure to hydrogen peroxide or GPX 
inhibitor. 3T3-L1 adipocytes were also shown to have increased reactive oxygen species 
(ROS) generation during the differentiation process and through 8 days of culture (12) 
and 8-day old 3T3-L1 adipocytes had higher ROS levels and lower GPX activity when 
compared to pre-adipocytes (51). These studies illustrate the correlation between lipid 
accumulation and oxidative stress.   
 
Mitochondria are the major source of ROS in the cell (157). It has been suggested that 
mitochondrial dysfunction caused by oxidative damage contributes to insulin resistance 
 (158, 159). An increase in glucose levels and free fatty acids (FFA) increases 
mitochondrial ROS levels. While low levels of ROS are important in several cellular 
processes, including signaling and gene expression (157, 158)  elevated levels of ROS 
due to increased production or incomplete removal by the cellular anti-oxidant 
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machinery, can damage DNA, protein, and lipids. Numerous studies have correlated 
oxidative stress with the etiology of insulin resistance (160, 161), diabetes (162, 163), 
and cardiovascular disease. Indeed, levels of enzymes and anti-oxidants involved in ROS 
scavenging (superoxide dismutase and catalase, the enzymes involved in superoxide 
radical removal, vitamin E) are all reduced during diabetes (164, 165). 
 
Because mitochondria are the site of metabolic processes that govern the extent of 
triglyceride accumulation, such as the TCA cycle and fatty acid oxidation, as well as a 
major source for ROS generation, we investigated the changes in adipocyte 
mitochondrial proteome during adipocyte differentiation and lipid loading-driven 
enlargement. While Molina et al. (15) characterized the 3T3-L1 adipocyte nuclear 
proteome and secreted proteome during differentiation (through day 7) using SILAC, 
and Cho et al. (26) studied changes in the mitochondrial proteome in isoproternol-treated 
adipocytes at a single time point, a quantitative study of the temporal dynamics of the 
3T3-L1 adipocyte mitochondrial proteome during differentiation and lipid loading-
driven enlargement has not been previously reported. Here, we report the quantitative 
profiling of the mitochondrial proteome at different stages of differentiation and 
enlargement – from undifferentiated adipocytes to young and mature adipocytes to 
enlarged adipocytes. A multiplex strategy using iTRAQ labeling was coupled with 
mitochondrial protein isolation and liquid-phase isoelectric focusing to quantitatively 
monitor proteome changes underlying increased lipid loading and oxidative stress in 
3T3-L1 adipocytes.   
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3.3. MATERIALS AND METHODS 
3.3.1. Reagents and Supplies 
Cell culture media and reagents were purchased from Hyclone (Logan, UT).  All 
reagents for mitochondrial protein extraction were purchased from Fisher Scientific 
(Hampton, NH).  Mammalian protease inhibitor cocktail was purchased from Sigma-
Aldrich (St. Louis, MO). The iTRAQ kit and reagents were purchased from Applied 
Biosystems (Foster City, CA). 
 
3.3.2. Adipocyte Cell Culture 
3T3-L1 preadipocytes (166) were routinely cultured to confluence in DMEM growth 
medium supplemented with calf serum (10%, v/v), penicillin (200 U/ml), and 
streptomycin (200 g/ml). During this period, medium was replenished every other day.  
Preadipocytes were subcultured in 10 cm dishes for mitochondrial protein extraction and 
12-well plates for biochemical assays as previously described (167). Cells were cultured 
for an additional 24 h after reaching confluence, and this time point was designated as 
day 0 (i.e., prior to differentiation). Differentiation of preadipocytes to adipocytes was 
induced as described earlier (167, 168). After the induction of differentiation, media was 
replenished every other day for the duration of the experiment.   
 
3.3.3. Mitochondrial Protein Isolation  
Mitochondrial proteins were isolated from three 100 mm dishes at each time point - days 
0 (i.e. undifferentiated preadipocytes), 4, 7, 10, 14, and 18 days post-differentiation – by 
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differential centrifugation (169).  Briefly, cells were washed twice with phosphate 
buffered saline, and 3 mL of 0.1X isolation buffer (3.5 mM Tris-HCl, pH 7.8, 2.5 mM 
NaCl, 0.5 mM MgCl2 with 0.3% v/v mammalian protease inhibitor (PI) cocktail) was 
added to each 10 cm dish. After 10 min incubation at room temperature, cells were 
scraped off the dish and centrifuged at 300 × g for 10 min at 4oC. This resulted in any 
undifferentiated (heavier) preadipocytes settling at the bottom, while the adipocytes 
(lighter) were in the supernatant. The supernatant was then lysed by passing through a 
27.5 gauge needle.  Three ml of 10X hypertonic buffer (0.35 M Tris-HCl, pH 7.8, 0.25 
M NaCl, 0.05 M MgCl2) was added to the lysed cells and the lysate was centrifuged at 
200 × g for 3 min at 4°C to pellet the nucleus.  The supernatant was transferred to 
another tube and centrifuged again at 200 × g for 3 min to remove any residual nuclear 
material or cellular debris.  The supernatant was centrifuged at 13000 × g for 10 min at 
4ºC and the pellet was washed with 100 l 1X hypertonic buffer (0.035 M Tris-HCl, pH 
7.8, 0.025 M NaCl, 0.005 M MgCl2, supplemented with 0.3% v/v PI cocktail and 1 mM 
tris-(2-carboxyethyl)-phosphine, TCEP). 
 
Supernatants containing mitochondrial proteins from the triplicate dishes were pooled, 
and the sample was centrifuged at 13000 × g for 10 min and the pellet was resuspended 
in 250 l homogenization buffer A (320 mM sucrose, 1 mM EDTA, 10 mM Tris-HCl, 
pH 7.4) supplemented with PI (0.3% v/v) and TCEP (1 mM).   The sample was 
centrifuged at 13000 × g for 1 min and the pellet resuspended in 250 l homogenization 
buffer B (25 mM sucrose, 95 mM sorbitol, 100 mM KCl, 0.05 mM EDTA, 5 mM 
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MgCl2, 10 mM H3PO4, 10 mM Tris-HCl, pH 7.4) supplemented with PI (0.3% v/v) and 
TCEP (1 mM).  The sample was then centrifuged at 1600 × g for 2 min to pellet down 
any residual debris, and the supernatant centrifuged at 13000 × g for 1 min to collect the 
mitochondrial pellet.  The pellet was resuspended in 100 l homogenation buffer B 
supplemented with PI (0.3% v/v) and TCEP (1 mM) and heated at 95ºC for 20 minutes 
to lyse the mitochondria.  Mitochondrial samples were stored at -80ºC until further use. 
 
3.3.4. iTRAQ Labeling of Mitochondrial Proteins 
Mitochondrial proteins were quantified using Pierce 660 nm Protein Assay Reagent 
(Pierce, Rockford, IL) and precipitated with cold acetone to remove tris, salts, and 
protease inhibitors, as described in the iTRAQ kit protocol.  The protein pellet was then 
resuspended in solubilization buffer (1M 1-(3-Sulfopropyl) pyridinium betain (NDSB-
201), 0.05 wt% SDS, 25 mM HEPES, pH 8.0) supplemented with TCEP (1 mM).  The 
NDSB-201 was used as it yielded best protein solubilization and was fully compatible 
with downstream fractionation steps (not shown).  The resuspended mixture was placed 
on ice and sonicated twice with a Model 60 sonic dismembrator (Fisher Scientific) at a 
setting of 4 W for 15 sec.  The sample was then incubated at 60ºC for 45 minutes.  
Protein concentrations were again determined using the Pierce 660 nm Protein Assay 
Reagent. Typical protein recovery yields were between 70 and 90 percent.   
 
Equal amounts of mitochondrial proteins were digested with trypsin prior to labeling 
with the iTRAQ reagents.  One l of cysteine blocking reagent, methyl methane-
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thiosulfonate (MMTS) (supplied with the iTRAQ kit, Applied Biosystems, Foster City, 
CA) was added to 100 g of protein, and incubated 10 minutes at room temperature.  
The cysteine blocked sample was combined with 1.2 g of sequencing grade trypsin 
(K/R cleavage) (Promega Corp., Madison, WI) and CaCl2 (5mM).  Protein digestion was 
conducted by placing the sample containing tube in a shaker at 37ºC for 8 hours, 
followed by addition of another 1.2 g of trypsin and incubation for another 8 hours. 
 
Trypsin-digested mitochondrial proteins were labeled with iTRAQ reagents from the 
iTRAQ 8plex Kit (Applied Biosystems) according to the manufacturer’s instructions.  
Reagents 113, 115, 117, 118, 119, and 121 were added to samples T0, T4, T7, T10, T14, 
and T18 respectively, which correspond to mitochondrial protein samples from days 0, 
4, 7, 10, 14, and 18 days post-differentiation.  Sample T0 corresponds to undifferentiated 
pre-adipocytes.  Labeled samples were stored at -80ºC until further use. 
 
3.3.5. Liquid Phase Isoelectric Point Fractionation 
The design, assembly and operation of the in-house isoelectric trapping device called 
“membrane separated wells for isoelectric focusing and trapping” (MSWIFT) have been 
previously described (170, 171).  Prior to separation, alumina separation wells were 
assembled serially to contain six separation wells.  The anode solution was 3 mM 
methanesulfonic acid and 3 mM sodium hydroxide was used as the cathode buffer.  
Compartment solutions were pH biased using ampholytic buffers (172) and tunable pH 
buffering membranes were synthesized in-house, as previously described (173-176).  
   
50 
5
0
 
The pH values of the buffering membranes were as follows:  2.9, 4.2, 5.4, 6.8, 7.5, 9.5 
and 11.0.  The digested sample was loaded in the fourth separation well (pH 6.8-7.5) and 
separated at 5 W constant power (upon reaching constant current) for one hour. 
Solutions obtained from each fraction were stored at -80◦C until further use.  
 
3.3.6. Liquid Chromatography (LC) and Tandem Mass Spectrometry (MS/MS)  
A 40 µL aliquot from each MSWIFT fraction was acidified with trifluoroacetic acid to 
pH ~ 2 and concentrated two-fold.  The concentrated sample was then injected (10 µL) 
onto an 150-µm x 15 cm column (Vydac) using an LC-Packings autosampler and pumps 
(LC Packings, Sunnyvale, CA) equipped with robotic spotting (ProBot, Dionex, 
Sunnyvale, CA), as previously reported (177). The LC gradient used for all samples 
spanned 2-60% (solvent B, 85% ACN, 5% IPA, 0.1% TFA) over 90 minutes.  The 
effluent was mixed with the matrix-assisted laser desorption/ionization (MALDI) matrix 
(7 mg mL-1 α-cyano-4-hydroxycinnamic acid, 60% ACN, 10% IPA, 10 mM dihydrogen 
ammonium phosphate) and a total of 840 spots were obtained per sample.  Positive ion 
MALDI-MS data was acquired using a model 4800 Proteomics Analyzer (Applied 
Biosystems, Foster City, CA).  The 30 highest intensity peaks (S/N >50) per spot were 
fragmented using collision induced dissociation and resulting tandem MS data were 
searched against the mouse genome database integrated in the Celera Discovery System 
(CDS, KBMS5.0, release date 03/02/2005, 115660 sequences) (178) using ProteinPilot 
software version 3.0 (Revision 114732) with the ParagonTM algorithm version 3.0.0.0 
37 (Applied Biosystems, Foster City, CA). Peak lists were generated via the ProGroup 
   
51 
5
1
 
Algorithm built into the ProteinPilot software.  The following modifications were 
included in the “thorough” database search: iTRAQ label (8-plex, peptides N-terminus 
and lysine), MMTS modification on cysteine residues and trypsin cleavage. Details 
regarding cleavage specificity, modifications and mass tolerance threshold were as 
previously described for the Paragon Algorithm (179). 
 
Protein quantitation values were calculated by taking the ratio of peak area of the 
iTRAQ labeled signal to the baseline label peak area.  Protein quantitation values are an 
average value of the highest confidence peptides as selected by the ProteinPilot 
Software.  Bias correction was performed using the ProGroup AlgorithmTM to correct 
for bias associated with systematic error.  Peptides with quantitation data that was blank, 
zero or 9999 were excluded as these were classified as discordant by the ProteinPilot 
software and p-values could not be calculated.  Proteins satisfying three criteria – (i) a 
ProtScore of at least 1.3 (corresponding to a  ≥ 95% CI), (ii) two peptides with unique 
sequences that were not discordant and in which one had a minimum confidence interval 
≥ 95% (180), and (iii) a measurable quantitation peak from the associated iTRAQ label 
across all 6 time point samples (i.e., present at all time points) - were chosen for 
analysis.  The global false discovery rate (FDR) was calculated using the PSPEP tool 
and a decoy database in the ProteinPilot Software package.  The initial 398 protein 
identifications correspond to an estimated FDR of ~8 percent at the protein level using a 
standard q-value approach as previously described (181). However, the lowest ranked 
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protein discussed in the text and presented in the figures on pages 60 and 62 and the 
tables on pages 64 and 68 has a rank of 314, which corresponds to a FDR of < 5 percent.   
 
Data generated from two independent iTRAQ labeling and MS runs were used as 
follows. Fold-change in protein expression at each time point was calculated relative to 
the corresponding expression value in preadipocytes (T0). Proteins that demonstrated a 
statistically-significant (p ≤ 0.05) change in expression (i.e., a change that has a 95 
percent probability of not being the result of chance) on both MS data sets were 
identified as being differentially expressed. Peptides from proteins that were identified 
as differentially expressed in replicate iTRAQ and MS experiments were used for 
determining the average fold-change in expression. The fold-change was calculated only 
using peptides that were common to each protein in the two data sets. In other words, 
although multiple peptides may have been used in the replicate runs for protein 
identification, fold-change quantitation was based only on common peptides between the 
two datasets. This data was presented in the figures on pages 60 and 62 and the tables on 
pages 64 and 68. The identified proteins, their quantitation ratios and the number of 
peptides as calculated by ProteinPilot are found in Supplemental Table S1.   
 
3.3.7. Adipocyte Triglyceride Assay 
Adipocyte triglyceride content was determined using the Adipored ™ assay reagent 
(Lonza, Walkersville, MD) according to the manufacturer’s instructions.  Measurements 
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were made in triplicate and the readings normalized to the corresponding cellular protein 
levels, which was determined using the Bradford assay (BioRad, Hercules, CA).  
 
3.3.8. ROS Production in 3T3-L1 Adipocytes 
Adipocyte ROS generation was measured by the reduction of nitro blue tetrazolium 
according to the method of Rook et al. (182).  The NBT assay indicates presence of the 
superoxide ( •2O
 ) ion by the reduction of yellow nitroblue tetrazolium to a dark blue 
formazan compound.  Cells were incubated for 90 minutes followed by rinsing and 
fixing with 10% v/v formalin in PBS. Formazan levels were normalized to the cellular 
protein content, as determined using the Bradford assay (BioRad). 
 
3.3.9. ATP Assay 
Cellular ATP was measured using a luminescence assay kit (Promega, Madison, WI) 
that is based on the ATP-dependent activity of luciferase. ATP levels were normalized to 
the corresponding sample protein content, which was determined using the Bradford 
assay (BioRad). 
 
3.4. RESULTS 
We report changes in the adipocyte mitochondrial proteome during differentiation, post-
differentiation maturation, and lipid loading-driven enlargement.  In order to decrease 
sample complexity and observe organelle-specific changes in protein expression, 
mitochondria were isolated from adipocytes and used for proteome analysis.  Tryptic 
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peptides from the mitochondrial proteins were also fractionated using a liquid phase 
isoelectric point separating device, MSWIFT (170) to increase the depth of proteome 
coverage.  The proteomics strategy used is shown in Figure 3.1. 
 
The hallmark of adipocyte differentiation and hypertrophy are the formation and 
enlargement of intracellular lipid droplets. Figure 3.2A-F shows transmitted light 
micrographs of adipocytes at different stages of differentiation, from undifferentiated 
preadipocytes with no lipid droplet (Fig. 3.2A) to mature adipocytes with normal sized 
droplets (Fig. 3.2D) and enlarged adipocytes with lipid droplets occupying on average ~ 
70 percent of the cell volume (Fig. 3.2F). Quantification of TG accumulation (Fig. 3.2G) 
shows that TG levels increase rapidly in adipocytes from day 4 though day 10, with a 
slower rate of increase observed beyond 10 days post-differentiation.  
 
A total of 398 mitochondrial proteins, including endoplasmic reticulum-associated 
mitochondrial proteins, were identified and quantified using the identification criteria 
described in Materials & Methods, and represented ~60 percent of the total identified 
proteins  (Figure 3.3A) and ~ 69 percent of identified peptides.  The 398 proteins were 
also sorted into 12 functional categories (Figure 3.3B) using the protein ontology 
information in the UniprotKB / Swiss-Prot database (http://www.uniprot.org/uniprot/) 
and scientific literature available at PubMed (http://www.ncbi.nlm.nih.gov/protein/).  
Broadly, these categories reflected changes that represent enhanced metabolic flux 
through the TCA cycle and fatty acid oxidation pathway.  The TCA cycle (8%), fatty 
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Figure 3.1. Flowchart for quantitative characterization of the mitochondrial 
proteome during adipocyte differentiation and lipid loading-driven enlargement. 
Mitochondria from three independent culture dishes were pooled for each time 
point. Two independent iTRAQ labeling and MS identification runs were 
performed. 
   
56 
5
6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Lipid accumulation in adipocytes. Representative transmitted light images of 
A) preadipocytes, and B) adipocytes at different stages of differentiation and 
enlargement – day 4, C) day 7, D) day 10, E) day 14, F) and day 18 – are shown. The 
lipid levels at the different time points were also quantified using the G) AdipoRed assay 
and normalized to the preadipocyte lipid levels. Data shown are mean ± standard 
deviation from three independent experiments. 
G 
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Figure 3.3. Classification of proteins by cellular location A) and function B). 
Mitochondrial proteins identified using the scheme described in Materials & Methods were 
classified using the protein ontology information provided in the UniprotKB/Swiss-Prot 
database (www.uniprot.org/uniprot), and scientific literature available at PubMed 
(www.ncbi.nlm.nih.gov/protein).   
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acid metabolism (11%), electron transport and ATP synthase complexes (10%), and 
antioxidant and detoxification (4%) categories accounted for 33 percent of the proteins 
that were identified (Fig. 3B). Changes in these major pathways are described below. 
 
3.4.1. The Citric Acid Cycle   
Sixteen enzymes involved in the TCA cycle were significantly up-regulated at different 
time points post-differentiation. Figures 3.4A & B show changes in the expression of 
enzymes involved in the TCA cycle and pyruvate handling. Pyruvate dehydrogenase 
(PDHA1) and pyruvate carboxylase (PCB), which allows pyruvate to enter the TCA 
cycle as acetyl-CoA, and extends it by one carbon and allows its entry into the cycle as 
oxaloacetate, respectively, were two of the enzymes that were significantly up-regulated 
by 2.7 to 2.9-fold from days 7 through 18.  These two enzymes allow proper balance of 
the substrates for citrate synthase (CS), which combines oxaloacetate and acetyl-CoA 
into citrate and is considered the overall rate limiting step for the TCA cycle (183).  Our 
data show that the expression of CS was also progressively up-regulated from days 4 to 
18 by 1.8 to 2.9-fold. Aconitase (ACO2) and isocitrate dehydrogenase (IDH) catalyze 
the next several cycle steps, converting citrate to aconitate, then to isocitrate and 
oxalosuccinate, and finally to -ketoglutarate.  The levels of ACO2 increased by 2.6 to 
3.4-fold from days 10 through 18 while IDH demonstrated a moderate (45 – 56%), but 
constant, increase in expression from day 7 to day 18.   
 
   
59 
5
9
 
TCA cycle enzymes downstream of ACO2 and IDH, including succinyl CoA lygase 
alpha (SUCLG1), that catalyzes the conversion of -ketoglutarate to succinyl CoA, was 
also significantly up-regulated on days 14 (1.5-fold) and 18 (1.7-fold).  The oxoglutarate 
dehydrogenase complex E2 (ODO2), succinate dehydrogenase (SDHA and SDHB), 
which catalyzes the formation of fumarate from succinate, fumarate hydratase, which 
converts fumarate to malate, and malate dehydrogenase (MDH2), which catalyzes the 
final conversion of malate to oxaloacetate, all demonstrated statistically significant 
increases in expression at different time points (Figs. 3.4A &B and Supplemental Table 
S1), which suggests increased flux through the TCA cycle. In addition to the TCA 
enzymes, the citrate transporter (CTP) and the mitochondrial dicarboxylate transporter 
(DIC) also were increased in expression on day 10 (2.8-fold) and day 7 (3.1-fold), 
respectively, and were consistently up-regulated at a high expression level until day 18 
(maximum fold change of 3.3-fold and 4.2-fold, respectively for CTP and DIC).  
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Figure 3.4. Changes in the expression of enzymes involved in the TCA cycle. A) 
Proteins whose expression was significantly altered (p ≤ 0.05) at any one of the time 
points, are indicated on the TCA cycle schematic. The schematic was drawn based on 
Lehninger Principles of Biochemistry (31).  B) The protein expression at different time 
points is represented as a heat map.  Statistically significant quantitative changes are 
based on the ratio of the average iTRAQ label peak area between duplicate experiments 
for each day relative to day 0 (undifferentiated pre-adipocytes). Fold increase is 
represented as red, while fold-decreases are in green as indicated by the vertical color vs. 
fold change legend.  Values appearing colorless were not determined to have a 
statistically-significant fold change. Data shown are average values from duplicate 
iTRAQ experiments. 
A B 
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3.4.2. Fatty Acid Metabolism 
Figures 3.5A & B schematically show changes in the enzymes involved in the 
mitochondrial import of fatty acids and their subsequent breakdown via beta-oxidation.  
Seven enzymes involved fatty acid metabolism were up-regulated in adipocytes during 
differentiation and enlargement. Acyl-CoA synthetase (ACSL1), the mitochondrial 
membrane protein that catalyzes activation of free fatty acids by combining them with 
CoA and preparing them for import by sterol carrier protein 2 (SCP2), was up-regulated 
at all time points during differentiation and enlargement, with the maximal up-regulation 
(6.9-fold) being observed at day 7 post-differentiation followed by a slight decrease to 
5.5-fold increase in expression at day 18. The expression of cartinine acyltransferase 
(CAT), which attaches cartinine to the acyl molecule in the inter membrane space, 
increases to a maximal level of 3.2-fold on day 14, and was slightly decreased (3.2-fold) 
at days 18.    
 
Enzymes that convert the trans-2-Enoyl CoA to hydroxyl CoA, the hydroxyl short chain 
enoyl-CoA hydratase (ECHS1) was also significantly up-regulated in expression (3.1 to 
4.3-fold) from day 10 to day 18.  The enzyme that dehydrogenates the hydroxyl group to 
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Figure 3.5. Changes in the expression of enzymes involved in the fatty acid metabolism. 
A) Proteins whose expression was significantly altered (p ≤ 0.05) at any one of the time 
points, are indicated on the fatty acid import and beta-oxidation pathway schematic. 
Intermediates are denoted in bold.  The schematic was drawn based on Lehninger 
Principles of Biochemistry (31). B) The protein expression at different time points is 
represented as a heat map Statistically significant quantitative changes are based on the 
ratio of the average iTRAQ label peak area between duplicate experiments for each day 
relative to day 0 (undifferentiated pre-adipocytes). Fold increase is represented as red, 
while fold-decreases are in green as indicated by vertical color vs. fold change legend.  
Values appearing colorless were not determined to have a statistically-significant fold 
change. Data shown are average values from duplicate iTRAQ experiments. 
A B 
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a keto group, hydroxyacyl-coenzyme A dehydrogenase (HADHA), was increased 1.9-
fold at day 7 and increased to 2.9-fold by day 18.  Similarly, beta-ketothiolase 
(HADHB), which catalyzes the removal of an acetyl group from acyl chain, was also 
increased in expression from 2.3-fold on day 10 to 3.0-fold on day 18. The acetyl-CoA 
generated during beta oxidation primarily enters the TCA cycle, but is also available as a 
substrate for acetyl-CoA acetyltransferase (ACAT1), which is the first step in the 
formation of acetoacetone and other ketone bodies (134). The expression of this enzyme 
increased 3.3-fold on day 10 and increased to 3.8-fold by day 18.  
 
3.4.3. Electron Transport Chain and ATP Synthase 
Proteins that are part of electron transport chain complexes II, and IV and V were 
differentially expressed (Table 3.1). Two proteins in complex II, which transfers 
electrons from succinate to CoQ via FADH2 and is not explicitly linked to transfer of 
protons across the inner membrane, were up-regulated during differentiation and 
enlargement. The expression of succinate dehydrogenase A (SDHA) was significantly 
increased by 2.4-fold at day 10 and increased to 2.5-fold by day 18. The expression of  
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Table 3.1. Temporal profile of mitochondrial electron transport chain and auxiliary 
electron carrier enzymes during 3T3-L1 adipocyte differentiation and enlargementa. 
 
Protein Name Accession  iTRAQ Label Quantitation Ratios 
  Day 4 Day 7 
Day 
10 
Day 
14 
Day 
18 
NADH-ubiquinone 
oxidoreductase 51 Q91YT0    1.4  
Electron transferring 
flavoprotein, alpha  Q99LC5   2.5 3.0 3.1 
Electron transferring 
flavoprotein, beta Q810V3    2.4 2.7 
ETF-ubiquinone 
oxidoreductase Q921G7   2.4 2.3 2.8 
Succinate dehydrogenase, 
alpha Q921P5   2.4 2.6 2.5 
Succinate dehydrogenase, 
beta Q9CQA3     1.8 
cytochrome C oxidase unit 6 Q9CPQ1 1.5     
cytochrome C (somatic) P62897    3.3  
ATP synthase alpha chain Q03265 1.5 1.9 2.3 2.2 2.2 
ATP synthase beta chain Q8CI65  1.8 2.3 2.1 2.3 
ATP synthase oligomycin 
sensitivity protein Q9DB20   2.3 2.3  
ADP,ATP carrier protein 2 P51881  3.2 4.3 4.0 3.8 
Phosphate carrier protein Q8VEM8   1.9   
 
a Statistically significant fold increase is represented as red while fold-decreases are in 
green.  White indicates that the change in expression was not statistically-significant.  
Other electron transport chain proteins (See Supplemental Table 1) were identified in the 
samples but the fold-changes in expression were not statistically-significant. 
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SDHB was significantly increased only on day 18 (1.8-fold). Two proteins in Complex 
IV, which catalyzes the oxidation of reduced cytochrome C with oxygen, also were 
increased in expression during adipocyte differentiation and enlargement. The 
cytochrome C oxidase subunit 6 (COX6C) was up-regulated 1.49-fold on day 4 and 
cytochrome C (somatic) was up-regulated 3.3-fold on day 14 post-differentiation. 
Complex V (ATP synthase) forms ATP by using energy stored in the proton gradient 
created by the other 4 complexes. The expression levels of three key enzymes (ATP5A1, 
ATP5B, ATP5O) increased in expression at different time points (Tab. 3.1). The 
expression of ATP5A1 was significantly increased from 1.5 on day 4 and remained 
significantly up-regulated (maximum value of 2.3-fold on day 10) throughout the 
duration of the experiment. Similarly, the expression of ATP5B was increased in 
expression from days 7-18 by 1.9 to 2.3-fold. Interestingly, none of the proteins in 
complex I, also known as NADH ubiquinone oxidoreductase that is the largest of the 
ETC complexes and transfers electrons from NADH to CoQ with a concomitant transfer 
of protons across the inner mitochondrial membrane, were differentially expressed. 
 
Two important transporters, adenine nucleotide translocator two (ANT2) and phosphate 
carrier protein (PCP), were also increased in expression at all time points. These 
transporters exchange ATP for ADP and import phosphate with H+, respectively.  ANT2 
increased 3.2-fold at day 7 and remained up-regulated until day 18 (3.8-fold), while PCP 
increased 1.9-fold at day 10.  These data suggest increased ATP generation from the 
mitochondria. Two other proteins, the electron transferring flavoproteins alpha and beta 
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(ETFA, ETFB) that are auxiliary proteins involved in recycling FAD from the electron 
transport chain, for use as a coenzyme by acyl CoA dehydrogenase (184), were also 
increased in expression during differentiation and enlargement. The expression of ETFA 
was significantly increased 3.0-fold on day 10 and progressively increased to 3.4-fold by 
day 18. ETFB increased by 2.4-fold on day 14 and 2.7-fold on day 18. The ETF-
ubiquinone oxidoreductase protein was also up-regulated 2.4-fold on day 10 and reached 
2.8-fold increase by day 18.  
 
Since the electron transport chain is critical for ATP synthesis, we also determined the 
ATP levels at different stages of adipocyte lipid accumulation. Figure 3.6 shows that the 
ATP level in differentiating adipocytes (i.e., day 3 after addition of the differentiation 
cocktail) was nearly 17-fold greater than undifferentiated pre-adipocytes. However, ATP 
levels rapidly decreased as adipocytes matured (days 4 through 9), and was slightly less 
than undifferentiated pre-adipocytes beyond day 10.   
 
3.4.4. Antioxidant and Detoxification Proteins 
Table 3.2 lists the changes in the expression of different antioxidant and detoxification 
proteins altered during adipocyte differentiation and enlargement.  Lung carbonyl 
reductase (adipocyte protein p27), involved in reducing endogenous carbonyls derived 
from lipid peroxidation and 3-ketoacyls was up-regulated by 2.7-fold at day 10 post-
differentiation and increased to a maximum of 3.7-fold on day 18.  Peroxiredoxin-3 and 
-5 are  both  thioredoxin  peroxidases  and serve important roles in reducing alkyl hydro- 
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Figure 3.6.  ATP level in adipocytes during differentiation and enlargement at 
different time points relative to undifferentiated 3T3-L1 fibroblasts.  The ATP levels 
were determined using a commercially available assay as describe in the Materials 
and Methods. Data shown are mean ± standard deviation from three independent 
experiments. 
   
68 
6
8
 
 
Table 3.2. Temporal profile of mitochondrial antioxidant and detoxification enzymes 
during 3T3-L1 adipocyte differentiation and enlargementa. 
Protein Name 
Accession 
Number iTRAQ Label Quantitation Ratios 
  
Day 4 Day 7 Day 10 
Day 
14 
Day 
18 
Lung carbonyl reductase P08074   2.7 3.5 3.7 
Thiosulfate sulfurtransferase P52196  1.3 1.6 2.4 2.3 
Superoxide dismutase, 
mitochondrial 
P09671 0.60 0.70    
 
a Statistically significant fold increase is represented as red while fold-decreases are in 
green.  White indicates that the change in expression was not statistically-significant.  
Seven other anti-oxidant proteins (See Supplemental Table 1) were identified in the 
samples but the fold-changes in expression were not statistically-significant. 
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peroxides formed during lipid peroxidation (185).  Thiosulfate sulfurtransferase which 
maintains mitochondrial iron-sulfur subunits and functions as a ROS scavenger in  
concert with thioredoxin (186), was up-regulated by 1.3-fold at day 7, and its expression 
progressively increased to 2.3-fold over baseline at day 18.  Surprisingly, superoxide 
dismutase (MnSOD), the enzyme that catalyzes removal of superoxide ion (187), was 
reduced in expression by 1.5 to 1.8-fold on days 4 and 7, but was unchanged in 
expression beyond day 7.  
 
We also determined the levels of ROS using the NBT assay (Figure 3.7).  ROS levels 
were increased initially (5.2-fold more than undifferentiated preadipocytes on day 3), 
decreased marginally (3.9-fold more than undifferentiated preadipocytes on day 7), and 
again increased to 5.5-fold more than baseline by day 10. However, as adipocytes further 
increased in size, cellular ROS levels continually decreased and was only 2.7-fold more 
than undifferentiated preadipocytes on day 18. 
 
3.5. DISCUSSION 
Based on a quantitative proteomic study of mitochondrial proteins during adipocyte 
differentiation and enlargement, we found a broad increase in the expression of proteins 
involved in the TCA cycle, fatty acid beta-oxidation, ATP generation, and anti-oxidant 
functions.  Our  conclusions  are  supported  by  the fact  that  multiple  proteins  in  each  
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Figure 3.7. Reactive Oxygen Species (ROS) levels in 3T3-L1 adipocytes during 
differentiation and enlargement. Cellular ROS levels were determined using the 
NBT assay.  Data shown are mean ± standard deviation from three independent 
experiments. 
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pathway (e.g., TCA cycle, fatty acid oxidation) were coordinately increased in 
expression across multiple time points and replicate measurements, with good across 
multiple time points and replicate measurements, with good concordance between 
changes in protein expression and metabolite levels.  
 
All major proteins of the TCA cycle (except SUCLG1 and SUCLG2) were found to be 
up-regulated throughout the time course.  The increase in the expression of these  
enzymes is indicative of overall increased metabolism during adipocyte lipid 
accumulation and enlargement. In addition to providing reducing equivalents for 
oxidative phosphorylation, one of the major reasons for up-regulation of TCA cycle 
proteins could be for the generation of citrate for fatty acid synthesis in the cytoplasm. 
The sustained up-regulation of the citrate transporter (CTP) also suggests increased flux 
of citrate towards fatty acid synthesis.   Similarly, the increase in the dicarboxylate 
carrier (DIC) suggests channeling of cytosolic malate into the mitochondria for use in 
the TCA cycle, as DIC translocates malate, malonate and succinate in exchange for 
phosphate, sulfate, sulfite or thiosulfate across the mitochondrial inner membrane. Thus, 
the increase in expression of DIC is consistent with the need to bring in more substrate 
from the cytosol (188) to fuel the TCA cycle.  
 
Enzymes involved in fatty acid import and beta-oxidation were found to be increased in 
expression throughout the time course.  Fatty acids that are being synthesized from 
citrate formed in the TCA cycle are, in part, consumed and converted into acetyl-CoA 
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that will re-enter the TCA cycle.  This pattern may represent metabolic flexibility in 
adipocytes necessary to maintain intracellular homeostasis, as the ability to generate 
acetyl-CoA and TCA intermediates from lipids would be necessary during times of 
fasting.  However, excess production of acetyl CoA (as is likely to be the case in high-
glucose growth medium) may be detrimental, as it can lead to excess reduced electron 
carriers that contribute to ROS formation in the electron transport complexes (4, 119, 
120). This putative increased demand for recycling electron carriers is supported by an 
increase in the expression of electron transport flavins (ETFA, ETFB).  ETFA 
experiences a large increase (2.4 fold) at 10 days post-differentiation, and this may 
correlate with the second peak of ROS production observed at day 10.  The up-
regulation of acetyl-CoA acetyltransferase (ACAT1) also may be indicative of a fraction 
of the acetyl-CoA being shuttled into ketone body formation.  It should be noted that 
adipocytes are not known for export of ketone bodies, but instead it is believed that 
ketone bodies are used by adipocytes as an additional pathway to make lipids (189).  
 
Other than complex II (which also participates in the TCA cycle) and complex V, the 
expression of proteins in the remaining ETC complexes was not observed.  The simplest 
explanations for this observation are that the basal expression level of the other ETC 
complexes is still sufficient to meet increased demand or proteins in the different ETC 
complexes have additional levels of regulation.  Complex I has been reported as not 
being the rate limiting step in the normal functioning mitochondrial respiratory chain 
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 (119, 190), and thus likely has reserve capacity, which explains the lack of increase in 
expression of proteins in complex I.  
 
The 5-fold increase in ROS with young adipocytes (day 3 post-differentiation) compared 
to undifferentiated preadipocytes is likely due to an increase in the overall metabolic 
activity of the cell that is required for lipid accumulation. Even though on an oxygen 
basis cellular metabolic activity produces the lowest •2O

 (120), there is likely still a 
significant amount produced due to the large quantities of O2 consumed. Interestingly, 
there is a transient, yet statistically-significant, ~ 30 percent decrease in the fold-increase 
in ROS levels on day 7 (relative to day 4) after differentiation. This may be due to 
alterations in cellular metabolism or up-regulation of the cellular anti-oxidant systems; 
however, we did not observe statistically-significant changes in the expression of 
antioxidant proteins.   
 
Although lipid accumulation has been linked to oxidative stress (12, 44), it was 
surprising that ROS levels between day 10 through day 18 were lower than that on day 
10 (i.e., lower ROS with higher lipid accumulation). This observation is likely due to the 
interplay between changes in ATP demand and levels of reduced electron carriers in the 
mitochondrion.  A recent review by Murphy (120) suggests that cells exist in three 
metabolic states with different levels of mitochondrial ROS. When the cellular ATP 
demand is high, the levels of reduced electron carriers (e.g., NADH/NAD+ ratio) are low 
due to continuous regeneration, and although high levels of ROS are produced, they are 
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efficiently scavenged by the cellular anti-oxidant system. On the other hand, when the 
production/consumption of ATP is low, the levels of reduced electron carriers are high 
as there is “backflow” of reduced electron carriers (120) which can lead to accumulation 
of ROS. For example, a high NADH/NAD+ ratio leads to the production of •2O
  at the 
ETC complex I (state 1) (120) or results in high levels of reduced CoQ10 and ΔpH 
across the mitochondrial membrane (and therefore, •2O
  production from CoQ10H2) 
(state 2) (120).   
 
Our proteomic and metabolic data suggest that cultured 3T3-L1 adipocytes develop 
metabolic conditions (accumulation of reduced electron carriers) similar to the 
mitochondrial state 1 and/or state 2 described by Murphy (120), which may be 
responsible for the high ROS levels detected at day 10 (Fig. 3.7).  The increase in the 
expression of (i) different TCA cycle enzymes which generates high NADH/NAD+ 
levels, (ii) enzymes involved in fatty acid oxidation (which leads to reduction of FAD+), 
(iii) ETFA and ETFB which transfers the reduced FADH2 to the ETC, and (iv) ETF-
ubiquinone oxidoreductase which transfers electrons from ETFA/ETFB to CoQ10, all 
support this hypothesis.  The fact that ROS levels decrease beyond day 10 is not 
surprising as levels of electron carriers will eventually level off if overall cellular 
metabolism is sufficiently reduced (i.e., slowdown in lipid accumulation).  It remains to 
be seen if the mitochondrial states attributed to this cultured adipocyte model can be 
identified in adipose tissue in vivo.    
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It was interesting that the major anti-oxidant protein superoxide dismutase (SOD2) was 
not up-regulated at any time point throughout the experiment (in fact, decreased in 
expression at days 4 and 7). One possible explanation for this could be aberrant calcium 
signaling.  Calcium homeostasis is a major mitochondrial function (119, 191-193) and 
our data presents evidence that calcium flux is increased during adipocyte differentiation 
and enlargement.  The proteins VDAC1 and GRP 75 (statistically significant changes in 
expression on days 7-18 and days 10-18, respectively; Supplemental Table S.1), along 
with IP3R (not increased in expression), form a junction between the mitochondria and 
the endoplasmic reticulum that primarily serves as channel to transport Ca2+ into the 
mitochondria from the ER to help support oxidative phosporylation (192, 193).  The 
large increase in ATP levels during differentiation may suggest depleted mitochondrial 
calcium stores, and a compensatory increase in the VDAC1-GRP75 junction to 
normalize mitochondrial calcium levels.  Since mitochondrial Ca2+ levels have also been 
reported to be critical as for SOD2 activation (191), it is possible that the drop in 
mitochondrial calcium leads to the decrease in SOD2 expression.   
 
Since oxidative stress primarily originates in the mitochondria (119), adipocyte 
mitochondrial proteins may be more sensitive to the effects of ROS, and such effects 
have been proposed to be a main cause of adipocyte dysfunction (12, 41, 194). An 
intriguing question arising from our data is whether adipocytes in states 1 and 2 
described by Murphy (120) (i.e., high ROS due to low ATP demand and high reduced 
electron carriers) are more susceptible to loss of function.  Recently, Hoehn et al. (195) 
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reported that insulin resistance may be part of a cellular defense against mitochondrial 
oxidative stress, as mitochondrial superoxide stress precedes insulin resistance and 
exposure to antioxidants or over-expression of SOD2 ameliorates insulin resistance in 
cell culture and animal models.  Although preliminary, our proteomic data strongly 
suggest that control of mitochondrial superoxide production (especially sources linked to 
excess reduced electron carriers arising from enhanced TCA cycle activity and/or fatty 
acid oxidation), and the resultant oxidative stress may be attractive targets for 
modulating adipocyte function and for the development of novel approaches against 
metabolic disorders.  
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CHAPTER IV  
DEVELOPMENT AND CHARACTERIZATION OF A DOXYCLINE 
INDUCIBLE CYP2E1 EXPRESSING HEPATOCYTE CELL LINE 
 
4.1. OVERVIEW 
We investigated if ROS produced from controlled expression of cytochrome P450 2E1 
leads to enhanced sensitivity to oxidative stress.  The ethanol inducible mono-oxygenase 
CYP2E1 is responsible for increased ROS production and oxidative stress in hepatocytes 
during chronic ethanol ingestion. We developed an inducible CYP2E1 expressing 
HepG2 cell line to investigate CYP2E1 mediated oxidative stress with greater control 
and sensitivity. Use of the pTet-On/pRevTRE inducible expression system, retroviral 
transduction, and single colony screening resulted in the isolation of a sub-clone (RD12) 
that shows minimal CYP2E1 activity in the absence of induction with doxycycline (i.e., 
tight control) and fast kinetics of induction (75 percent of maximal activity is obtained 
after 12 hours induction).  RD12 cells demonstrated 30 percent higher CYP2E1 activity 
as measured by p-nitrophenol oxidation than the established HepG2 E47 cell line that 
constitutively expressed CYP2E1.  RD12 cells also demonstrated higher susceptibility to 
oxidative stress induced by CYP2E1-metabolism of acetaminophen, as cells exposed to 
20 mM acetaminophen for 24 hours had 30 percent lower viability than E47 cells.  RD12 
cell incubated with acetaminophen for 2 hours also had 25 percent lower glutathione 
than E47 cells, which further corroborates the increased oxidative stress.  The control 
over CYP2E1 induction and increased sensitivity to oxidative stress makes this cell line 
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a powerful tool for analyzing the effect of fatty acids, cytokines, and antioxidants on 
cellular metabolism and function.      
 
4.2. INTRODUCTION 
Experimental approaches for inducing oxidative stress in different cell types utilize 
exogenous addition of an oxidant (e.g., hydrogen peroxide, tert-butyl hydroperoxide) 
 (196) to increase oxidative stress for observing its effects on cell viability and/or 
expression of marker proteins.  While such approaches are likely to give an population-
wide, averaged response to a step-change in oxidative stress, the resultant general 
increase in concentration of reactive oxygen species (ROS) throughout the cell and the 
cellular response do not accurately represent what is encountered in vivo. First, the 
production of ROS and the resultant oxidative stress occurs gradually inside cells due to 
accumulation of ROS (as compared to a step-change arising from external addition of 
pro-oxidants). Moreover, oxidative stress and ROS are typically highly localized in 
organelles such as the mitochondrion and endoplasmic reticulum (ER). Therefore, 
widespread and general oxidative damage to all cellular components resulting from 
exogenous addition of pro-oxidants does not represent effects of physiological profiles 
of ROS production. 
 
Attempts have been made to create model systems that more accurately represent 
biologically relevant induction of oxidative stress (27, 197).  The most notable of these 
is the HepG2 E47 cell line constitutively expresses the CYP2E1 enzyme (27).  CYP2E1 
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is an ethanol-inducible member of the cytochrome p450 family and is involved in the 
metabolism of ethanol and other small molecules (84, 198, 199).  However, the increase 
in metabolic activity due to the breakdown of small molecules results in the generation 
of ROS and possibly toxic intermediates (84, 198, 199).  The E47 cell line has been used 
extensively since its development (27, 28, 93, 112, 113), and has contributed to a 
fundamental understanding of oxidative stress mechanisms at the molecular level.  
However, a drawback with this cell line is that CYP2E1 expression is constitutive, which 
leads to a higher basal level of oxidative stress in these cells. More importantly, 
constitutive generation of ROS and oxidative stress also leads to higher baseline activity 
of anti-oxidant systems (e.g., catalase, gamma-glutamyl cysteine synthetase) (28)  As a 
result of the increased anti-oxidant activity, elaborate treatment regimes, such as time 
dependent, sequential exposure to different compounds, is required to generate a 
significant increase in oxidative stress.  One such regimen used to generate oxidative 
stress in E47 cells involves a three-step sequential treatment process, as cells are first 
treated with chelated iron, followed by loading with polyunsaturated fatty acids, and 
then exposure to ethanol to induce oxidative stress (113).  Other approaches that have 
been used to overcome this problem include reducing cellular capacity to produce 
glutathione either by serum starvation (200) or by direct inhibition of glutathione 
synthetase  (27); however, these have also only proved to be moderately successful. 
 
Consideration of the biological imprecision of direct addition of an exogenous oxidant 
and complex strategies to induce oxidative stress is the motivation for development of a 
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cell line with inducible expression of CYP2E1.  There are two main advantages in 
developing an inducible CYP2E1 expression system.  First, an inducible CYP2E1 
expression system will enable presenting cells with any pharmacological agent or 
molecule that may enhance or mitigate the effects of oxidative stress, prior to the 
induction of oxidative stress, as investigation of pre-treatment cannot be conducted using 
a constitutive CYP2E1 expression system.  In addition, this also allows utilizing some of 
the powerful new tools in proteomics, such as isotopic labeling (15) and chemical 
tracers (144), prior to the induction of CYP2E1, which enables dynamic studies to 
measure changes in metabolite or protein expression levels due to CYP2E1 expression.  
It is also likely that an inducible system will have lower levels of basal anti-oxidant 
systems and be more sensitive to CYP2E1 induced oxidative stress, which would allow 
determining the toxicity of a particular compound or its metabolic intermediates, since 
the activation of molecules through the CYP450 enzymes often leads to the production 
of more toxic intermediates as well as high levels of oxidative stress.   
 
In this chapter, we describe the development of an inducible CYP2E1 expression system 
in HepG2 cells that is a well-established model cell line for toxicity studies. We further 
demonstrate the utility of this cell system by applying it to investigate the sensitivity and 
oxidative stress of HepG2 cells with acetaminophen treatment. 
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4.3. MATERIALS AND METHODS 
4.3.1. Reagents and Supplies 
All cell and bacterial culture media and reagents were purchased from Thermo Fisher 
Scientific (Waltham, MA).  Tetracycline-free fetal bovine serum was purchased from 
HyClone (Logan, UT). Ampicillin, G418, hygromycin-B, doxycycline, and oleic acid 
were purchased from MP Bio (Solon, OH).  Cell culture dishes (10 cm), 6-well, 12-well, 
and 24-well cell culture plates, cloning cylinders (6 × 8 mm) were purchased from 
Corning (Lowell, MA).  Silicone vacuum grease was purchased from Thermo Fisher 
Scientific.  Para-nitrophenol and Triton-X100 were purchased from Sigma-Aldrich (St. 
Louis, MO).   
 
4.3.2. HepG2 Culture 
HepG2 E47 cells (referred to as E47 cells henceforth) were a kind gift from Prof. A. I. 
Cederbaum (Mount Sinai School of Medicine, New York). HepG2 cells were purchased 
from ATCC. Both HepG2 and E47 cells were cultured in MEM-EBSS, supplemented 
with 10% fetal calf serum, 100 units of penicillin per milliliter, 100 mg/ml of 
streptomycin, and 2 mM glutamine in a humidified atmosphere in 5% CO2 at 37°.  
Experiments with the inducible CYP2E1 cells used the same media formulation, except 
that tetracycline-free FBS was used.  PBS (8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4, 
0.24 g/l KH2PO, pH 7.3) was used for rinsing cells.  Dulbecco’s PBS consists of PBS 
supplemented with 0.41 g/l MgSO4·6H2O, 0.37 CaCl2·2H2O, 50 mg/l sodium pyruvate, 
pH 7.3. 
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4.3.3. Cloning of Full Length CYP2E1 cDNA into pRevTre-MCS Expression 
Vector 
The pRevTRE / pTet-On inducible plasmid expression system (Clontech, Mountainview, 
CA) was used to create an inducible CYP2E1 expression system.  In this system, 
plasmid pTet-On expresses the tTA (Tet-transactivator) protein that, when bound with a 
ligand such as doxycycline, binds to the Tet response element DNA sequence and 
initiates transcription from a minimal promoter. In the absence of a ligand, tTA does not 
bind to the target DNA sequence; thereby, providing an On/Off switch for controlling 
expression of a target gene cloned downstream of the Tet response element.  Plasmid 
p91023 containing full length human CYP2E1 cDNA was a kind gift from Dr. F. J. 
Gonzalez at the National Cancer Institute, Bethesda, MD. 
 
PCR was used to add a Kozak consensus sequence (to initiate translation) (201), and 
appropriate restriction sites (HindIII, and Hpa1) to plasmid p91023 prior to cloning 
CYP2E1 into the pRevTRE plasmid.  The forward primer containing a 5’ HindIII 
restriction site and a Kozak sequence (underlined) was TTATGAGTGAAAGCT-
TGCCACCATGTCTGCCCTC.  The reverse primer containing a 3’ HpaI restriction site was 
ATACGATATGCTGTTAACTCATGAGCGGGG.  The Primer extension reaction was performed 
with Phusion DNA Polymerase (New England Biolabs, Ipswich, MA) according to the 
manufacturer’s instructions.  Briefly, a total reaction volume of 25 l containing 10 ng 
of template DNA, 0.2 l Phusion DNA Polymerase, and 1 M forward and reverse 
primers was placed in a Bio-Rad Icycler (Bio-Rad, Hercules, CA) for 0.5 min at 98°C 
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followed by 35 cycles of 0.2 min at 98°C, 0.3 min at 71°C, 0.35 min at 72°C, and a 5-
min final step at 72°C.  The PCR product was purified with the Wizard PCR clean-up 
system (Promega, Madison, WI) using the provided protocol. 
 
Approximately 2.5 g of amplified DNA containing the CYP2E1 gene was sequentially 
digested with HpaI and HindIII according to standard protocols for 2 h each (202). The 
pRevTRE-MCS plasmid was also sequentially digested with HpaI and HindIII using 7.5 
g of plasmid DNA.  The digested vector (6.5 kb) and CYP2E1 insert (1.45 kb) were 
gel-purified  a 1% low melting point agarose gel, followed by purification with Wizard 
PCR clean-up system (Promega, Madison, WI).   
 
The purified pRevTRE-MCS vector was phosphatase treated according to the protocol 
provided by NEB. The CYP2E1 insert was ligated into pRevTRE-MCS using T4 DNA 
ligase (NEB) with a 3:1 molar ratio of insert to vector DNA for 4 h at 16oC. Ligation 
reactions were heat inactivated at 65°C for 15 minutes prior to electroporation 
 
Two μL (~ 20 ng) of the ligation reaction was electroporated into ~ 1011 
electrocompetent E. coli XL1-Blue cells (Stratagene, La Jolla, CA) in 2 mm gap 
electroporation cuvettes (Bio-Rad) according to the standard Bio-Rad protocol. 
Immediately following electroporation, cells were incubated at 37ºC for 1 hour with 
agitation (203).   
 
   
84 
8
4
 
Plasmid DNA was extracted from 12 colonies and the insert verified by restriction 
digests.  Inserts were sequenced to verify the fidelity of the CYP2E1 gene using the Big 
Dye Terminator v3.1 sequencing kit with a 3130xl Genetic Analyzer, both from Applied 
Biosystems (Foster City, CA) according to manufacturer’s instructions.   
 
4.3.4. Generation of Retroviral Particles  
Retroviral particles containing the genes of interest (pTet-On and pRevTRE-CYP2E1) 
were generated by co-transfecting the CYP2E1 expression plasmid with POL, GAG and 
VSVG plasmids that code for reverse transcriptase, capsid, and envelope proteins, 
respectively, created by standard protocols (204).  Briefly, 12 μg of the target expression 
plasmid (pTet-On or pRevTRE-CYP2E1), 1.0 μg of plasmid pGAG, 1.0 μg pPOL, and 
1.2 μg pVSV-G were gently mixed in 100 μl of DMEM complete media.   The pooled 
plasmids were complexed with FuGene 6 transfection reagent (Roche, Basel, 
Switzerland) for 15 min at 20oC as per the manufacturer’s protocol and added dropwise 
to 293T cells cultured in a 100 mm dish at 60% confluency.  The medium was 
replenished after 48 hours and the supernatant collected after 96 hours. Cell debris was 
removed by filtering through a 0.45 μm syringe filter and the virus concentrated to a 
viral titer of 2.0×105 TU/ml using a 500 kDa Centricon centrifugal filter (Millipore, MA) 
according to the manufacturer’s instructions. Viral stocks were aliquoted and stored at -
80°C until further use. 
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4.3.5. Generation of the Inducible CYP2E1 HepG2 Cell Line 
HepG2 cells were seeded in 10 cm dishes and allowed to reach reaching 40% 
confluency.  Polybrene (Millipore) was added to HepG2 media at a final concentration 
of 8 ng/ml, and then 125 μl of the pTet-On virus stock was added to each ml media.  
This dilution corresponded to a multiplicity of infection of 0.01-0.015 and gave the 
largest number of viable, single colonies.  Cells were exposed to virus-like particle 
containing media for 24 h and then the media was replaced with normal growth media 
supplemented with 880 µg/mL of G418 and replenished every 48 h. After 96 h, the 
media was switched to a mixture of 50% fresh growth medium and 50% cell-free spent 
medium from HepG2 cells, with G418 supplementation.  The addition of spent media 
was found to greatly increase the viability of the HepG2 clones.  The media was changed 
every two days for approximately two weeks until the majority of cells were dead and 
single colonies of surviving cells were evident.  Single colonies were isolated as 
described by Wieder et. al. (205), and each colony was transferred to a single well of a 
24-well culture plate. The sub-clones were maintained in the fresh/spent medium 
mixture supplemented with 550 µg/mL G418.  
 
A two-step strategy was adopted for generating the inducible CYP2E1 line. HepG2 cells 
were first transduced with pTet-On virus to express the tTA protein. Clonal populations 
of HepG2 pTet-On cells were collected and propagated in a 12-well plate as described 
above.  At ~ 40% confluency, cells were transiently transfected with a reporter plasmid 
pRevTRE-d2EGFP (206) using the GenJet Transfection Reagent for HepG2 (Signagen, 
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Ijamsville, MD) according to the manufacturer’s instructions.  After 24 hours, 10 ng/ml 
of doxycycline was added to induce GFP expression from the reporter plasmid.  The 
extent of GFP induction in each clone was quantified with an Axiovert 500M fluorescent 
microscope (Zeiss, Thornwood, NY).  Clones with highest induction of fluorescence 
signal with low background fluorescence in the absence of doxycycline were identified 
(6 out of approximately 50) and used for introducing the CYP2E1 expression plasmid.   
 
HepG2 clones stably integrated with the pTet-On plasmid were subsequently transduced 
with pRevTRE-CYP2E1 virus particles as described above for the pTet-On virus, except 
that cells were maintained in 0.55 mg/ml G418 until viral transduction and sub-clones 
were selected for stable integration of the CYP2E1 virus particle using 280 µg/mL 
Hygromycin-B and 0.55 mg/ml G418.   
 
Clonal populations containing both the pTet-On and pRevTRE-CYP2E1 plasmids were 
propagated in phenol red-free media in a 12 well plate.  After reaching 60% confluency, 
CYP2E1 expression was induced through addition of 20 ng/ml doxycycline to each 
clone in triplicate.  After 24 hours, the media was replaced with fresh media containing 
20 ng/ml doxycycline and 0.2 mM p-nitrophenol and incubated for 18 hours to assess the 
CYP2E1 mediated conversion of p-nitrophenol to p-nitrochatecol  (91, 207).  This assay 
is non-destructive and no harm was observed in cells.  After incubation, 100 μl of the 
yellow supernatant was mixed with 10 μl of 0.1 M EDTA and 10 μl of 10 M NaOH to 
convert the p-nitrochatecol to a pink chromophore  (91).  The levels of the pink 
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chromophore were quantified by measuring absorbance at 510 nm in triplicate. The three 
sub-clones that produced the highest absorbance at 510 nm while maintaining very low 
CYP2E1 activity in the absence of doxycycline were selected for further propagation. 
 
4.3.6. Comparison of p-Nitrophenol Oxidation in Inducible CYP2E1 Expressing 
Cells and  E47 Cells 
The CYP2E1 activity of the doxycycline inducible clones was compared to the 
established constitutive CYP2E1 expressing E47 cell line (27, 112).  E47 cells were 
cultured according to recommended protocols (112), except that the E47 media 
contained 0.55 mg/ml G418.   E47 cells (passage 3-5) and the doxycycline inducible 
clone were plated into 12 well plates at 1.0 x 105 cells per well in phenol red-free media.  
Expression of CYP2E1 was induced as described above. The cells were processed in 
manner as the previously described section to measure absorbance of p-nitrocatechol.  
The molar extinction coefficient of p-nitrocatechol is 1.3 × 104 (208).  Instead of 
returning fresh media to cells, they were rinsed with PBS, and then 200 l of 1% v/v 
Triton X-100 was added to each well followed by incubation at 20°C for 15 minutes.  
The lysed cells were collected in micro-centrifuge tubes, vortexed, and centrifuged 
13000 × g for 30 seconds at 20°C.  The supernatant protein concentration was measured 
for normalization, using the 660 nm Protein Assay (Thermo Fisher Scientific) according 
to the manufacturer’s instructions. 
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4.3.7. Comparison of Cytotoxicty in Paracetamol Treated Inducible CYP2E1 
Expressing Cells and E47 Cells 
E47 cells and the doxycycline inducible clone were plated into 24 well plates at 0.50 × 
105 cells per well.  After 2 days, 20 ng/ml doxycycline was added to the inducible cell 
line alone to induce CYP2E1 expression.  After 24 hours, all cells received fresh media 
containing paracetamol concentrations of: 0, 2.5, 5, 10, and 20 mM, with 20 ng/ml 
doxycycline added to the inducible line.  After an incubation of 12 and 24 hours, 200 μl 
samples of the supernatant media were collected.  Cell toxicity was determined using the 
CytoTox-One LDH membrane integrity assay (Promega, Madison, WI) according to 
manufacturer’s instructions.   
 
4.3.8. Comparison of Glutathione in Paracetamol Treated Inducible CYP2E1 
Expressing Cells and E47 Cells 
E47 cells and the doxycycline inducible clone were plated into 24 well plates at 0.50 × 
105 cells per well and CYP2E1 expression induced as described above. After 24 hour 
induction, all cells received fresh media with 20 mM paracetamol; in addition, the 
inducible line (except for negative control) received 20 ng/ml doxycycline.  After an 
incubation of two hours, the cells were incubated with ThiolTracker fluorescent 
glutathione dye (Invitrogen, Carlsbad, CA) according to the manufacturer’s instruction 
to determine relative levels of glutathione.  The ThioTracker was then rinsed once and 
fluorescence read at 410/530 nm in a SpectraMax GeminiEM (Molecular Devices, 
Sunnyvale, CA). All conditions were tested in triplicate.   
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4.4. RESULTS 
4.4.1. Development of an Inducible CYP2E1 Expressing Cell Line 
Here we report the development of a doxycycline inducible CYP2E1 expressing HepG2 
cell line, hence referred to as RD12.  This cell line is based on the pTet-On/pRevTRE 
two-plasmid system  (46, 209) that utilizes an artificial transcription factor (tTA )and its 
affinity to the tetracycline response element (TRE) for regulating target gene expression, 
and has been used in multiple studies (167, 210, 211).  The inducible system offers two 
advantages over a cell line that constitutively over-expresses CYP2E1. First, the 
expression of CYP2E1 can be induced at any time point through addition of tetracycline 
or doxycycline. Second, the extent of induction can also be controlled by varying the 
concentration of the inducer (212).  These advantages are especially important as it 
enables investigating the cellular response to varying effect of oxidative stress.  Different 
levels of oxidative stress produce different effects; high levels are associated with 
apoptosis and loss of function (11, 12, 29), and lower levels have been shown to actually 
induce anti-oxidant effects (28, 30).  Precise control allows pre-treatment of cells with 
fatty acids or cytokines, such as TNF which has been implicated in the progression of 
alcoholic steatohepatitis (106).  
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4.4.2. Verification of CYP2E1 Activity 
Cytochrome P450 2E1 activity was measured by determining the rate of oxidation of p-
nitrophenol to p-nitrocatechol (PNP) (91, 207).  We are certain PNP oxidation is the 
result of CYP2E1 activity because in the absence of doxycline, RD12 cells and regular 
HepG2 cells show negligible PNP oxidation.  Traditional assays for CYP2E1 activity 
have been based on collecting the microsomal fraction from hepatocytes and conducting 
the oxidation reaction in a tube with NADPH as the required co-factor (27, 112).  The 
PNP oxidation product, p-nitrocatechol forms a bright pink chromophore at high pH, and 
allows spectrophotometric determination of the conversion rate.  The disadvantages of 
the microsomal method are that it is labor intensive and requires ultracentrifugation, 
many cells per assay (~107), and the addition of NADPH to the reaction mixture.  We 
used and adapted a method of measuring CYP2E1 activity based on the direct addition 
of PNP to the cell culture media, collecting the media, and measuring the concentration 
of p-nitrocatechol (85, 92).  We found the highest rates of rates of CYP2E1 activity in 
inducible cells occurs at 24 hours after the addition of doxycycline, but significant 
activity occurs in 12 hours.  In both RD12 and E47 cells, maximal PNP oxidation was 
greater in fresh media than in spent media, and this may be related to the metabolic 
requirement for pyruvate or other source for cellular NADPH production previously 
mentioned (85).  We observed no ill effects to cells upon adding PNP to culture media, 
and this was an advantage in the screening process, as clones were screened after single 
colonies expanded to several wells of 12 well plate, and cells used to perform the first 
CYP2E1 screening test were further propagated to become the stable clone.  
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The  newly created RD12 line CYP2E1 activity was compared to that of E47 cells, and 
showed 33 percent greater PNP oxidation activity (Figure 4.1).  The measured activity of 
0.121 nm/mg protein/min correlates very well to the PNP oxidation of  0.130 nm/mg 
protein/min found in primary hepatocytes exposed to 100 mM ethanol (92).  While an 
exact conversion is not possible, it has been noted that activity from microsomal protein 
can be approximated using 5 times as much total cellular protein (112), and thus gives an 
equivalent activity of 0.65 nm/mg microsomal protein/min, which is in line with 
published results (27).  CYP2E1 activity was not detected in the absence of doxycycline, 
as RD12 cells without doxycycline had identical activity to normal HepG2 cells. 
 
4.4.3. CYP2E1 Mediated Acetaminophen Toxicity in RD12 and E47 Cells 
Acetaminophen (APAP) is converted to the toxic intermediate NAPQI by CYP2E1 and 
has been shown to be toxic to CYP2E1 expressing cells (87, 114, 213, 214).  We sought 
to determine if RD12 were more sensitive than E47 cells to APAP, by determining if 
APAP exposure caused more cellular lactate dehydrogenase LDH leakage.  A common 
way to characterize the cytotoxicity of compound is measurement of LDH released from 
damaged cells (215, 216).   
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Figure 4.1. Comparison of CYP2E1 activity in clone RD12 to that of E47 cell line. Cells 
were exposed to doxycycline (20 ng/ml) for 24 hours and then media was changed to 
1000 l of media containing doxycycline and 0.2 mM p-nitrophenol.  100 l of this 
supernatant was collected after 18 hour exposure and read for absorbance at 510 nm as 
described in Materials and Methods. * indicates statistical significance at p < 0.05. 
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We exposed cells to increasing doses of APAP for 12 and 24 hours and then collected 
supernatants to measure LDH activity. In most cases, the nominal value of the LDH 
fluorescence for RD12 cells was higher than that of E47 cells, however the data appear 
noisy, and only the 24 incubation produced a statistically significant increase of 30 
percent more LDH fluorescence than E47 cells (Figure 4.2). 
 
It is interesting that the RD12 cells treated with doxycycline (to induce CYP2E1) did not 
experience significant increases in LDH fluorescence over RD12 cells not treated with 
doxycycline.  This was unexpected, as the CYP2E1 mediated metabolism of APAP was 
expected to induce cellular damage.  In a related trend in the E47 cells treated with 
APAP for both 12 and 24 hours experienced less LDH release with increasing APAP 
concentration.  This inverse correlation was roughly linear, and E47 cells exposed to 20 
mM APAP had 35 percent and 40 percent lower rates of LDH release after 12 and 24 
hours of exposure when compared to cells not receiving APAP, respectively. 
 
It has been reported that E47 cells have enhanced glutathione production compared to 
non-CYP2E1 expressing cells (28).  In order to determine if RD12 cells are more 
sensitive to oxidative stress than E47 cells, we determined if relative glutathione levels 
were lower in RD12 cells after the induction of CYP2E1.  Because the CYP2E1 
activated APAP metabolite NAPQI is detoxified with glutathione (214, 217), we also  
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Figure 4.2. Cytotoxicity as measured by LDH fluorescence for CYP2E1 
expressing HepG2 cells exposed to acetaminophen (APAP) for 12 (A) and 24 
(B) hour exposure. Clone RD12 cells were incubated for 24 hours with 20 nM 
Doxycycline prior to APAP exposure to induce. 
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sought to determine if APAP treated RD12 cells had lower glutathione than E47 cells.  
Relative reduced glutathione levels were determined by using the ThiolTracker dye from 
Invitrogen.  This binds to free thiols to form a fluorophore, and can be measured with a 
fluorescent plate reader at 530/590 nm. The RD12 cells treated with doxycycline had 
glutathione levels 20 percent higher than non-doxycycline treated cells and levels 
essentially equivalent to E47 cells (Figure 4.3).  This counter-intuitive effect reinforces 
that CYP2E1 expression itself is correlated to an increase in glutathione levels.  
Doxycycline treated RD12 cells incubated with APAP did show 25 percent lower 
glutathione levels than cells treated with doxycycline alone, and happened to be 
equivalent to untreated RD12 cells, likely indicating full metabolism of APAP was 
consuming significant glutathione (Fig. 4.3).   
 
Cells not treated with doxycycline but treated with APAP showed the same glutathione 
as untreated RD12 cells, thus confirming the CYP2E1 activation of APAP.  Somewhat 
surprisingly, E47 cells treated with APAP did not show lower glutathione levels than 
non-APAP treated E47 cells.  This finding along with results from the LDH assay may 
provide further evidence of the ability E47 cells to up-regulate its glutathione production 
or turnover capabilities.  
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Figure 4.3. Cytotoxicity as measured by LDH fluorescence for CYP2E1 expressing 
HepG2 cells exposed to acetaminophen (APAP) for 12 (A) and 24 (B) hour exposure. 
Clone RD12 cells were incubated for 24 hours with 20 nM doxycycline prior to APAP 
exposure to induce CYP2E1. 
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4.5. DISCUSSION 
The goal of this project was to create a cell line with an inducible CYP2E1 expression 
that would enable greater control and sensitivity to CYP2E1 mediated oxidative stress.   
This allows for more precise measurement and determination of the effects of 
biologically relevant sources of oxidative stress, and to our knowledge a stable, 
inducible CYP2E1 expressing hepatocyte line has not been reported. The development 
of a double stable clone, here dubbed RD12, required development and refinement of 
molecular cloning techniques and meticulous screening and propagation of candidate 
cell populations.  The result is a cell line that after induction has a higher CYP2E1 
activity (as measured by PNP oxidation) than previously developed constitutive cell 
lines (27).  To evaluate CYP2E1 activity on a large scale, PNP was added directly to cell 
culture media, and this proved successful and is likely a better representation of the 
CYPE1 activity that occurs in experiments conducted in cell culture.  
 
We chose to use the well characterized APAP-CYP2E1-NAPQI metabolic pathway to 
demonstrate sensitivity to oxidative stress because it places stress on antioxidant systems 
by ROS generated from the CYP2E1 catalytic cycle (99) and the reactive intermediate 
can be conjugated to glutathione for detoxification (87, 114).  RD12 cells showed are 
more sensitive to CYP2E1 mediated oxidative stress by showing a direct increase in 
cytotoxicity (Fig. 4.2) and with lower glutathione levels (Fig. 4.3).  These results 
indicate a modest, but notable increase in sensitivity, especially considering RD12 cells 
had a 30 percent increase in CYP2E1 activity.  However, E47 cells demonstrated a 
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remarkable ability to adapt to conditions designed to increase oxidative stress.  The E47 
line has been report as having up-regulated glutathione and expression of gamma 
glutamyl-cysteine synthetase, the first enzyme in glutathione synthesis (28).  It is likely 
that creation of the E47 cell line selected for traits in the underlying HepG2 line leading 
to this adaptation (i.e. high CYP2E1 activity required attenuation of oxidative stress).  
Because RD12 cell share the same base HepG2 line, it may share a degree of 
adaptability.  Considering that RD12 cells have shown 30 percent greater CYP2E1 
activity, it is not surprising that RD12 cells have a modest but not radical increase in 
sensitivity to oxidative stress. 
 
Given the high oxygen demand, mitochondrial number, and metabolic demand of 
hepatocytes, it is expected that hepatocytes have the ability to deal with elevated levels 
of oxidative stress.  Numerous studies have shown an acute adaptability of hepatocytes 
to mutagenic, toxic, or pro-oxidant compounds.  The pretreatment of H4 hepatoma cells 
with low non-toxic doses of the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine 
(MNNG) renders the cells more resistant to future toxic and mutagenic doses when 
compared to non-pretreated controls (218).  HepG2 cells treated with wastewater 
concentrate containing chlorine dioxide and peracetic acid experienced reduced 
glutathione levels after a two hour exposure, but after 24 hours experienced an increase 
over control levels (219).  Pretreatment of HepG2 cells with oleic acid induced a cyto- 
protective effect that made cells more resistant to a subsequent exposure to t-butyl 
hydro-peroxide (30).  Taken together this reinforces the notion that when studying 
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oxidative stress, especially in hepatocytes, it should not be viewed as a binary 
phenomenon where a cell has or does not have oxidative stress, but rather what systems 
are activated or deactivated by the overall re-dox state of the cell. 
 
In summary the inducible cell line RD12 has demonstrated good CYP2E1 activity and 
increased sensitivity.  Future studies will take advantage of the inducible nature of the 
RD12 cells line and allow for pretreatment of cells with compounds that enhance or 
mitigate oxidative stress.  This could be important in modeling certain conditions such as 
alcoholic liver disease where progression of the disease requires fat accumulation and 
oxidative stress, in the so called “two hit” hypothesis (21), or inflammation, where cells 
could be pre-stimulated with cytokines.  The control in an inducible system allows 
experiments of a dynamic nature to determine the precise roll metabolite availability on 
CYP2E1 activity, or the rate and magnitude of protein expression in response to 
CYP2E1 related oxidative stress. 
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CHAPTER V  
EFFECT OF DIETARY FATTY ACIDS AND PRO-OXIDANT CHALLENGE ON 
PROTEIN CARBONYLATION IN HEPG2 HEPATOCYTES 
 
5.1. OVERVIEW 
The effects of dietary fatty acids on the accumulation of fat in the liver (steatosis) are not 
fully understood. Results from many steatotic models suggest that different fatty acids 
may exert time and concentration dependent effects on hepatocytes.  For example, 
studies with palmitic and linoleic acid loading in hepatocytes found an increase in 
certain markers of oxidative stress and cytotoxicity in hepatocytes; however, low doses 
of oleic acid were found to reduce cytotoxicity to subsequent pro-oxidant challenge.  We 
hypothesized that the ability of hepatocytes to respond to pro-oxidant challenge depends 
on the level to which different fatty acids induce oxidative stress, which would result in 
different levels and patterns of protein carbonylation. HepG2 cells were exposed to 
different doses (0 - 0.5 µM) of oleic, linoleic, and palmitic acid, followed by challenge 
with a pro-oxidant molecule t-butyl hydroperoxide.  Cells pre-loaded with 0.2 mM oleic 
acid for 48 hours demonstrated a statistically-significant 20 % reduced cytotoxicity after 
treatment with 0.5 mM t-butyl hydroperoxide for 8 hours.  This protective effect was not 
observed at other concentrations of oleic acid or with any concentration of palmitic acid 
and linoleic acid. Affinity chromatography was used to purify carbonylated proteins 
from oleic acid-treated HepG2 cells and SDS-PAGE analysis indicated that the protein 
carbonylation pattern was different upon oleic acid pre-treatment; however, only a few 
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proteins demonstrated a clear change in expression.  Subsequent experiments suggested 
that the non-specific binding of proteins to the affinity column and sub-optimal degree of 
separation of carbonylated proteins were issues of concern. Current recommendations to 
improve the affinity chromatography separation are to enhance the specificity of the 
affinity separation through pre-blocking of the column with ovalbumin, optimizing the 
protein loaded, and using detergents to reduce protein aggregation. 
 
5.2. INTRODUCTION 
The accumulation of fat in the liver, or steatosis, occurs due to a variety of reasons 
including those that are dietary (220), viral (e.g. hepatitis C (221)), and/or behavioral 
(e.g., alcohol consumption (6, 21)).  The degree of fat accumulation correlates to the 
general susceptibility of the liver to further damage, but it is believed that fat 
accumulation alone is not sufficient to trigger development of more serious pathologies 
such as steatohepatitis (56). According to this “two-hit” hypothesis (21),  additional 
stressors such as oxidative stress and cytokine action are likely involved in the 
progression of steatosis to steatohepatitis (6, 21, 56).  The cellular accumulation of fat is 
linked to increased lipid peroxidation in both non-alcoholic steatohepatitis (77, 222) and 
alcoholic related oxidative stress (21, 92, 94, 222). Lipid peroxidation products have 
been found to form protein adducts (6, 223), and are a major cause of protein 
carbonylation (1, 10, 224, 225), the most permanent and deleterious oxidative protein 
modification (1, 225). 
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Several groups have developed in-vitro models of steatosis (29, 30, 226, 227); and a 
survey of recent findings reveals that individual fatty acids have dissimilar effects on 
steatosis that are time and concentration dependent.   Moderate to high concentrations of 
palmitic acid has been found to be toxic to HepG2 cells and shown to activate pro-
apoptotic pathways (29, 226), and are linked to increased hydrogen peroxide production 
 (29).  On the other hand, Damelin et al. have recently shown that low to moderate doses 
of oleic acid actually bolsters cellular resistance to subsequent pro-oxidant challenge 
 (30).  Low doses of linoleic acid have been found to produce greater cell death and 
more lipid peroxidation than palmitic or oleic acid (227).  These results suggest that cells 
treated with different dietary fatty acids undergo different levels of basal oxidative 
stress, and therefore, different susceptibility to subsequent pro-oxidant challenge. 
Furthermore, because these fatty acids have different effects and susceptibility to lipid 
peroxidation it is expected that they produce different amounts and patterns of protein 
carbonylation. It would be expected that linoleic acid treated cells would likely have the 
highest degree of carbonylation. Based on the cytoprotective effect of low levels of oleic 
acid (30), it may be expected to have the lowest level of carbonylated protein.  However, 
the protein modifications at high doses of palmitate cannot be easily predicted because 
even though saturated fatty acids are not susceptible to lipid peroxidation on the scale of 
unsaturated fatty acids (137), palmitate does induce H2O2 production (29).  Because of 
the permanent and deleterious nature of protein carbonylation, linking it to fatty acid 
loading may provide mechanistic information on how steatotic cells are vulnerable to 
oxidative stress induced damage. 
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In this study, we exposed HepG2 cells to different concentrations of three dietary fatty 
acids – oleic, linoleic, and palmitic acid – and investigated its effect on the cellular 
response to challenge with a pro-oxidant molecule. We also isolated carbonylated 
proteins to determine whether the extent of carbonylation correlates with the effect of the 
different fatty acids on HpeG2 cells.  
 
5.3. MATERIALS AND METHODS 
5.3.1. Reagents and Supplies 
All cell culture media and reagents were purchased from Thermo Fisher Scientific 
(Waltham, MA).  Mammalian protease inhibitor cocktail was purchased from Sigma (St. 
Louis, MO). Disposable 5 ml spin columns, monomeric avidin agarose beads, and 
Tween20 were purchased from Thermo Fisher Scientific.  Palmitic, linoleic and oleic 
acid were purchased from MP Bio (Solon, OH).  Cytotox-One LDH cytotoxicity assay 
was purchased from Promega (Madison, WI).   
   
5.3.2. Cell Culture  
HepG2 cells were cultured in MEM-EBSS without phenol red, supplemented with 10% 
fetal calf serum, 100 units of penicillin per milliliter, 100 mg/ml of streptomycin, and 2 
mM glutamine in a humidified atmosphere in 5% CO2 at 37°.   All the experiments were 
carried out while the cells were in exponential growth phase.  The cells were passed  
from the culture flasks at 70-80% confluence with 0.25% trypsin in PBS with 0.02% 
EDTA, and resuspended in media containing 10% FBS. 
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5.3.3. Preparation of Fatty Acid Stock Solution 
Linoleic and oleic acid stock solution (75 mM) were each prepared by dissolving 0.375 
mmol fatty acid  in 4.5 ml of 4 g/l bovine serum albumin (Thermo Fisher) in dd H2O, pH 
8.5.   The fatty acid mixture was heated to 37°C, vortexed vigorously, and then titrated 
with 2M NaOH, with vortexing between additions until the fatty acid dissolved to form a 
clear solution.  Water was added to the clear fatty acid solution for a final volume of 5.0 
ml and then passed through a 0.22 m syringe filter for sterilization and stored at -80°C.  
Palmitic acid stock solution (2.0 mM) was prepared by dissolving pure, molten palmitic 
acid in 100 ml of complete media pH 8.5, with stirring on a hot plate at 37°C.  The 
palmitic acid containing media was readjusted to pH 7.3, and then passed through a 0.22 
m syringe filter for sterilization and was stored at 4°C. 
 
5.3.4. Fatty Acid Pre-Loading and Pro-Oxidant Challenge with tert-Butyl 
Hydroperoxide 
HepG2 cells were seeded in a 24-well plate (1×105 cells/well).  Upon reaching 60 – 70 
% confluency, fatty acid (oleic, palmitic, or linoleic) were diluted into fresh growth 
media at concentrations ranging from 0.1 – 1.0 mM and used to pre-treat cells for 48 
hours.  Following fatty acid exposure, fresh growth media containing 0.50 mM tert-butyl 
Hydroperoxide (t-BHP) was added to the cells, followed by incubation for 8 hours. 
Culture supernatants were collected before and after t-BHP addition and stored at -80oC.   
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5.3.5. LDH Cytotoxicity Assay 
Culture supernatants collected after fatty acid exposure and t-BHP challenge were 
assayed in triplicate for release of the intracellular enzyme LDH using the Cytotox-One 
LDH cytotoxicity assay (Promega).  The supernatants were assayed using the 100 μl 
micro plate format with a 15 minute exposure period, according to manufacturer’s 
instructions. 
 
5.3.6. Carbonylated Protein Isolation 
After fatty acid and t-BHP exposure, approximately 3.0×107 cells (cells from two 10 cm 
dishes) were harvested using trypsin, resuspended in 800 μl PBS and stored at -80 °C 
until further use.  Carbonylated proteins were isolated from the frozen cell suspension as 
previously described (142, 228) with minor modifications. Specifically, affinity columns 
were sequentially loaded and used in batch-mode instead of high performance liquid 
chromatography,  protease inhibitor cocktail was added to a final concentration of 0.3% 
v/v, biotin hydrazide (Thermo Fisher) was used at a concentration of 8 mM, and SDS 
was added at a concentration of 0.5% wt/v.  Each cell solution was sonicated using a 
Model 60 sonic dismembrator (Fisher Scientific) at a power setting of 4 watts for 15 
seconds on ice.  The mixture was incubated for 30 min and then sodium 
cyanoborohydride was added to a concentration of 10 mM to reduce hydrazone 
bonds (146).  The samples were dialyzed to remove excess reagents using 3 ml Slide-A-
Lyzer Cassettes (7.5 k MWCO, Thermo Fisher).  The samples were dialyzed for 24 
hours at 4 °C in 300 ml dialysis buffer (PBS with 4 mg/ml BSA, pH 7.3), with the 
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dialysis buffer changed every 8 hours.  The protein content of the dialyzed sample was 
assayed using the 660 nm Protein Assay dye (Thermo Fisher) according to the 
manufacturer’s instructions.  
 
Affinity purification of biotinylated carbonylated proteins was performed in disposable 
5ml chromatography spin columns.  Each column was filled with 1.2 ml of 50% wt. 
supported monomeric avidin slurry to obtain approximately 0.6 ml of settled monomeric 
avidin beads in the column. The avidin beads were prepared and equilibrated according 
to the manufacturer’s instructions.  Briefly, 1 ml of eluting and blocking buffer (2 mM 
D-Biotin in 25 mM ammonium bicarbonate (ABC) pH 7.6) was added to each column 
and centrifuged in order to bind non-reversible sites.  Biotin was removed by adding 1 
ml of stripping buffer (100 mM glycine pH 2.8) to the column, followed by 
centrifugation.  Each of the samples were added to a column and incubated on rocker for 
30 minutes to capture biotinylated carbonylated proteins.  The samples were centrifuged 
and the supernatants were discarded.  The avidin beads were washed and centrifuged 4 
times with 4 ml PBS with 0.05% v/v Tween to remove non-specifically bound protein 
and then washed and centrifuged with 25 mM ABC to remove salt and detergent.  
Biotinylated carbonylated proteins were eluted by adding 300 μl eluting and blocking 
buffer to the column and eluting four times for each sample.  The elute samples were 
lyophilized and stored at -80°C. 
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5.3.7. SDS-PAGE 
Lyophilized carbonylated protein samples were rehydrated using SDS-PAGE buffer with 
0.8% v/v BME and 0.05% v/v bromophenol blue and were resolved on a pre-cast 4-20% 
gel at 100 V until the dye front reached 2-3 mm from the bottom of the gel.  The gel was 
carefully removed from the cassette, rinsed with DI water and then fixed by incubating 
in a solution containing 20% v/v methanol and 7% v/v acetic acid for 20 minutes.  After 
incubating with DI H2O for 20 minutes, the gel was stained with GelCode Blue Stain 
Reagent (Thermo Fisher) overnight and then destained in DI water, according to 
manufacturing instructions.  Gels were imaged with a Versa Doc 3000 imaging system 
(Bio-Rad, Hercules, CA).  
  
5.4. RESULTS 
5.4.1. The Effects of Fatty Acid Loading on HepG2 Cells 
The effects of fatty acid loading on hepatocytes have been reported to be concentration 
and dose dependent.  Palmitic acid has been shown to increase H2O2 production (29) and 
induce pro-apoptotic pathways (29, 226), linoleic acid has increased lipid peroxidation 
products (227, 229), and low doses of oleic acid bolstered cellular defenses against pro-
oxidant challenge (30).  We decided to focus on the three most common dietary fatty 
acids - oleic, linoleic, and palmitic acid – and investigated their effect on hepatocyte 
cytotoxicity based on LDH levels in culture supernatants.  The effect of different 
concentrations of the three fatty acids on HepG2 cells is shown in Figure 5.1.  Cells 
exposed to only oleic acid demonstrated a 14 - 20 percent statistically significant 
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decrease in cytotoxicity at concentrations of 0.15 and 0.2 mM compared to untreated 
cells.  This trend was reversed at concentrations above 0.2 mM as exposure to 0.3 mM 
oleic acid showed no difference over control, and concentrations greater than 0.3 mM 
eliciting 16 (0.4 mM) and 40% (0.5 mM) increase in cytotoxicity compared to untreated 
controls. (Fig. 5.1A).  On the other hand, cells exposed to linoleic acid did not 
demonstrate any statistically significant change over control at 0.15, 0.2, and 0.3 mM.  
At 0.4 and 0.5 mM, the cytotoxicity was 19 and 33 percent higher than untreated 
controls (Fig. 5.1B). 
 
Palmitic acid increased LDH values at all concentrations (Fig. 5.1C), with 
concentrations of 0.15 mM resulting in a 12 percent increase in toxicity than the control. 
Loadings of 0.2 and 0.3 mM produced LDH values 100 and 300 percent fold higher 
untreated control.  Palmitic acid loadings of 0.4 and 0.5 mM resulted in significant cell 
death as with more than 600 percent increase in cytotoxicity.   
 
5.4.2. Effect of Fatty Acid Pre-Loading on Subsequent Pro-Oxidant Challenge 
The accumulation of fat in the liver is correlated to the onset of potential disorders 
alcoholic and non-alcoholic fatty liver disease (20); therefore, we investigated if pre-
loading with dietary fatty acids would affect the subsequent response of HepG2 cells to 
the pro-oxidant molecule t-BHP.  HepG2 cells were pre-loaded with different 
concentrations of oleic, linoleic, and palmitic acid for 48 hours, and exposed to 0.5 mM 
t-BHP for 8 hours.  
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Figure 5.1. LDH fluorescence of culture supernatant of HepG2 cells incubated with 
varying (A) oleic, (B) linoleic, or (C) palmitic acid concentrations for 48 hours.  Note ** 
Palmitic acid concentrations of 0.4 mM and 0.5 mM result in LDH fluorescence values 
of 10100 and 12600, respectively.  
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Figure 5.2 shows that oleic acid pre-treatment affected the response of HepG2 cells to t-
BHP in a dose-dependent manner. Cells exposed to 0.15 mM and 0.2 mM oleic acid, 
followed by t-BHP demonstrated 10 and 20 percent lower cytotoxicity, respectively, 
than HepG2 cells treated with t-BHP alone (Fig. 5.2A).  However, HepG2 cells 
pretreated with 0.3 and 0.4 mM oleic acid demonstrated a 40 and 80 percent increase in 
cytotoxicity, while cells treated with 0.5 mM oleic demonstrated a 500 percent increase 
in cytotoxicity. Linoleic acid treated cells also demonstrated a similar response, with 
cells pretreated with 0.15 mM and 0.2 mM fatty acid having no statistically significant 
change over cells treated with t-BHP alone (Fig. 5.2B).  Cells treated with 0.3, 0.4 and 
0.5 mM linoleic acid had 30, 60, and 100  percent, respectively, more cytotoxicity than 
cells treated only with t-BHP.  Cells pretreated with 0.15 mM palmitic acid resulted in 
80 percent more LDH activity than t-BHP treatment only (Fig. 5.2C).  Since pre-
treatment with concentrations above 0.15 mM palmitic acid led to significant cell death, 
subsequent t-BHP exposure could not be carried out. 
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Figure 5.2. LDH fluorescence of culture supernatant of HepG2 cells incubated with 0.5 
mM t-BHP for 8 hours, after 48 hours incubation with varying (A) oleic, (B) linoleic, or 
(C) palmitic acid concentrations. Note** Palmitic acid concentrations 0.2 mM and above 
result in massive cell death, so LDH values cannot be accurately be reported.  
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5.4.3. Resolution of Carbonylated Proteins in HepG2 Cells Treated with Fatty 
Acids and t-BHP 
Biotinylated carbonylated proteins isolated as described in the Materials and Methods 
were resolved on a gel and stained with Coomassie Blue (Figure 5.3).  Carbonylated  
proteins from cells treated with only 0.2 mM oleic acid and 0.2 mM palmitic acid appear 
to have the most protein in them due to the overall intensity of bands in lanes C and D. 
In these samples, a protein just below 100 kDa also appears to be over-expressed (short 
arrows) as compared to the other samples.  Similarly, treatment with t-BHP appears to 
correlate with disappearance of a band between 75 and 50 kDa (see long arrows on lanes 
B, D, F, and H), as this protein band is present in all samples not treated with t-BHP 
(lanes A, C, E, G) and disappears on samples that were exposed to t-BHP (lanes B, D, F, 
H).  
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Figure 5.3. Carbonylated proteins isolated from oleic acid (left side) and palmitic 
acid (right side) treated HepG2 cells, according to procedure described in the 
materials and methods.  A) Control, no fatty acid or t-BHP treatment, B) Cells 
treated with 0.50 mM t-BHP for 8 hours, C) Cells treated with 0.2 mM oleic acid 
for 48 hours, D) Cells treated with 0.2 mM oleic acid for 48 hours, followed by 8 
hour exposure to 0.50 mM t-BHP.  E) Control, no fatty acid or t-BHP treatment, 
F) Cells treated with 0.50 mM t-BHP for 8 hours G) Cells treated with 0.2 mM 
palmitic acid for 48 hours, H) Cells treated with 0.2 mM palmitic acid for 48 
hours, followed by 8 hour exposure to 0.50 mM t-BHP. 
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5.5. DISCUSSION 
We sought to investigate the effect of fatty acid exposure on the ability of HepG2 cells 
to withstand subsequent insult or inflammation. Our data show that all fatty acids tested 
are toxic and cause cell death at concentrations greater than 0.3 mM. However, HepG2 
cells treated 0.2 mM oleic acid alone demonstrated decreased cytotoxicity, as seen from 
the decrease in LDH activity in the supernatant. This result is especially interesting as 
accumulation of fatty acids and lipids are thought to increase cell death through an 
increase in oxidative stress brought about by the increase in breakdown of these fatty 
acids. However, it is possible that exposure to low concentrations of oleic acid leads 
only to a basal level of reactive oxygen species and oxidative stress that HepG2 cells are 
capable of withstanding. In addition, it is also possible that the level of oxidative stress 
induced by fatty acids with a higher degree of saturation such as palmitic acid is high 
enough to cause cell death. Thus, there appears to be a narrow optimal range where 
exposure to fatty acids reduces cell death. 
  
We also investigated if pre-exposure to fatty acids impacted the subsequent effect of 
exposure to a pro-oxidant molecule. This is a realistic model of what has been described 
as the “Two-Hit” hypothesis; where a second insult such as oxidative stress is required 
in addition to fat accumulation to damage hepatocytes in liver disease (21, 52).   
Interestingly, only pre-exposure to oleic acid protected cells from subsequent exposure 
to t-BHP. These results are consistent with those observed by Damelin et al. (30), who 
reported that exposure to 0.15 mM oleic acid for 48 hours followed by a 0.5 mM t-BHP 
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challenge for 18 hours produced nearly a two-fold reduction in LDH based toxicity, 
compared to non-fat loaded cells.   
 
It is intriguing to speculate that exposure to low concentrations of oleic acid activates the 
cellular anti-oxidant machinery that confers resistance to subsequent pro-oxidant 
challenge. At higher concentrations, the induced oxidative stress could be too large for  
the cell’s anti-oxidant machinery to handle; thereby, leading to cell death. In other 
words, we propose that exposure to moderate concentrations of fatty acid “primes” the 
cellular defense machinery to resist subsequent insults. While we have demonstrated this 
effect only with oleic acid, it is possible that other dietary fatty acids, either individually 
or in combination, can also induce a similar phenomenon. 
 
One of the characteristics of oxidative stress is the modification of cellular proteins (1, 
139, 144).  Of these modifications, protein carbonylation is an important modification as 
it is considered irreversible (1, 139), and requires degradation and re-synthesis of 
affected proteins (1, 225). Carbonylated proteins are also capable of cross-linking and 
forming aggregates that can inhibit proteasomes (113).  Lipid peroxidation products, 
especially MDA and 4-HNE (10, 223, 225) are also associated with increased protein 
carbonylation. Therefore, it was of interest to determine the extent of protein 
carbonylation under conditions presented here. Investigating the extent of carbonylation 
with 0.15 mM oleic acid loading was of highest interest, as HepG2 cells loaded with this 
concentration of oleic acid were more resistant to subsequent oxidative challenge, as was 
reported earlier (30).  While it might be expected that such pretreatment would then lead 
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to lower levels of protein carbonylation, the same study  (30) revealed lower levels of 
free glutathione in oleic acid treated cells, suggest the cellular response to oleic acid may 
be related to an oxidative stress marker such as protein modification. Protein 
modifications such methione oxidation (139) or binding of 4-HNE (10, 225) have been 
proposed to be involved in cell signaling. Thus, the observed cytoprotective effect may 
be cellular adaptation to increased oxidative stress, and we sought to determine if protein 
carbonylation played a role in this process.  In addition, since double bonds of 
unsaturated fatty acids are subject to oxidation more than saturated fatty acids  (229), we 
also expected to find more carbonylation in linoleic acid-loaded cells than in cells 
exposed to oleic acid.  It was also of interest to determine the relative levels of protein 
carbonylation in palmitic acid loaded cells relative to oleic and linoleic acid-loaded cells 
as palmitic acid was shown to have the highest cytotoxicity and results in greater 
production of ROS, such as hydrogen peroxide (29).  But in an in vivo study, saturated 
fatty acids also ameliorated alcohol based damage (230), indicating that the cellular 
response to palmitic acid may be more complex. But, inspection of the carbonylated 
protein gel (Figure 5.3) shows a similar degree of carbonylation between the different 
fatty acid pre-treatments, including the control samples.  While it is expected that the 
untreated controls contain some carbonylated protein, as even newborn rat tissue was 
found to have almost 50 percent of the total protein carbonylation of 24 month old 
rats (231).  However, this does not rule out technical difficulties in the biotin/avidin 
affinity chromatography used for isolating carbonylated proteins.  To test the degree of 
separation between biotinylated carbonylated and non-carbonylated proteins, we 
repeated the affinity purification scheme described in Materials and Methods, except that 
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the biotin hydrazide was omitted. Without the biotin tagging, eluates are expected to 
have minimal proteins; however, we observed that samples even without biotin 
hydrazide contained proteins comparable to those obtained with biotin tagging. This 
surprising result suggested that non-specifically bound proteins are a problem that 
overwhelms the detection of carbonylated proteins.  Therefore, it could not be 
conclusively determined if the differentially expressed protein bands are a result of 
changes in protein carbonylation or a change in protein expression. The problem of non-
specific binding is known to be a problem in any protein detection technique such as 
Western blotting or ELISA.  But, it is especially a problem in affinity chromatography 
that is not only compounded by the high surface area of the agarose bead packing 
material, but also the fact that these surfaces are covered with biological ligands (232, 
233).  There are several strategies that are recommended to improve the experimental 
protocol and reduce non-specific binding.  The first is the use of a blocking agent to pre-
block the surface of the agarose beads.  Bovine serum albumin or powdered milk are 
traditional choices, but using BSA as a blocker would interfere with the use of 
biotinylated BSA as a positive control for testing avidin/biotin binding and release.  
Powdered milk is poor choice as well because it may contain traces of free biotin, and 
the casein in dry milk is actually a set of several proteins and further contributes to 
sample complexity.  Therefore, we suggest use of the egg white protein, ovalbumin.  
Ovalbumin is a 45 kDa monomer in size, compared to 67 kDa for BSA, and therefore 
the appearance of an ovalbumin band on a gel will be readily identified and not interfere 
with a biotinylated BSA band.  The second strategy is to dilute the load sample protein 
concentration and add detergent to the sample buffer and to the wash buffer.  This 
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should reduce protein-protein, and protein-surface interaction and minimize nonspecific 
binding.  Of course the buffer conditions have to be tested so that they do not interfere 
with the target binding of the biotin to avidin.  Thirdly, strepavidin-linked agarose beads 
may be used over the monomeric avidin-linked beads currently described in the protocol.  
Monomeric avidin beads were used because they possess far milder eluting conditions (2 
mM free biotin via competitive binding or 150 mM Glycine, pH 2.5), are reusable, and 
because they were referenced in recent papers describing the isolation of carbonylated  
protein (142, 228).  The streptavidin-biotin interaction is among the strongest non-
covalent interaction known, and elution is done with guanidine or by boiling with SDS-
PAGE buffer, and renders the beads unusable afterwards.  Rather than seen as weakness, 
the stronger binding characteristics of the streptavidin could be exploited in order to 
allow for harsher sample buffer and washing conditions.  In fact, we have inadvertently 
proven the stripping buffer (150 mM glycine, pH 2.5) used to regenerate the monomeric 
avidin beads is capable of removing non-specifically bound proteins.  But, even this 
stripping buffer is not able to disrupt the full streptavidin-biotin interaction.  In some 
methodologies SDS could interfere with downstream procedures, but because in our 
procedure the eluted proteins are intended for resolution by SDS-PAGE, then elution by 
SDS-PAGE buffer should not be problematic.  And, finally pre-clearing the sample by 
passing it over blank agarose beads is possible, and this is recommended for co-
immunoprecipitation techniques.  It is expected that these suggested improvements will 
lead to better purification and recovery of carbonylated proteins.  
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CHAPTER VI  
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1. CONCLUSIONS 
In this work, we have successful profiled the mitochondrial proteome of 3T3-L1 pre-
adipocytes and 4, 7, 10, 14, and 18 day old adipocytes using the iTRAQ 8-plex peptide 
amine labeling kit.  As part of the protein profiling experiment, we used the MSWIFT 
liquid phase isoelectric trapping device to increase proteome coverage and reduce 
sample complexity.  Concurrent biochemical assays were conducted to measure lipid 
loading, ROS production, and ATP levels.  We found citric acid cycle proteins such as 
pyruvate carboxylase, citrate synthase, and citrate transporter, as well as beta-oxidation 
enzymes; cartinine acyl transferase and long-chain enoyl-CoA hydratase up-regulated 
from 7 through 18 days post differentiation onset. These data indicate TCA cycle up-
regulation for enhanced metabolic and citrate output necessary for lipid synthesis in 
aging and growing adipocytes.  The data also show the simultaneous increase in the fatty 
acid beta oxidation pathway. Biochemical assays showing peaks in ATP and ROS 
generation in 3 day old adipocytes indicate a peak in metabolic output during the 
differentiation. A second peak in ROS generation was observed in 10 day old 
adipocytes.  Concurrently at day 10, ATP generation reduced to near pre-adipocyte  
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levels, and this may indicate a metabolic shift to a state that results in increased 
production of mitochondrial ROS.  This metabolic mode is characterized by excess of 
reduced electron carriers (High NADH/NAD+ and CoQH2/CoQ ratios), high H+, low 
ATP levels, and low O2 consumption).   Shift to this mode is supported by increases in 
expression of ETFA, ETFB, and ETF-ubiquinone oxidoreductase, which together shuttle 
electrons from fatty acid oxidation to the electron transport chain.  This metabolic shift 
likely results in the observed increase in ROS in 10 day old adipocytes and this may be 
general mechanism for increased oxidative stress in hypertrophic adipocytes.   
 
We developed a doxycycline inducible CYP2E1 expressing HepG2 cell line using the 
pTet-On/pRevTRE expression system to allow greater control and sensitivity in the 
generation CYP2E1 mediated oxidative stress.  A thorough clone-screening process 
resulted in the isolation of the cell line (RD12), which demonstrated stability and tight 
expression control.  After exposure to doxycycline for 12 hours, RD12 cells showed 75 
percent of the CYP2E1 activity of the established constitutive CYP2E1 expressing E47 
 (112) cell line, and after a 24 hour exposure, RD12 cells showed 30 percent greater 
CYP2E1 activity based the oxidation p-nitrophenol per mg of protein.  In the absence of 
doxycycline RD12 cells showed essentially no activity.  RD12 cells showed 30 percent  
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greater toxicity than E47 cells when exposed to 20 mM acetaminophen for 24 hours, 
indicating RD12 cells are more sensitive to the effects reactive intermediates generated 
by CYP2E1.  RD12 cells also showed 25 percent less free glutathione than E47 cells 
after a two hour exposure to acetaminophen. These results indicate the successful 
development of an inducible CYP2E1 expressing hepatocyte line with increased 
sensitivity to CYP2E1 mediated oxidative stress. 
 
We investigated the toxicity of dietary fatty acids (oleic, linoleic, and palmitic) on 
HepG2 hepatocytes in order to determine fatty acid doses that induced metabolic 
changes, but not excessive cell death.  The dose of 0.20 mM linoleic for 48 hours 
produced very little toxicity, and palmitic acid produced toxicity that increased rapidly 
with increasing concentration.  Oleic acid at 0.20 mM actually produced lower toxicity 
than untreated cells, indicating an adaptive response.  After fatty acid exposure cells 
were treated with a pro-oxidant to determine which fatty acid increased the susceptibility 
to protein carbonylation.   
 
Our results and other published studies (29, 30, 226, 227) demonstrate that treating 
hepatocytes with different fatty acids produces different levels of cytotoxicity.  We 
hypothesized that the cytotoxicity produced by fatty acids would correlate with the level 
of carbonylation induced after a pro-oxidant challenge.  We therefore expected palmitic 
and linoleic acid treatment to produce greater carbonylation than oleic acid. The result of  
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the carbonylated protein isolation procedure indicated the palmitic acid may induce more 
carbonylation than oleic acid.  The resolution of carbonylated protein on an SDS-PAGE 
gel revealed a small number of differentially-expressed protein bands may be present in 
palmitic acid treated cells, however the protein pattern of all samples were extremely 
similar. These results indicate greater efficiency in the isolation procedure is required for 
a confidant determination of carbonylated protein in fatty acid loaded hepatocytes.   
 
6.2. RECOMMENDATIONS 
The results of the proteomic and biochemical profiling presented in the current 3T3-L1 
adipocyte study present many interesting targets for further research.  Overall the data 
appear to provide an in vitro cell culture base example of mitochondrial metabolic 
operating modes described by Murphy, with the peaks in ROS generation in 3 and 10 
day old adipocytes corresponding closely to the metabolic states 3 and 2, respectively 
 (120).  By, operating in mode 2 one might expect Day 10 adipocytes to have higher 
ROS generation than 3 day old adipocytes, but our data show day 3 adipocytes have the 
highest level of ROS.  In this instance, it appears the metabolic burst necessary for 
protein and lipid synthesis in newly differentiating adipocytes is so great, that even 
though ATP level is high, ROS generation is very high.  Further biochemical 
measurements such as O2 consumption, NADH/NAD+, CoQH2/CoQ ratios may provide  
greater elucidation of this subject.  Perhaps oxygen consumption is so great in day 3 
adipocytes, that even though they presumably operate in the “normal” mode (mode 3 
 (120)), ROS generation is still relatively high.  Considering this makes the second ROS 
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peak observed in 10 day old adipocytes even more interesting.  If oxygen consumption is 
proportional to ATP levels, then Day 10 adipocytes would be consuming 15-20 times  
less oxygen than day 3 adipocytes, even though they only produce approximately 20 
percent less ROS.  This would indicate that on an oxygen basis, day 10 adipocytes 
produce far more ROS than day 3 adipocytes, which would coincide with metabolic 
modes outlined by Murphy (120).  We have implicated the up-regulation of ETFA, 
ETFB, and ETF-ubiquinone oxidoreductase in the increased ROS observed in day 10 
adipocytes, verification of the activity of these enzymes in this process is warranted.  
 
The current study reflected conditions experienced by 3T3-L1 adipocytes cultured 
according to standard protocols for 18 days.  It would be very interesting to determine if 
conditions exist that allow cells to re-enter the mode 2 and produce the high ROS 
demonstrated in 10 day old adipocytes.  In other words, is metabolic cycling possible 
that allows adipocytes to continually re-enter high ROS producing states.  And for 
further relevance, it would be necessary to verify potential adipocyte metabolic modes in 
an animal study.   
 
In addition, to increase sensitivity to CYP2E1 generated ROS, we were motivated to 
develop the RD12 inducible cell line in order to gain control of CYP2E1 expression.  
Such control allows cells to be pretreated with agents such as fatty acids, antioxidants or 
those who may form toxic intermediates prior to CYP2E1 induction.  This control also  
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allows pre-labeling of cells with radioactive isotopes or SILAC reagents, so that 
profiling or degradation experiments can be conducted upon the induction of CYP2E1.   
 
We wanted to determine which of the dietary fatty acids (oleic, linoleic, palmitic) 
induced greater amounts of protein carbonylation upon challenge with pro-oxidant t-
BHP.   The affinity chromatography experiment designed to isolate carbonylated protein 
was overwhelmed by a large amount of non-specifically bound protein.  Several methods 
to reduce the problem of non-specifically bound protein include: pre-blocking with a 
protein such as ovalbumin, diluting the protein concentration and including detergent in 
the load sample, and increasing salt and detergent concentration in wash buffer.   
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APPENDIX 
Protein Name
Accession 
#
Fig. 
Abbrev.
N First 
Run 
Un-
used
% Cov-
erage
Pep-
tides 
(≥95%)
115: 
113
117: 
113
118: 
113
119: 
113
121: 
113
TCA Cycle Day 4 Day 7Day 10Day 14Day 18
Pyruvate dehydrogenase E1 component alpha subunit, somatic form mitochondrial precursor (EC 1.2.4.1) (PDHE1-A type I) P35486 PDHA1 57 16.9 30.0 8 1.5 2.1 2.7 2.8 2 9
Pyruvate dehydrogenase E1 component beta subunit, mitochondrial precursor (EC 1.2.4.1) (PDHE1-B) Q9D051 PDHB1 75 14.2 39.6 6 1.3 1.5 2.0 2.2 2.2
Dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) Q8R339 DLAT 79 14.0 25.1 6 1.1 1.8 2.3 2.7 2.3
dihydrolipoamide dehydrogenase O08749 DLD 22 27.2 45.0 14 1.5 1.9 2.1 2.3 2.2
Pyruvate carboxylase, mitochondrial precursor (EC 6.4.1.1) (Pyruvic carboxylase) (PCB) Q05920 PCB 1 112.7 65.4 57 1.9 2.5 3.2 3.7 3.7
Citrate synthase, mitochondrial precursor (EC 2.3.3.1) Q9CZU6 CS 31 24.4 47.0 11 1.3 1.8 2.3 2.9 2.9
Aconitase 2, mitochondrial Q99KI0 ACO2 9 42.5 55.4 19 1.3 2.0 2.6 3.1 3.4
Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial precursor (EC 1.1.1.41) (Isocitric dehydrogenase) (NAD+-specific ICDH) P70404 IDH 110 9.8 23.4 4 1.3 .5 1.4 1.6 1.6
NADP+-specific isocitrate dehydrogenase Q9EQK1 ICDPH 30 24.5 39.8 13 1.3 1.4 1.5 1.6 1.7
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrialQ9D2G2 ODO2 92 11.9 32.4 6 1.4 1.9 2.4 2.6 2.4
Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial precursor (EC 6.2.1.4) (Succinyl-CoA synthetase, alpha chain) (SCS-alpha) Q9WUM5 SUCLG1 141 7.1 18.6 3 1.2 1.4 1.7 1.5 1.7
Succinyl-CoA ligase [GDP-forming] beta-chain, mitochondrial precursor (EC 6.2.1.4) (Succinyl-CoA synthetase, betaG chain) (SCS-betaG) (GTP- specific succinyl-CoA synthetase beta subunit) (Fragment) Q9Z2I8 SUCLG2 142 7.0 20.8 3 1.1 1.2 1.6 1.6 1.5
Sdha protein (Fragment) Q921P5 SDHA 43 21.1 38.7 10 1.3 1.9 2.4 2.6 2.5
Succinate dehydrogenase [ubiquinone] iron-sulfur protein mitochondrial precursor (EC 1.3.5.1) (Ip) (Iron-sulfur subunit of complex II) Q9CQA3 SDHB 60 16.6 48.9 6 1.0 1.5 1 9 2.0 1.8
Fumarate hydratase, mitochondrial precursor (EC 4.2.1.2) (Fumarase) (EF-3) P97807 FH1 38 2 3 37.1 11 1.5 1.7 2.3 2.8 2.6
Malate dehydrogenase 2, NAD (Mitochondrial) Q8R1P0 DH2 12 34.4 67.5 19 1.6 1.9 2.4 2.8 3.1
Solute carrier family 25, member 1 Q8JZU2 CTP 42 21.3 51.5 10 1.4 2.1 2.8 3.3 3.0
Mitochondrial dicarboxylate carrier Q9QZD8 DIC 116 9.3 33.5 4 1.6 3.1 4.2 4.2 4.1
Mitochondrial 2-oxoglutarate/malate carrier protein (OGCP) Q9CR62 OGCP 155 6.5 26.5 3 1.1 1.5 1.9 1.6 1.9
Mitochondrial glutamate carrier 1 (Glutamate/H(+) symporter 1) (Solute carrier family 25, member 22) Q9D6M3 C1 254 3.5 17.3 1 1.1 2.0 2.4 3.5 3.0
Fatty acid metabolism 0.0 0.0 0.0 0.0 0.0
acyl-CoA synthetase long-chain family member 1 P41216 ACSL1 4 58.9 51.5 31 3.5 6.9 6.5 5.7 5.5
Carnitine acetyltransferase Q923A6 CAT 26 25.4 33.1 12 1.4 2.3 2.8 3.2 3.2
carnitine palmitoyltransferase 2 P52825 CPT1 36 22.8 29.3 10 1.7 2.0 2.6 2.3 2.3
Nonspecific lipid-transfer protein, mitochondrial precursor (NSL-TP) (Sterol carrier protein 2) (SCP-2) (Sterol carrier protein X) (SCP-X) (SCPX) P32020 SCP2 95 11.6 19.7 6 2.8 2.8 3.0 2.3 2.6
Acyl-Coenzyme A dehydrogenase, short chain Q91W85 SCAD 47 19.0 38.6 9 1.4 1.9 2.5 2.9 3.1
Acetyl-Coenzyme A dehydrogenase, medium chain Q91WS8 MCAD 41 21.5 45.6 10 1.3 1.5 2.1 2.3 2.5
Acyl-CoA dehydrogenase, long-chain specific, mitochondrial precursor (EC 1.3.99.13) (LCAD) P51174 LCAD 35 23.7 39.5 12 0 .0 1.4 1.6 1.7
Acyl-CoA dehydrogenase, very-long-chain specific, mitochondrial precursor (EC 1.3.99.-) (VLCAD) (MVLCAD) P50544 VCAD 72 14.7 22.3 8 1.4 1 4 1.9 1.6 1.6
Delta3,5-delta2,4-dienoyl-CoA isomerase, mitochondrial precursor (EC 5.3.3.-) O35459 ECH1 212 4.3 31.8 2 1.7 1.6 1.9 1.8 2.1
Dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenyme A isomerase), full insert sequence Q8QZV3 DCI 249 3.6 12.8 1 1.4 2.0 2.3 3.2 3.7
2,4-dienoyl CoA reductase 1 mitochondrial, full insert sequence Q9DCI7 DECR1 89 12.2 36.1 5 1.2 1.6 2.0 2.2 2.5
Enoyl-CoA hydratase 1Q99LX7 ECHS1 25 26.0 61.5 13 1.7 2.1 3.1 3.9 4.3
Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (Trifunctional protein), alpha subunit Q8BMS1 HADHA 10 40.7 43.9 21 1.3 1.9 2.3 2.7 2.9
Short chain 3-hydroxyacyl-CoA dehydrogenase, mitochondrial precursor (EC 1.1.1.35) (HCDH) (Medium and short chain L-3-hydroxyacyl-coenzyme A dehydrogenase) Q61425 HADHSC 132 7.7 32.5 3 1.3 1.4 1.8 2.1 2.2
Trifunctional enzyme beta subunit, mitochondrial precursor (TP-beta) [Includes: 3-ketoacyl-CoA thiolase (EC 2.3.1.16) (Acetyl-CoA acyltransferase) (Beta-ketothiolase)] Q99JY0 HADHB 19 28.0 42.1 14 1.2 1.7 2.3 2.5 3.0
Acetyl-CoA acetyltransferase, mitochondrial precursor (EC 2.3.1.9) (Acetoacetyl-CoA thiolase) Q8QZT1 ACAT1 46 19.8 59.2 13 1.8 2.4 3.3 3.7 3.8
ETC Complex 1
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial precursor (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-75Kd) (CI-75Kd) Q91VD9 NDUFS1 104 10.2 19.5 5 0.9 0.9 1.0 1.0 1.0
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8 Q9CQ75 NDUFA2 281 2.9 24.3 1 1.2 1.4 0.7 1.2 1.3
NADH-ubiquinone oxidoreductase 39 kDa subunit, mitochondrial precursor (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-39KD) (CI-39KD) Q9DC69 NDUFA9 185 5.0 19.4 3 0.9 1.0 0.9 1.0 0.8
iTRAQ Quantitation Ratios 
(averaged) 
3.
S1.  Supplemental adipocyte protein table
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NADH-ubiquinone oxidoreductase 51 kDa subunit, mitochondrial precursor (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-51KD) (CI-51KD) Q91YT0 NDUFV1 244 3.7 14.9 2 0.1
NADH-ubiquinone oxidoreductase MLRQ subunit (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-MLRQ) (CI-MLRQ) Q62425 NDUFA4 168 6.0 0.5 3 1.2 1.3 1.1 1.2 1.3
NDUFAF2, RIKEN cDNA 1810058I14 Q59J78 NDUFAF2 300 2.5 28.0 1
Auxillary Electron Carriers
Electron transferring flavoprotein, alpha polypeptide Q99LC5 ETFA 20 27.6 59.5 13 1.5 1.8 2.5 3.0 3.4
Electron transferring flavoprotein, beta polypeptide Q810V3 ETFB 77 14.1 51.0 6 1.3 1.5 2.2 2.4 2.7
Electron transfer flavoprotein-ubiquinone oxidoreductase mitochondrial precursor (EC 1.5.5.1) (ETF-QO) (ETF-ubiquinone oxidoreductase) (ETF dehydrogenase) (Electron-transferring- flavoprotein dehydrogenase) Q921G7 ETF-QO 96 11.4 22.9 4 1.4 1.9 2.1 2.3 2.8
ETC Complex 2*
Sdha protein (Fragment) Q921P5 SDHA 43 21.1 38.7 10 1.3 1.9 2.4 2.6 2.5
Succinate dehydrogenase [ubiquinone] iron-sulfur protein mitochondrial precursor (EC 1.3.5.1) (Ip) (Iron-sulfur subunit of complex II) Q9CQA3 SDHB 60 16.6 48.9 6 1.0 1.5 1 9 2.0 1.8
ETC Complex 3
Ubiquinol-cytochrome C reductase complex 11 kDa protein, mitochondrial precursor (EC 1.10.2.2) (Mitochondrial hinge protein) (Cytochrome C1 nonheme 11 kDa protein) (Complex III subunit VIII) P99028 UQCRH 139 7.3 67.4 4 1.1 1.0 0 1.2 0.6
Ubiquinol-cytochrome-c reductase complex core protein 2, mitochondrial precursor (EC 1.10.2.2) (Complex III subunit II) Q9DB77 UQCRC2 149 6.8 24.3 3 1.0 1.0 0.9 0.9 1.2
Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial precursor (EC 1.10.2.2) Q9CZ13 UQCRC1 161 6.1 18.3 1 0.8 0.6 0.8 0.7 0.7
ETC Complex 4
Cytochrome c oxidase assembly protein COX15 homolog Q8BJ03 COX15 285 2.8 9.4 1 1.5 3.1 4.0 4.0 4.3
Cytochrome c oxidase, subunit VaQ9D2W1 COX5A 233 4.0 26.7 2 0.5 0.5 0.4 0.4 0.4
Cytochrome c oxidase polypeptide VIb (EC 1.9.3.1) (Cytochrome c oxidase subunit AED) P56391 COX6B 222 4.1 42.4 2 1.0 1.0 1.0 0.9 1.0
Cytochrome c oxidase polypeptide VIc (EC 1.9.3.1) Q9CPQ1 COX6C 255 3.5 56.0 1 1.5 1.3 1.4 1.2 1.4
Cytochrome c oxidase subunit IV isoform 1, mitochondrial precursor (EC 1.9.3.1) (COX IV-1) (Cytochrome c oxidase polypeptide IV) P19783 COX4A 98 10.9 50.3 5 1.6 1.5 1.4 1.2 1.5
Cytochrome c, somatic P62897 CYCS 159 6.2 51.9 4 1.6 1.9 2.4 3.3 3.3
ATP Synthase
ATP synthase alpha chain, mitochondrial precursor (EC 3.6.3.14) Q03265 ATP5A1 5 53.6 67.5 27 1.5 1.9 2.3 2.2 2.2
ATP synthase beta chain, mitochondrial precursor (EC 3.6.3.14) Q8CI65 ATP5B 6 50.5 72.8 27 1.5 1.8 2.3 2.1 2.3
ATP synthase B chain, mitochondrial precursor (EC 3.6.3.14) Q9CQQ7 ATP5F1B 216 4 2 20.7 2 1.4 1.5 1.7 1.7 1.5
ATP synthase D chain, mitochondrial (EC 3.6.3.14) Q9DCX2 ATP5H 137 7.4 51.9 4 1.1 1.3 1.7 1.8 1.7
ATP synthase delta chain Q9DCZ0 ATP5D 197 4.7 29.2 2 1.0 1.4 1.3 1.3 1.3
ATP synthase oligomycin sensitivity conferral protein, mitochondrial precursor (EC 3.6.3.14) (OSCP) Q9DB20 ATP5O 113 9.6 42.3 6 1.5 1.8 2.3 2.3 2.1
ATP synthase f chain, mitochondrial (EC 3.6.3.14) P56135 ATP5F 194 4.8 50.6 2 1.6 2.1 2.5 2.3 2.4
ATP synthase gamma-subunit precursor Q91VR2 ATP5C1 78 14.1 34.2 6 1.3 1.6 1.9 1.6 1.8
ATP synthase g chain, mitochondrial (EC 3.6.3.14) (ATPase subunit G) Q9CPQ8 ATP5L 239 3.9 31.8 2 1.4 2.0 2.1 2.1 2.3
ATP synthase coupling factor 6, mitochondrial precursor (F6) P97450 ATP5J 182 5.2 45.4 3 1.0 1.0 1.1 1.0 1.0
ATP/ADP, Phosphate Transporters
ADP,ATP carrier protein 2 (ADP/ATP translocase 2) (Adenine nucleotide translocator 2) (ANT 2) (Solute carrier family 25, member 5) P51881 NT2 11 34.4 59.9 21 2.1 3.2 4.3 4.0 3.8
Phosphate carrier protein, mitochondrial precursor (36.7 kD)Q8VEM8 PCP 53 17.6 41.9 8 1.3 1.6 1.9 1.9 1.7
Antioxidant Proteins
Lung carbonyl reductase [NADPH] (EC 1.1.1.184) (NADPH-dependent carbonyl reductase) (LCR) (Adipocyte P27 protein) (AP27) P08074 70 14.8 32.4 7 1.4 2.0 2.7 3.5 3.7
Thiosulfate sulfurtransferase (EC 2.8.1.1) (Rhodanese) P52196 81 13.6 47.3 6 0.8 1.3 1.6 2.4 2.3
Superoxide dismutase [Mn], mitochondrial precursor (EC 1.15.1.1) P09671 123 8.5 41.9 5 0.6 0.7 1.1 1.2 1.3
Aldehyde dehydrogenase, mitochondrial precursor (EC 1.2.1.3) (ALDH class 2) (AHD-M1) (ALDHI) (ALDH-E2) P47738 24 26.6 35.7 13 1. 1.4 1.8 2.2 2.2
MOSC domain-containing protein 2Q922Q1 87 12.7 30.5 7 1.2 1.9 2.2 2.4 2.3
Peroxiredoxin 3, Thioredoxin-dependent peroxide reductase, mitochondrial precursor  P20108 101 10.5 32.3 6 1.7 2.0 2.1 2.3 2.0
Peroxiredoxin 5, mitochondrial precursor (Prx-V) (Peroxisomal antioxidant enzyme) (PLP) (Thioredoxin peroxidase PMP20) (Antioxidant enzyme B166) (AOEB166) (Liver tissue 2D-page spot 2D-0014IV) P99029 163 6.0 29.5 3 1.4 1.5 2.0 2.2 2.4
Mutant catalase (EC 1.11.1.6) Q91XI2 150 6.7 16.5 2 1.1 1.1 1.3 1.3 1.3
Cytochrome B5 outer mitochondrial membrane isoform Q9D8R3 170 5.7 33.6 2 1.0 1.0 1.4 1.1 1.3
Microsomal glutathione S-transferase 1Q91V 7 286 2.8 31.6 1 0.9 1.3 1.6 1.8 1.9
Other Proteins
Ribosome-binding protein 1 (Ribosome receptor protein) (mRRp) Q99PL5 2 73.5 50.6 38 1.1 0.9 0.7 0.6 0.6  
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60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa chaperonin) (CPN60) (Heat shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) (HSP-65) P63038 3 73.4 88.5 38 1.9 1.9 1.6 1.4 1.4
Stress-70 protein, mitochondrial precursor (75 kDa glucose regulated protein) (GRP 75) (Peptide-binding protein 74) (PBP74) (P66 MOT) (Mortalin) P38647 49.7 58.9 23 1.4 1.8 2.2 2.2 2.1
Methylmalonate-semialdehyde dehydrogenase (EC 1.2.1.27) (Mus musculus adult male cecum cDNA, RIKEN full-length enriched library clone:9130015C07 product:METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE (EC 1.2.1.27), full insert sequence) Q8CIB4 8 44.8 56.3 20 1.6 2.8 4.1 4.7 4.9
dnaK-type molecular chaperone grp78 precursor - mouse P20029 13 34.2 45.8 14 1.3 1.4 1.3 1.3 1.3
Protein disulfide-isomeraseP09103 14 33.8 42.8 15 1.5 1.6 1.4 1.4 1.4
Glutamate dehydrogenase, mitochondrial precursor (EC 1.4.1.3) (GDH) P26443 15 33.3 8.2 16 2.3 2.4 2.8 2.3 2.0
Actin, cytoplasmic 1 (Beta-actin) P63260 16 32.3 64.0 19 0.5 0.3 0.2 0.3 0.2
alpha 3 type VI collagen isoform 3 precursor O88493 17 31.4 18.9 12 1.2 1.1 1.1 1.2 1.2
Programmed cell death protein 8, mitochondrial precursor (EC 1.-.-.-) (Apoptosis-inducing factor) Q9Z0X1 18 28.4 35.0 13 1.3 1.7 2.1 1.9 1.9
Voltage-dependent anion-selective channel protein 1 (VDAC-1) (mVDAC1) (mVDAC5) (Outer mitochondrial membrane protein porin 1) (Plasmalemmal porin) Q60932 21 27.5 61.8 13 1.4 1.8 2.0 1.8 1.9
Glucose regulated protein Q99LF6 23 26.7 45.5 12 1.1 1.1 1.2 1.1 1.3
NRAA Best Hit: IDHA_CAEEL Probable isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial precursor (Isocitric dehydrogenase) (NAD+-specific ICDH) Q9D6R2 27 25.0 47.1 12 1.2 1.8 2.5 2.7 2.7
BAP (Repressor of estrogen receptor activity) Q61336 28 25.0 68.6 11 1.5 1.9 2.2 1.9 2.2
Aspartate aminotransferase, mitochondrial precursor (EC 2.6.1.1) (Transaminase A) (Glutamate oxaloacetate transaminase-2) P05202 32 24.3 39.3 11 1.4 1.0 1.1 1.0 0.9
Serpin H1, 47 kDa heat shock proteinP19324 33 24.2 53.7 13 1.2 1.2 1.1 1.1 0.9
Isovaleryl dehydrogenase precursor (Isovaleryl coenzyme A dehydrogenase) (Isovaleryl CoA dehydrogenase) Q9CYI3 34 24.2 41.0 11 1.5 1.7 2.2 2.7 2.4
Histone H2b (Histone protein Hist1h2bh) (OTTMUSP00000000538) Q6ZWY9 37 22.7 91.3 16 1.1 0.9 0.6 0.7 0.5
Mitofilin; motor protein cra|mCP110172 39 22.2 36.2 9 1.4 1.6 2.2 2.1 2.1
Calreticulin precursor (CRP55) (Calregulin) (HACBP) (ERp60) P14211 40 21.7 4 .4 12 1.1 1.3 1.2 1.1 1.1
Tumor rejection antigen gp96 P08113 44 21.0 25.9 7 1.5 1.7 1.6 1.4 1.6
Acetyl-Coenzyme A acyltransferase 2 (Mitochondrial 3-oxoacyl-Coenzyme A thiolase) Q8JZR8 45 19.8 42.3 10 1.0 1.2 1.4 1.6 1.7
Calnexin precursor P35564 48 18.7 25.6 8 1.4 1.2 1.0 1.0 1.3
Aldh4a1 protein (Fragment) Q8CHT0 49 18.3 34.9 9 1.2 1.7 1.1 1.6 1.2
Branched-chain-amino-acid aminotransferase, mitochondrial precursor (EC 2.6.1.42) (BCAT(m)) O35855 50 18.1 31.6 8 2 3.4 4.5 4.8 4.8
Histone protein Hist1h2af (OTTMUSP00000000536) P10812 51 18.1 56.9 11 1.2 1.1 0.7 0.7 0.5
Polymerase I and transcript release factor O54724 52 18.0 40.3 10 1.4 1.6 1.4 1.4 1.2
Mitochondrial ATP-dependent protease Lon precursor Q9DBP9 54 17.4 29.1 8 1.0 1.3 1.6 1.6 1.8
Prohibitin (B-cell receptor associated protein 32) (BAP 32) P67778 55 17.0 58.8 9 1.3 1.7 2.1 1.9 2.0
Fibronectin precursor (FN) P11276 56 16.9 12.8 6 0.3 0.2 0.3 0.3 0.3
Voltage-dependent anion-selective channel protein 3 (VDAC-3) (mVDAC3) (Outer mitochondrial membrane protein porin 3) Q60931 58 16.9 52.7 9 1.2 1.3 1.6 1.5 1.6
AHNAK (Fragment) Q6UL10 59 16.8 26.5 9 0.8 0.7 0.6 0.6 0.6
Lipoprotein lipase precursor (EC 3.1.1.34) (LPL) P11152 61 16.4 39.0 7 1.0 1.7 1.7 2.2 1.8
Annexin A2 (Annexin II) (Lipocortin II) (Calpactin I heavy chain) (Chromobindin 8) (p36) (Protein I) (Placental anticoagulant protein IV) (PAP-IV) P07356 62 16.0 45.9 7 1.0 0.9 0.9 0.7 0.9
Cai protein (Fragment) P08003 63 15.7 30.9 9 1.5 2.1 2.0 2.1 1.8
Acetyl-Coenzyme A acyltransferase 1 (Peroxisomal 3-ketoacyl-CoA thiolase A) (EC 2.3.1.16) Q921H8 64 15.7 35.1 7 1.1 1.6 1.7 1.7 1.7
SERINE HYDROXYMETHYLTRANSFERASE (EC 2.1.2.1) (SERINE METHYLASE) (GLYCINE HYDROXYMETHYLTRANSFERASE) (SHMT), full insert sequence (Mus musculus 16 daysQ99K87 65 15.6 30.8 7 0.9 1.0 1.0 0.9 0.8
Caveolin-1 P49817 66 15.5 47.8 9 1.6 1.8 1.6 1.4 1.3
ADP,ATP carrier protein, heart/skeletal muscle isoform T1 (ADP/ATP translocase 1) (Adenine nucleotide translocator 1) (ANT 1) (Solute carrier family 25, member 4) (mANC1) P48962 67 15.3 63.6 19 1.0 .1 1.3 1.3 1.3
similar to glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)  (EC 1.2.1.12) - mouse P16858 68 15.3 36.1 8 0.8 0 8 0.7 0.9 0.9
Mus musculus 10 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2610509I15 product:similar to 3- HYDROXYISOBUTYRYL-COENZYME A HYDROLASE Q8QZS1 69 15.1 40.5 8 1.2 1.6 1.9 2.5 2.2
Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4932403A10 product:DOLICHYL- DIPHOSPHOOLIGOSACCHARIDE-- PROTEIN GLYCOSYLTRANSFERASE 67 kDa SUBUNIT (EC 2.4.1.119) (RIBOPHORIN I) (RPN-I) homolog Q91YQ5 71 14.7 24.0 7 1.2 1.0 0.9 0.8 0.8
Txndc7 protein Q922R8 73 14.5 35.7 6 1.6 1.4 1.6 1.5 1.6
Phosphoenolpyruvate carboxykinase, mitochondrial precursor [GTP] (EC 4.1.1.32) (Phosphoenolpyruvate carboxylase) (PEPCK-M) Q8BH04 74 14.5 29.1 6 1.1 1.3 1.2 1.1
Hist1h4i protein (Fragment) P62806 76 14.2 69.6 9 1.3 1.2 0.9 0.7 0.5
10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10) Q64433 80 3.8 84.2 6 1.9 2.1 2.4 2.3 2.2
RIKEN cDNA 1110030L07 gene cra|mCP20737.1 82 13.5 31.1 6 1.5 1.9 2.6 2.1 2.1
Semicarbazide-sensitive amine oxidase (EC 1.4.3.6) Q66JM4 83 13.4 23.7 5 1.3 1.5 1.7 1.8 1.7
NRAA Best Hit: dehydrogenase, E1 component and Transketolase, central region (115.7 kD) (4F462) [Caenorhabditis elegans] Q60597 84 13.3 19.0 6 1.3 1.4 1.9 1.8 1.8
Voltage-dependent anion-selective channel protein 2 (VDAC-2) (mVDAC2) (mVDAC6) (Outer mitochondrial membrane protein porin 2) Q99L98 85 13.2 34.6 8 1.2 1. 1.8 1.7 1.7
Vimentin P20152 86 12.9 28.0 6 0.8 0.5 0.5 0.5 0.7
ERO1-like protein alpha precursor (EC 1.8.4.-) (ERO1-Lalpha) (Oxidoreductin 1-lalpha) (Endoplasmic oxidoreductin 1-like protein) (ERO1-L) Q8R180 88 12.2 29.5 5 0.8 1.2 1.2 1.0 1.3  
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Ribophorin II Q61833 90 12.0 24.3 5 0.9 0.7 0.8 0.7 0.9
NRAA Best Hit: AC006695_4 Receptor mediated endocytosis protein 1, isoform d [Caenorhabditis elegans] cra|mCP23754.1 91 11.9 26.3 6 1.2 1.2 1.3 1.3 1.1
Mus musculus adult male kidney cDNA, RIKEN full-length enriched library, clone:0610016L08 product:NADH-CYTOCHROME B5 REDUCTASE (EC 1.6.2.2) homolog (Diaphorase 1) (Cytochrome b-5 reductase) Q9DCN2 93 11.9 32.9 7 1.0 0.9 0.9 0.9 1.0
Lamin A, full insert sequence P48678 94 11.7 30.4 5 1.0 1.0 0.7 1.0 0.9
Histone protein Hist2h3c1 P68433 97 11.0 47.5 5 1.0 1.0 0.7 0.7 0.5
Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial precursor (EC 2.8.3.5) (Somatic-type succinyl CoA:3-oxoacid CoA- transferase) (Scot-S) Q9D0K2 99 10.8 35.0 5 1.3 1.8 2.2 1.8 2.1
hydroxysteroid (17-beta) dehydrogenase 4 P51660 100 10.5 22.9 4 1.2 1.5 1.2 1.1 0.9
GrpE protein homolog 1, mitochondrial precursor (Mt-GrpE#1) Q99LP6 102 10.4 44.2 5 1.7 2.1 2.5 2.1 2.0
Tumor-related protein (Isocitrate dehydrogenase 3, beta subunit) Q91VA7 103 10.3 24.2 5 1.4 2.1 3.0 3.0 3.0
Serum deprivation response (Mus musculus 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130091M01 product:serum deprivation response, full insert sequence) Q63918 105 10.1 18.4 5 2.0 2.5 2.0 2.7 2.3
Dihydrolipoamide branched chain transacylase E2 Q7TND9 106 10.1 22.4 5 1.0 1.6 1.9 2.1 2.1
Propionyl Coenzyme A carboxylase beta polypeptide, full insert sequence (Mus musculus adult male liver tumor cDNA, RIKEN full-length enriched library, clone:CQ8CFZ3 107 10.1 21.4 5 1.3 1.7 1.8 2.4 2.3
NRAA Best Hit: similar to ribosome-binding protein p34 - rat Q922Q8 108 10.1 28.5 5 1.3 1.1 1.0 0.8 0.9
Procollagen, type III, alpha 1 P08121 111 9.8 12.6 4
unnamed protein product Q63ZW4 112 9.8 32.9 5 1.1 1.1 1.6 1.4 1.4
ELONGATION FACTOR TU, MITOCHONDRIAL (P43) homolog (Mus musculus 13 days embryo heart cDNA, RIKEN full- length enriched library, clone:D330035P20 product:ELONQ8BFR5 114 9.6 28.8 4 0.7 0.7 0.7 0.8 0.8
Trap1 protein (Fragment) Q9CQN1 115 9.3 20.7 4 1.2 1.2 1.5 1.4 1.5
Growth and transformation-dependent protein Q9D6U8 117 9.2 46.5 4 1.3 1.5 2.0 1.8 2.1
RIKEN cDNA D330038I09 Q8K009 118 9.0 19.3 4 0.7 0.8 0.8 0.8 0.9
Ornithine aminotransferase, mitochondrial precursor (EC 2.6.1.13) (Ornithine--oxo-acid aminotransferase) P29758 119 8.9 22.8 4 1.0 1.3 1.5 1.2 1.1
Mus musculus 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130094F09 product:similar to MITOCHONDRIAL ISOLEUCINE TRNA SYNTHETASE Q8BIJ6 120 8.8 16.0 4 1.2 1.6 2.1 2.0 2.1
Peptidylprolyl isomerase B, full insert sequence (Ppib protein) P24369 121 8.6 36.1 4 1.4 1.6 1.4 1.5 1.5
Protein kinase C, delta binding protein Q91VJ2 122 8.5 30.8 4 1.6 1.4 1.4 1.0 1.2
Procollagen, type VI, alpha 2 Q8K229 124 8.5 14.7 3 1.6 1.5 1.7 1.9 1.7
NRAA Best Hit: IM44_RAT Import inner membrane translocase subunit TIM44, mitochondrial precursor O35857 125 8.4 35.0 4 1.3 1.9 2.1 2.0 1.9
Succinyl-CoA ligase [ADP-forming] beta-chain, mitochondrial precursor (EC 6.2.1.5) (Succinyl-CoA synthetase, betaA chain) (SCS-betaA) (ATP- specific succinyl-CoA synthetase beta subunit) Q9Z2I9 126 8.4 17.7 4 1.2 1.1 1.6 1.5 1.6
Collagen alpha 1(I) chain precursor P11087 127 8.1 11.4 4 0.8 0.6 0.5 0.6 0.4
AFG3(ATPase family gene 3)-like 2 Q8JZQ2 128 8.1 16.7 3
Histone H1' (H1.0) (H1(0)) P10922 129 8.1 35.8 3 0.6 1.0 0.7 1.0 0.6
ES1 protein homolog, mitochondrial precursor Q9D172 130 7.9 27.4 4 1.4 1.5 1.9 2.8 2.7
Sideroflexin 1 Q99JR1 131 7.9 23.0 4 1.4 1.5 2.1 1.9 1.8
Acyl-Coenzyme A dehydrogenase short branched chain Q9DBL1 133 7.6 16.9 4 1.0 1.5 2.4 1.7 1.5
UBQ-2 protein (corresponding sequence ZK1010.1)Q8R0Z9 134 7.6 42.5 3 1.1 1.1 0.7 0.7 0.7
Hexokinase type II (EC 2.7.1.1) (HK II) O08528 135 7.6 12.8 4
Histone H1.5 (H1 VAR.5) (H1b) P43276 136 7.5 55.0 7
Delta-1-pyrroline-5-carboxylate synthaseQ9Z110 138 7.4 18.8 3 0.9 0.7 0.8 0.8 0.6
Histone H1.4 (H1 VAR.2) (H1e) P43274 140 7.3 67.4 11 1.4 1.4 1.0 1.0 0.7
Mitochondrial import receptor subunit TOM22 homolog (Translocase of outer membrane 22 kDa subunit homolog) Q9CPQ3 143 7.0 66.9 3 1.0 1.2 1.0 1.1 0.9
NRAA Best Hit: Lethal protein 2, isoform a [Caenorhabditis elegans] P08122 144 6.9 8.7 3 1.1 0.9 1.2 0.8 0.8
60S ribosomal protein L13 (A52) P47963 145 6.9 36.7 2 1.1 1.0 0.8 0.9 0.8
Mus musculus adult male tongue cDNA, RIKEN full-length enriched library, clone:2310014M14 product:BA134O15.1 (SIMILAR TO CITRATE LYASE) homolog (Citrate lyase beta like) Q8R4N0 146 6.9 19.2 3 1.5 1.9 3.0 3.3 3.4
adenylate kinase 3 alpha-like 1 Q9WTP7 147 6.9 37.9 3 1.0 1.3 1.5 1.9 1.7
plasma membrane associated protein, S3-12 O88492 148 6.8 23.0 3 2.6 2.5 3.2 2.6 2.7
Acyl-CoA desaturase 1 (EC 1.14.19.1) (Stearoyl-CoA desaturase 1) (Fatty acid desaturase 1) (Delta(9)-desaturase 1) P130 1 151 6.7 23.1 4 0.8 1.1 0.9 1.2 1.2
B-cell receptor-associated protein 31 (BCR-associated protein Bap31) (p28 Bap31) Q61335 152 6.7 23.0 3 1.7 1.8 1.8 1.8 1.8
RIKEN cDNA 1500032D16 gene Q91WP8 153 6.6 24.4 3
Mus musculus adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730019E03 product:adenylate kinase 2, full insert sequence Q9WTP6 154 6.6 35.6 3 1.3 1.4 2. 2.4 2.2
P32-RACK (Complement component 1, q subcomponent binding protein) O35658 156 6.4 26.5 4 1.3 1.6 1.8 1.9 1.8
Histone H1.2 (H1 VAR.1) (H1c) P15864 158 6.2 70.1 11 1.3 1.4 0.9 1.3 0.7
NADPH--cytochrome P450 reductase (EC 1.6.2.4) (CPR) (P450R) P37040 160 6.1 13.9 2 1.7 1.7 1.9 1.6 1.8
Prostaglandin E synthase 2 Q8BWM0 162 6.1 15.1 3 1.0 1.0 1.1 1.0 1.0  
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TIM9, Mitochondrial import inner membrane translocase subunit Q9WV98 164 6.0 57.3 3 1.2 1.8 1.8 1.5 1.5
Ras-related protein Rab-7 P51150 165 6.0 28.0 3 0.9 0.9 1.3 0.9 0.9
Adiponectin precursor (Adipocyte, C1q and collagen domain containing protein) (30 kDa adipocyte complement-related protein) (ACRP30) (Adipocyte specific protein AdipoQ) Q60994 166 6.0 19.4 3 1.3 2.4 2.7 3.0 3.1
Mitochondrial carrier homolog 2 Q9D050 167 6.0 21.5 2 2.0 2.4 3.1 3.8 2.8
60S ribosomal protein L7 P14148 169 5.8 29.3 2 1.0 0.8 0.9 0.8 0.7
NRAA Best Hit: guanine nucleotide-binding protein -like (35.8 kD) (4K941) [Caenorhabditis elegans] P68040 171 5.7 23.1 3 1.1 0.8 0.8 0.7 0.8
Mus musculus 18-day embryo whole body cDNA, RIKEN full-length enriched library, clone:1110007B06 product:hypothetical protein, full insert sequence (Mus musculus adult male kidney cDNA, RIKEN full-length enriched library, clone:0610006P19 product:hypothetQ91VG6 172 5.7 24.2 2 1.3 1.7 2. 2.0 1.6
alpha glucosidase 2 alpha neutral subunit Q9R1N7 173 5.6 12.6 3 1.1 1.3 1.3 1.5 1.5
MKIAA0719 protein (Fragment) Q9CZW5 174 5.6 15.3 2 0.9 1.1 1.1 0.8 0.9
Mus musculus adult male pituitary gland cDNA, RIKEN full-length enriched library, clone:5330402C17 product:OLIGOSACCHARYL TRANSFERASE STT3 SUBUNIT HOMOLOG (B5) (INTEGRAL MEMBRANE PROTEIN 1) homolog P46978 175 5.6 10.4 2 1.0 0.9 0.8 0.6 0.7
AAA-ATPase TOB3 Q8C6C6 176 5.5 26.1 2 0.9 0.9 0.9 1.0 1.0
Sideroflexin 3 Q91V61 177 5.5 26.2 2 0.4 0.4 0.4 0.3 0.3
translation elongation factor eEF-1 alpha chain - mouse P10126 178 5.5 16.7 2 1.1 0.9 0.9 0.7 0.7
Single-stranded DNA-binding protein, mitochondrial precursor (Mt-SSB) (MtSSB) Q9CYR0 179 5.5 28.3 3
Basement membrane-specific heparan sulfate proteoglycan core protein precursor (HSPG) (Perlecan) (PLC) Q05793 180 5.4 8.4 2
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (EC 3.6.3.8) (Calcium pump 2) (SERCA2) (SR Ca(2+)-ATPase 2) (Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform) (Endoplasmic reticulum class 1/2 Ca(2+) ATPase) O55143 181 5.3 10.3 1 1.0 0.9 0.9 0.8 0.9
3-hydroxyisobutyrate dehydrogenase, mitochondrial precursor (EC 1.1.1.31) (HIBADH) Q99L13 183 5.1 27.2 2 1.2 1.6 2.3 2.1 2.1
Calumenin precursor (Crocalbin) O35887 184 5.1 26.0 2 1.2 1.6 1.4 1.6 1.7
Mitochondrial import inner membrane translocase subunit TIM13 A P62075 186 5.0 47.4 2 0.9 0.9 1.2 1.3 1.2
NRAA Best Hit: Ribosomal protein L22p/L17e (21.5 kD) [Caenorhabditis elegans] Q6PHZ1 87 4.9 24.5 2 1.0 0.9 0.6 0.7 0.6
Vesicle trafficking protein SEC22b (SEC22 vesicle trafficking protein- like 1) O08547 188 4.9 24.7 2 1.1 0.9 0.9 1.0 0.7
Neutral amino acid transporter ASCT2 (Solute carrier family 1 (Neutral amino acid transporter), member 5) Q5U647 189 4.9 16.2 2 2.5 1.7 1.2 0.7 0.6
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit precursor (EC 2.4.1.119) (Oligosaccharyl transferase 48 kDa subunit) (DDOST 48 kDa subunit) O54734 190 4.9 18.1 2 1.1 1.2 0.9 1.0 1.0
60S ribosomal protein L8 P62918 191 4.9 30.5 1 0.9 0.9 0.9 0.9 1.1
similar to Rpl7a protein P12970 192 4.9 27.6 2 1.2 1.3 1.1 1.1 1.2
hydroxysteroid 11-beta dehydrogenase 1 P50172 193 4.9 20.4 2 0.8 1.6 1.5 1.2 1.8
Leucine aminopeptidase 3 (EC 3.4.11.1) Q9CPY7 195 4.8 16.4 2 1.3 1.6 2.3 2.0 2.2
Trimethyllysine dioxygenase, mitochondrial precursor (EC 1.14.11.8) (Epsilon-trimethyllysine 2-oxoglutarate dioxygenase) (TML-alpha- ketoglutarate dioxygenase) (TML hydroxylase) (TML dioxygenase) (TMLD) Q91ZE0 196 4.7 4.7 2 0.9 1.1 1.1 1.2 1.1
MKIAA0152 protein (Fragment) Q6ZQI3 198 4.7 21.6 2 1.3 1.3 1.2 1.3 1.3
40S ribosomal protein S11 P62281 199 4.7 26.6 2 1.7 1.3 1.4 1.1 1.2
prolyl 4-hydroxylase alpha(I)-subunit Q60715 200 4.6 17.1 2 0.7 0.9 0.8 0.6 1.2
60S ribosomal protein L15 Q9CZM2 201 4.6 23.7 2
CD63 antigen P41731 202 4.6 13.1 2 1.3 1.5 1.3 2.0 2.0
NRAA Best Hit: S44636 f22b7.5 protein - Caenorhabditis elegans Q99M87 203 4.6 13.4 2 0.7 0.5 0.8 0.6 0.8
Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 1 (Transducin beta chain 1) P62880 204 4.5 15.0 2
Mus musculus 0 day neonate thymus cDNA, RIKEN full-length enriched library, clone:A430101M19 product:ribosomal protein S5, full insert sequence (Mus musculus adult male kidney cDNA, RIKEN full-length enriched library, clone:0610006D06 product:ribosomal prP97461 205 4.5 35.3 2 1.1 0.9 0.9 1.1 0.9
60S ribosomal protein L18a P62717 207 4.4 39.8 1
Nuclear transplantation upregulated protein 1 Q6ZPX6 208 4.4 12.6 1 0.8 0.7 0.7 0.7 0.8
hypothetical protein Q922H2 209 4.4 17.4 2 1.0 0.7 0.9 0.8 0.8
RAB1, member RAS oncogene family P62821 210 4.3 27.2 2 1.3 1.2 1.2 1.0 1.1
40S ribosomal protein S4, X isoform P62702 211 4.3 22.5 2
hypothetical protein P02468 213 4.3 9.7 2
RIKEN cDNA 2600017P15 gene Q8JZN5 214 4.2 12.3 2 1.2 1.4 1.3 1.3 1.4
NRAA Best Hit: similar to aspartly beta-hydroxylase Q8BSY0 215 4.2 8.5 2 1.2 1.0 0.8 0.7 0.9
60S ribosomal protein L14 Q811L0 217 4.2 27.3 2 1.1 0.9 0.8 0.6 1.0
Collagen alpha 1(VI) chain precursor Q99LW4 218 4.1 12.6 2 0.8 0.9 0.9 1.0 1.0
60S ribosomal protein L13a (Transplantation antigen P198) (Tum-P198 antigen) P19253 219 4.1 27.7 1
RIKEN cDNA 9430083G14 Q9CZB4 220 4.1 26.8 2 1.2 1.0 1.2 1.2 1.3
transmembrane trafficking protein Q6P227 221 4.1 23.3 2 1.2 1.3 1.5 1.2 1.9
ribosomal protein L27 P61358 223 4.1 23.2 2 0.8 0.7 0.6 0.5 0.6
Adipocyte plasma membrane-associated protein (Protein DD16) Q9D7N9 224 4.1 18.3 2 1.7 3.7 4.0 3.8 3.1  
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17beta-hydroxysteroid dehydrogenase type 10/short chain L-3- hydroxyacyl-CoA dehydrogenase (Hadh2 protein) (Mus musculus 8 days embryo whole body cDNA, RIKEN full-length enriched library clone:5730571C21 product:hydroxysteroid (17-beta) dehydrogenase 10 fQ9CYT3 225 4.0 23.4 2 1.6 1.4 2.1 2.1 2.0
Mus musculus 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700065P13 product:peptidylprolyl isomerase A full insert sequence P17742 226 4.0 31.7 2 0.9 0.9 0.8 .9 0.9
Calpactin I light chain (S100 calcium-binding protein A10) (p10 protein) (p11) (Cellular ligand of annexin II) P08207 227 4.0 33.3 2 1.2 1.0 0.9 1.0 1.2
triosephosphate isomerase P17751 228 4.0 17.1 2
similar to ribosomal protein L31 P62900 229 4.0 20.0 2 1.1 1.0 0.8 1.0 0.8
Histone H2A.X P27661 230 4.0 56.3 8
60S acidic ribosomal protein P2 P99027 231 4.0 27.8 2 0.6 0.4 0.4 0.2 0.2
Ras-related protein Rap-1b (GTP-binding protein smg p21B) Q9D1G1 232 4.0 20.1 2 1.4 1.3 0.8 0.9 0.9
Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial precursor (EC 3.4.21.92) (Endopeptidase Clp) O88696 234 4.0 9.6 2
60S ribosomal protein L28 P41105 235 4.0 32.4 1 1.1 1.0 0.8 0.9 0.7
40S ribosomal protein S15a P62245 236 3.9 39.5 1 1.4 1.3 1.1 1.0 1.0
myosin heavy chain IX 237 3.9 14.0 1
NADP transhydrogenase Q61941 238 3.9 7.8 2 1.0 0.9 0.9 0.9 1.0
60S ribosomal protein L24 Q8BP67 240 3.8 29.3 2 0.9 0.7 0.8 0.7 0.7
Gbas protein O55126 241 3.8 24.2 1 1.4 1.9 2.4 2.6 2.7
cytochrome b-5 P56395 242 3.8 32.0 2 0.8 1.2 1.1 1.2 1.3
RIKEN cDNA 2310005O14 Q8K1Z0 243 3.7 16.3 2 1.5 1.9 2.7 2.5 2.4
DNA segment, Chr 4, ERATO Doi 765, expressed Q8R3K4 245 3.6 22.3 1 1.5 1.2 1.5 1.5 1.2
carbonic anhydrase 5b, mitochondrial Q9QZA0 246 3.6 15.7 2 1.4 1.0 0.9 1.0 1.1
Mannosyl-oligosaccharide glucosidase (EC 3.2.1.106) (Glycoprotein processing glucosidase I) (Glucosidase 1) Q80UM7 247 3.6 10.0 2 1.6 1.3 1.5 1.2 1.3
glycerol-3-phosphate dehydrogenase Q64521 248 3.6 17.5 2
septin 7 O55131 250 3.6 16.7 1 0.8 0.7 0.6 0.6 0.6
Synaptic glycoprotein SC2 Q9CY27 251 3.6 12.0 1 1.4 1.3 1.4 1.4 1.6
Heme oxygenase 2 (EC 1.14.99.3) (HO-2) O70252 252 3.5 21.0 2
60S ribosomal protein L5 P47962 253 3.5 29.1 1 0.7 0.5 0.6 0.4 0.4
Membrane associated progesterone receptor component 1 Q80UU9 256 3.4 22.2 2
QIL1 (Mus musculus ES cells cDNA, RIKEN full-length enriched library clone:2410015M20 product:hypothetical protein, full insert sequence) (Mus musculus ES cells cDNA, RIKEN full-length enriched library clone:2410152P10 product:hypothetical protein, full iQ8R404 257 3.4 26.1 2 1.0 1.3 1.2 1.1 1.1
Leucine zipper-EF-hand containing transmembrane protein 1 Q8CGJ3 258 3.4 18.6 1 2.4 3.4 4.3 4.2 5.0
Putative steroid dehydrogenase KIK-I (EC 1.1.1.-) O70503 259 3.4 8.0 2 0.8 1.3 0.9 1.0 0.9
Ribosomal protein L6 P47911 261 3.4 17.9 1 0.9 1.0 0.7 0.9 0.7
hypothetical protein Q80VY8 262 3.3 23.9 1 1.1 0.9 1.1 1.0 1.1
60S ribosomal protein L4 (L1) Q9D8E6 263 3.3 20.5 1 1.0 0.8 0.7 0.6 0.7
Collagen alpha 1(IV) chain precursor P02463 264 3.3 10.2 1 1.4 1.4 0.7 0.9 1.1
Ribosomal protein L10A P53026 265 3.2 14.8 1
Histone H2a(A)-613 (Histone protein Hist2h2ab) (Histone protein Hist2h2ac) Q8CGP4 266 3.2 55.0 7 1.0 1.1 0.6 0.6 0.6
similar to 60S ribosomal protein L26 P61255 267 3.2 28.4 1
NRAA Best Hit: glutaryl-CoA dehydrogenase [Macaca fascicularis] Q6P8N6 268 3.2 16.1 1 0.8 1.3 1.1 1.5 1.5
Collagen alpha 2(I) chain precursor Q01149 269 3.2 10.4 1 0.5 0.5 0.3 0.3 0.4
Ribosomal protein L3 (Mus musculus 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430034L18 product:ribosomal protein L3, full insert sequence) P27659 270 3.2 21.1 1 1.2 1.1 0.9 0.8 0.7
low molecular mass ubiquinone-binding protein Q9CQ69 271 3.1 20.3 1 1.2 1.1 1.4 1.2 1.5
laminin B1 subunit 1 P02469 272 3.1 10.0 1 1.3 1.1 0.8 1.1 0.9
Pdk1 protein Q8R2U8 273 3.0 13.0 1
Mus musculus 18-day embryo whole body cDNA, RIKEN full-length enriched library, clone:1100001E09 product:ribosomal protein S3a, full insert sequence P97351 274 3.0 25.4 2 1.1 1.0 0.8 .9 0.6
Aquaporin-CHIP (Water channel protein for red blood cells and kidney proximal tubule) (Aquaporin 1) (Early response protein DER2) Q02013 275 3.0 17.2 1 0.9 0.8 0.8 0.6 0.4
Lrpap1 protein (Fragment) P55302 276 2.9 20.9 1 0.9 1.3 1.2 1.3 1.3
Mus musculus adult male small intestine cDNA, RIKEN full-length enriched library, clone:2010107K03 product:ATPase inhibitor, full insert sequence (ATPase inhibitory factor 1) O35143 277 2.9 49.1 1 1.3 1.2 1.3 1.1 1.0
UBX domain-containing protein 2 Q6ZQF6 278 2.9 15.4 1 1.3 2.5 3.6 3.2 3.7
similar to ribosomal protein S12 P63323 279 2.9 20.5 1 1.6 1.3 1.2 1.1 0.9
splicing factor, arginine/serine-rich 2 (SC-35) Q62093 283 2.9 32.8 1 1.7 1.5 1.1 1.0 0.7
mitochondrial outer membrane protein MOM35 Q9QYA2 288 2.8 17.1 1 0.9 1.0 0.9 1.0 1.0
similar to 40S ribosomal protein SA (p40) (34/67 kDa laminin receptor) P14206 289 2.8 26.3 1 2.8 2.2 1.6 1.8 2.0  
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PREDICTED: similar to Acidic ribosomal phosphoprotein P0 P14869 290 2.7 10.8 1 1.3 1.0 0.7 0.6 0.7
Sodium/potassium-transporting ATPase alpha-1 chain precursor (EC 3.6.3.9) (Sodium pump 1) (Na+/K+ ATPase 1) Q8VDN2 291 2.7 7.6 1
60S ribosomal protein L23 P62830 292 2.7 18.6 1
Mitochondrial acyl-CoA thioesterase 1 Q9QYR9 294 2.7 21.4 1 0.7 0.9 1.5 1.7 1.7
Methylmalonyl-CoA mutase, mitochondrial precursor (EC 5.4.99.2) (MCM) P16332 295 2.7 9.1 1
40S ribosomal protein S7 P62082 296 2.6 17.0 1 0.9 1.0 0.9 0.9 1.0
ribosomal protein S3 P62908 297 2.6 17.1 1 1.3 2.2 2.7 3.1 3.0
Thioredoxin domain containing protein 1 precursor Q8VBT0 298 2.6 16.6 1 1.4 1.7 2.2 1.9 2.0
Mus musculus adult male liver cDNA, RIKEN full-length enriched library, clone:1300001G13 product:CHLORIDE ION PUMP-ASSOCIATED 55 kDa PROTEIN homolog (Prenylcysteine oxidase 1) (Mus musculus adult male lung cDNA, RIKEN full-length enriched library, clone:1Q69ZW0 299 2.6 12.7 1 1.0 1.0 .0 1.0 1.0
Fatty acid-binding protein, adipocyte (AFABP) (Adipocyte lipid-binding protein) (ALBP) (A-FABP) (P2 adipocyte protein) (Myelin P2 protein homolog) (3T3-L1 lipid binding protein) (422 protein) (P15) P04117 303 2.5 26.0 1 1.9 3.1 3.1 2.5 3.0
Glucosidase II beta subunit precursor (Protein kinase C substrate 60.1 kDa protein, heavy chain) (PKCSH) (80K-H protein) O08795 306 2.4 11.3 1.4 1.7 1.3 1.8 1.5
L-gicerin/MUC18 Q9ESS7 308 2.4 7.3 1 1.1 1.7 1.8 1.7 1.4
Mus musculus adult male lung cDNA, RIKEN full-length enriched library clone:1200009A14 product:ATP-binding cassette, sub-family D (ALD) member 3, full insert sequence P55096 309 2.4 13.2 1 0.1 .1 0.0 0.0 0.0
RIKEN cDNA 2400003B06 gene Q99KF1 310 2.4 26.8 1 1.0 0.9 1.1 1.0 1.1
Fech protein P22315 311 2.4 17.5 1 0.9 1.2 1.6 2.5 2.8
methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) Q99MR8 312 2.4 14.9 1 1.0 1.0 1.3 1.3 1.4
similar to 60S ribosomal protein L10 (QM protein homolog) Q6ZWV3 313 2.4 30.4 1 1.0 1.0 0.8 0.9 0.7
RIKEN cDNA 4732490P18 gene cra|mCP13941.2 314 2.4 9.9 1 1.6 1.5 1.0 1.2 0.9
OVARIAN CARCINOMA IMMUNOREACTIVE ANTIGEN (TPA018) (HYPOTHETICAL 27.6 kDa PROTEIN) homolog (Hypothetical protein) (Mus musculus adult male testis cDNA,Q9CRD0 315 2.4 23.9 1 1.2 1.3 1.7 2.0 2.1
Mus musculus 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700005I17 product:SIMILAR TO OVER-EXPRESSED BREAST TUMOR PROTEIN homolog (RIKEN cDNA 1110002E23) (1110002E23Rik protein) (Mus musculus 18-day embryo whole body cDNA, RQ9CQN3 316 2.4 55.4 1 0.8 0.7 0.8 .8 0.8
leucine-rich PPR-motif containing Q6PB66 317 2.4 12.1 1 1.4 1.3 1.2 1.3 1.4
hypothetical protein Q8CGN5 319 2.3 11.6 1 0.0 0.0 0.0 0.0 0.0
Plasminogen activator inhibitor 1 RNA-binding protein (PAI1 RNA- binding protein 1) (PAI-RBP1) Q9CY58 321 2.3 18.9 1 0.0 0.0 0.0 0.0 0.0
Calcium-binding protein p22 (Calcium-binding protein CHP) (Calcineurin homologous protein) (Sid 470) P61022 322 2.3 24.7 1 0.0 0.0 0.0 0.0 0.0
Thioesterase superfamily member 2 Q9CQR4 323 2.3 26.4 1 0.0 0.0 0.0 0.0 0.0
60S ribosomal protein L32 P62911 324 2.3 11.3 1 0.0 0.0 0.0 0.0 0.0
Propionyl-Coenzyme A carboxylase, alpha polypeptide Q91Z 3 326 2.3 12.9 1 1.2 1.4 2.1 2.0 2.9
P100 co-activator Q78PY7 327 2.2 14.2 1 1.6 1.4 0.8 1.1 1.0
NRAA Best Hit: unnamed protein product Q8R3N9 328 2.2 19.3 1 1.0 1.5 1.2 1.7 1.6
Aldolase 1, A isoform P05064 329 2.2 15.1 1 1.0 1.2 1.0 1.0 0.7
similar to 40S ribosomal protein S25 P62852 330 2.2 27.1 1 1.2 0.8 0.5 0.9 0.5
similar to Mitochondrial ribosomal protein L12 Q9DB15 331 2.2 9.1 1 0.0 0.0 0.0 0.0 0.0
ribosomal protein L18 P35980 332 2.2 24.5 1 0.9 0.9 0.5 1.1 0.5
Mus musculus 2 days neonate thymus thymic cells cDNA, RIKEN full- length enriched library, clone:C920025O04 product:unknown EST, full insert sequence (Vesicle-associated membrane protein, associated protein B and C) (Mus musculus 16 days embryo head cDNA,Q9QY76 333 2.2 15.2 1 0.6 0.5 0.6 0.6 0.6
Epoxide hydrolase 1, microsomal P97869 334 2.2 10.8 1
Hypothetical protein BC009118 Q91VT4 335 2.2 8.9 1 0.9 1.1 1.5 2.2 1.5
Oligosaccharyl transferase (OTAse) STT3 subunit containing protein, full insert sequence Q921E3 336 2.2 9.2 1
Mitochondrial processing peptidase alpha subunit, mitochondrial precursor (EC 3.4.24.64) (Alpha-MPP) (P-55) Q9DC61 337 2.2 18.1 1 1.4 1.5 1.4 2.1 1.7
Mus musculus 18-day embryo whole body cDNA, RIKEN full-length enriched library, clone:1110004A14 product:ethanol induced 6, full insert sequence (Coiled-coil-helix-coiled-coil-helix domain containing 2) (Mus musculus 2 days neonate thymus thymic cells cDNQ9D1L0 345 2.1 28.1 1
Acyl coenzyme A thioester hydrolase 2, mitochondrial precursor (EC 3.1.2.-) (48 kDa acyl-CoA thioester hydrolase) (p48) (Mt-ACT48) (Protein U8) (MTE-2) Q9R0X4 347 2.1 13.0 1 0.7 0.8 0.5 0.5 0.7
Bcl-2-like 13 protein (Mil1 protein) (Bcl-rambo) P59017 349 2.1 9.7 1 1.1 1.3 1.7 1.0 1.6
Mus musculus adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230045M11 product:weakly similar to C1- tetrahydrofolate synthase P18155 351 2.1 13.4 1 0.8 0.9 0.8 0.7 0.7
Dynamin-like 120 kDa protein, mitochondrial precursor (Large GTP binding protein) (LargeG) P58281 352 2.1 15.1 1 1.3 1.3 1.3 2.0 1.5
similar to 40S ribosomal protein S8 P62242 353 2.1 23.6 1 2.1 1.6 2.1 1.6 1.2
Phospholipid and glycerol acyltransferase (from 'motifs_6.msf') containing protei full insert sequence Q8C0N2 354 2.1 13.5 1
Hmgcl protein P38060 355 2.1 8.9 1 1.3 1.5 1.6 1.7 1.5
Mitochondrial import receptor subunit TOM20 homolog (Mitochondrial 20 kDa outer membrane protein) (Outer mitochondrial membrane receptor Tom20) Q9DCC8 356 2.1 24.8 1 0.5 0.6 0.8 0.5 0.5
Rps13 protein P62301 357 2.1 12.1 1 2.3 1.8 1.2 1.6 1.1
Mus musculus 13 days embryo liver cDNA, RIKEN full-length enriched library, clone:2510001K09 product:TRANSLOCON-ASSOCIATED PROTEIN, ALPHA SUBUNIT (TRAP-ALPHA) (SIGNAL SEQUENCE RECEPTOR ALPHA SUBUNIT) (SSR- ALPHA) homolog (Signal sequence receptor, alpha) Q99MP2 358 2.1 13.3 1 0.6 0.6 0.4 0.4 0.6
Cytochrome c oxidase copper chaperone P56394 360 2.1 43.6 1
Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4921511C13 product:tropomodulin 2, full insert sequence (Mus musculus adult male diencephalon cDNA, RIKEN full-length enriched library, clone:9330157M12 product:tropomodulin 2,Q9JKK7 362 2.1 14.3 1 1.9 3.3 3.2 7.0 5.8  
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RIKEN cDNA C330023F11 (Mus musculus 7 days neonate cerebellum cDNA RIKEN full-length enriched library, clone:A730039H11 product:hypothetical NAD(P)-binding Rossmann-fold domains structure containing protein, full insert sequence) (Mus musculus adult male Q8R127 363 2.1 10.5 1 1.5 1.9 1.5 1.5 1.6
NRAA Best Hit: Hypothetical protein R08C7.3 [Caenorhabditis elegans] Q8R029 365 2.1 23.5 1 0.6 0.6 0.7 0.8 0.6
Fe-containing alcohol dehydrogenase 1 (Mus musculus adult male hypothalamus cDNA, RIKEN full-length enriched library clone:A230068K11 product:CDNA FLJ32430 FIS, CLONE SKMUS2001129, WEAKLY SIMILAR TO NAD-DEPENDENT METHANOL DEHYDROGENASE (EC 1.1.1.244) homoQ78SV3 366 2.1 9.0 1
Bifunctional methylenetetrahydrofolate dehydrogenaseP18155 367 2.0 15.4 1
similar to ribosomal protein S19 Q9CZX8 368 2.0 18.0 1
PREDICTED: similar to Myosin light polypeptide 6 (Myosin light chain alkali 3) (Myosin light chain 3) (MLC-3) (LC17) Q60605 369 2.0 38.8 1 0.6 0.3 0.3 0. 0.3
Mitsugumin 23 Q8R006 370 2.0 16.1 1 1.3 1.3 1.4 1.1 1.5
MKIAA1181 protein (Fragment) Q9DC16 371 2.0 10.6 1
Ribosomal protein S14 P62264 372 2.0 17.5 1 1.4 1.6 1.6 1.5 1.1
Alpha-globin P01942 373 2.0 24.7 1 1.0 1.8 1.4 2.4 2.4
ATP-dependent Clp protease ATP-binding subunit ClpX-like mitochondrial precursor Q6P8N8 374 2.0 13.3 1
Hnrpc protein Q9Z204 375 2.0 20.6 1
Nsep1 protein P62960 376 2.0 23.0 1
NRAA Best Hit: C. elegans RPL-29 protein (corresponding sequence B0513.3) [Caenorhabditis elegans] P47915 378 2.0 17.5 1
hypothetical protein Q9ES97 381 2.0 12.3 1
Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) P08228 385 2.0 12.4 1 0.4 1.8 2.0 1.6 1.8
Transmembrane protein induced by tumor necrosis factor alpha Q8C1E7 386 2.0 10.5 1
Ras-related protein Rab-1B Q9D1G1 388 2.0 21.4 2
Ras-related protein Rab-10 P61027 389 2.0 20.0 1 0.9 0.9 0.6 0.6 0.7
RAB35, member RAS oncogene family Q6PHN9 392 2.0 17.4 1
22 kDa neuronal tissue-enriched acidic protein Q91XV3 398 2.0 16.4 1 1.4 1.0 1.8 1.8 1.4
Diacylglycerol O-acyltransferase 1 (EC 2.3.1.20) (Diglyceride acyltransferase) Q9Z2A7 401 2.0 9.4 1 1.1 1.2 1.7 2.1 1.7
Hydroxysteroid (17-beta) dehydrogenase 7 (17beta-hydroxysteroid dehydrogenase type 7) Q8K5C9 402 2.0 9.9 1
Mus musculus 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732455H22 product:similar to DJ351K20.2.1 (NOVEL ENOYL COA/ACYL COA HYDRATASE/DEHYDROGENASE TYPE PROTEIN (ISOFORM 1)) (SIMILAR TO UNCHARACTERIZED HYPOTHALAMUS PROTEIN HCDASQ9CTC5 406 2.0 11.2 1 1.5 1.4 0.8 1.3 1.5
Heme binding protein 1 O888 4 409 2.0 15.3 1
Cop-coated vesicle membrane protein p24 precursor (p24A) (Sid 394) Q9R0Q3 410 2.0 11.0 1
Ras-related protein Rab-5C P35278 412 2.0 15.7 1
Tyrosine phosphatase-like protein, PTPLA (24.6 kD) (5H319) [Caenorhabditis elegans] Q9D3B1 413 2.0 .7 1
Mus musculus 10 days neonate intestine cDNA, RIKEN full-length enriched library, clone:5133400E10 product:similar to UNCHARACTERIZED HEMATOPOIETIC STEM/PROGENITOR CELLS PROTEIN MDS030 (RIKEN cDNA 5033414D02) Q9D3P8 414 2.0 19.7 1
similar to acidic ribosomal phosphoprotein P1 P47955 416 2.0 19.0 1 0.9 1.1 1.0 1.1 1.2
NRAA Best Hit: Glutathione S-transferases [Caenorhabditis elegans] Q9JJA0 417 2.0 11.6 1
Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4930518E06 product:hypothetical protein, full insert sequence Q9CQN5 418 2.0 15.4 1 1.4 1.6 1.8 1.6 1.3
Uncharacterized hematopoietic stem/progenitor cells protein MDS029 homolog Q91WS0 419 2.0 15.7 1 1.9 2.1 2.8 2.6 2.4
Transcription factor A, mitochondrial precursor (mtTFA) (Testis- specific high mobility group protein) (TS-HMG) P40630 420 2.0 18.5 1
Acyl carrier protein, mitochondrial precursor (ACP) (NADH-ubiquinone oxidoreductase 9.6 kDa subunit) (CI-SDAP) Q9CR21 421 2.0 16.7 1 1.3 1.5 2.3 1.7 2.4
60S ribosomal protein L36a (60S ribosomal protein L44) P83882 422 2.0 20.0 1 1.2 1.1 0.8 0.8 0.8
DnaJ homolog subfamily C member 5 (Cysteine string protein) (CSP) P60904 423 2.0 12.6 1
Cytochrome c oxidase polypeptide VIIc, mitochondrial precursor (EC 1.9.3.1) P17665 424 2.0 27.0
NRAA Best Hit: C. elegans RPS-26 protein (corresponding sequence F39B2.6) [Caenorhabditis elegans] P62855 425 2.0 23.5 1
Microsomal glutathione S-transferase 3 (EC 2.5.1.18) (Microsomal GST- 3) (Microsomal GST-III) Q9CPU4 426 2.0 19.6 1
ATP synthase lipid-binding protein, mitochondrial precursor (EC 3.6.3.14) (ATP synthase proteolipid P2) (ATPase protein 9) (ATPase subunit C) P56383 427 2.0 11.0 1 1.9 2.6 3.1 3.4 3.3
Mus musculus adult male kidney cDNA, RIKEN full-length enriched library, clone:0610038P07 product:TRANSLOCON-ASSOCIATED PROTEIN, GAMMA SUBUNIT (TRAP-GAMMA) (SIGNAL SEQUENCE RECEPTOR GAMMA SUBUNIT) (SSR- GAMMA) homolog (Signal sequence receptor, gamma) (MuQ8C0Z8 428 2.0 11.9 2 0.6 0.5 0.5 0.4 0.5
Thy-1 membrane glycoprotein precursor (Thy-1 antigen) (CDw90) (CD90 antigen) P01831 429 2.0 14.2 1 1.1 0.7 0.6 0.6 0.6
Mus musculus 10 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2610204L23 product:unknown EST, full insert sequence Q920S6 431 2.0 5.0 1
vesicle-associated membrane protein, associated protein A Q9WV55 437 2.0 23.0 1 0.8 0.7 0.8 0.6 0.7
Solute carrier family 2, facilitated glucose transporter, member 1 (Glucose transporter type 1, erythrocyte/brain) (GT1) P17809 438 2.0 9.4 1
CD9 antigen P40240 440 1.9 12.9 1
hypothetical protein Q80WJ7 451 1.8 10.7 1
Metaxin 2, full insert sequence Q8C454 452 1.8 9.1 1 1.2 1.4 1.4 1.4 1.5
Ndufv2 protein (Mus musculus 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:6530404K08 product:NADH dehydrogenase (ubiquinone) flavoprotein 2, full insert sequence) Q9D6J6 456 1.7 23.4 1 1.0 0.9 0.9 0.7 0.9
Ubiquinol-cytochrome c reductase iron-sulfur subunit, mitochondrial precursor (EC 1.10.2.2) (Rieske iron-sulfur protein) (RISP) Q9CR68 461 1.7 13.1 1 1.6 1.7 2.1 2.3 2.5  
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Histone macroH2A1.2 variant (MacroH2A1.2) Q91VZ2 467 1.7 16.1 1
Expressed sequence AI648866 Q80ZS3 470 1.7 19.0 1
similar to 40S ribosomal protein S6 (Phosphoprotein NP33) P62754 471 1.6 26.1 1
similar to 60S ribosomal protein L9 P51410 479 1.6 26.0 1 1.1 0.9 0.8 0.8 0.8
Acyl-CoA dehydrogenase family member 8, mitochondrial precursor (EC 1.3.99.-) (ACAD-8) (Isobutyryl-CoA dehydrogenase) Q9D7B6 480 1.6 5.8 1
NRAA Best Hit: similar to ARG99 protein Q9WVA2 481 1.5 9.5 1 1.2 1.0 1.0 1.0 1.0
Trypsinogen 16 Q9Z1R9 489 1.5 13.4 1 1.2 1.2 1.4 0.9 1.8
ATP synthase e chain, mitochondrial (EC 3.6.3.14) Q06185 492 1.5 15.7 1 2.2 2.6 3.6 2.8 2.8
Fdxr protein (Fragment) Q61578 498 1.5 15.2 1
Fatty acid-binding protein, epidermal (E-FABP) (Psoriasis-associated fatty acid-binding protein homolog) (PA-FABP) (Keratinocyte lipid- binding protein) Q05816 503 1.4 23.7 1 0.7 0.8 0.9 0.8 0.7
sulfite oxidase Q8R086 504 1.4 8.2 2 0.8 0.7 0.8 0.8 0.7
Heat shock protein 84b P11 99 507 1.4 14.5 1 0.2 0.3 0.3 0.3 0.3
Rps16 protein (Fragment) P14131 514 1.4 19.1 1 0.9 1.1 1.1 1.2 1.1
1. N number corresponds to overall Protein Pilot score (N=1 is highest score)
2. These proteins are also listed in the TCA Cycle
3.  These protein quantitations are based on peptides that are found in 
both experimental data sets for each protein.  Each protein was found to 
have a quantitation p-value <= 0.05 in each data set respectively
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Figure S.3. Representative tandem mass spectrum of iTRAQ labeled tryptic peptides. Ion signals corresponding to b-type and 
y-type fragment ions from the tryptic peptide GATPYGGVK (acetyl CoA-acetyl transferase) are labeled in blue and red, 
respectively.  Inserted is a zoom-in of the spectrum in the low mass range displaying the iTRAQ reporter ions.   
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